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ABSTRACT 
 
Breast cancer is the leading cause of death among women in developing countries. 
Approximately 10% of all cases of breast cancer are inherited, exhibiting a familial pattern of 
incidence, which have been attributable to mutations in high penetrance susceptibility genes, 
such as BRCA1 and BRCA2. However, these mutations only account to approximately 25% of the 
families with inherited breast cancer; therefore, identification of genes that are associated with a 
small or modest cancer risk is an important step to define breast cancer risk. It has been 
determined that different genetic backgrounds due to the combination of subtle sequence 
variants or polymorphisms, within low-penetrance genes, can explain the remaining familial and 
sporadic breast cancer risks.  
Many environmental factors have been associated with risk of breast cancer development, 
being sources of a wide range of DNA damage. The cellular response to DNA damage and its 
ability to maintain genomic integrity by DNA repair are crucial in preventing cancer initiation and 
progression. Previous studies have suggested an influence of gene variants in different DNA 
repair pathways regarding their capacity to repair. Therefore, polymorphisms in these genes may 
contribute to breast cancer susceptibility.  
The general aim of this thesis was to understand the association of different polymorphisms 
(XRCC1 Arg399Gln, XPD Lys751Gln, RAD51 G135C, XRCC3 Thr241Met, TP53 Arg72Pro and 
TP53 PIN3 Ins16bp) belonging to the DNA damage signalling and repair mechanisms with breast 
cancer susceptibility, in familial and sporadic breast cancer, in the Portuguese population. 
Furthermore, we intended to characterize the protein expression profiles of the most relevant 
polymorphisms found in breast cancer patients and human breast cancer cell lines, correlating 
the protein expression profile with the polymorphic status. 
Our findings identified RAD51 G135C polymorphism as a real risk modifier in familial breast 
cancer cases. Furthermore, we pointed out that XRCC1 Arg399Gln and XRCC3 Thr241Met 
polymorphisms as important biomarkers to sporadic breast cancer susceptibility. Moreover, our 
results also showed that TP53 PIN3 A2 allele in a haplotype combination confer increased breast 
cancer susceptibility among women carriers of FH of the disease.  
According to our findings from the association between the polymorphism and the clinical-
pathological parameters from breast cancer patients, we clearly underlined the role of XRCC1 
Abstract 
 
Arg399Gln and RAD51 G135C polymorphisms in the prediction of breast tumor aggressiveness 
and patients’ survival. Furthermore, our results suggested TP53 Arg72Pro and PIN3 Ins16bp 
polymorphisms as predictive factors of presence of lymph node metastases. Additionally, we 
demonstrated that XRCC1, XRCC3 and P53 expressions did not correlate with the respective 
genetic polymorphisms analysed, in breast cancer patients and in human breast cancer cell 
lines.  
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RESUMO 
 
O cancro da mama é a principal causa de morte por cancro em mulheres em todo o mundo. 
Aproximadamente 10% de todos os cancros da mama exibem um padrão de incidência familiar, 
tendo este sido atribuído a mutações em genes de susceptibilidade de elevada penetrância, tal 
como o BRCA1 e BRCA2. No entanto, dados mais recentes têm demonstrado que mutações 
nestes genes contribuem apenas para cerca de 25% das doentes com história familiar de cancro 
da mama. Assim, a identificação de genes que possam estar associados a um risco pequeno ou 
moderado para cancro torna-se uma etapa importante na determinação de mais factores de 
risco para cancro da mama. Com o conhecimento de que dispomos, é perceptível que a 
existência de diferentes padrões genéticos, devido à combinação de pequenas alterações em 
determinados genes, designados de genes de susceptibilidade de baixa penetrância, possa 
explicar a diferente susceptibilidade para os restantes casos de cancro familiar da mama e para 
os casos da mama esporádicos. Além disso, muitos factores ambientais têm também sido 
associados com uma maior risco de desenvolvimento de cancro da mama, produzindo uma 
vasta gama de lesões no DNA. A resposta das células aos danos no DNA e a sua capacidade 
para manter a integridade genómica, através da reparação de DNA, é crucial para prevenir a 
iniciação e progressão do cancro. Trabalhos prévios têm sugerido uma forte associação de níveis 
elevados de danos no DNA e menor capacidade de reparação. Deste modo, polimorfismos 
nestes genes podem contribuir para a susceptibilidade para cancro da mama. 
O objectivo geral desta tese foi compreender a associação de alguns polimorfismos genéticos 
em genes de reparação de DNA (XRCC1 Arg399Gln, XPD Lys751Gln, RAD51 G135C, XRCC3 
Thr241Met, TP53 Arg72Pro e TP53 PIN3 Ins16bp) e a susceptibilidade para cancro da mama, 
familiar e esporádico, na população Portuguesa. Além disso, caracterizou-se o perfil de 
expressão proteica dos polimorfismos identificados como relevantes para risco de cancro da 
mama, numa série de pacientes com a doença, bem como em linhas celulares humanas de 
cancro da mama, correlacionando com o respectivo perfil polimórfico.  
Os nossos resultados mostraram o polimorfismo RAD51 G135C como um importante 
modificador de risco para cancro da mama familiar. Adicionalmente, nós identificámos os 
polimorfismos XRCC1 Arg399Gln e XRCC3 Thr241Met como relevantes biomarcadores na 
susceptibilidade para cancro da mama esporádico. Este trabalho indicou também que uma 
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combinação haplotípica do alelo TP53 PIN3 A2 conduz a um aumento do risco para cancro da 
mama familiar. Quando se relacionaram a presença destes polimorfismos com parâmetros 
clínico-patológicos numa série de carcinomas da mama, verificou-se que os polimorfismos 
XRCC1 Arg399Gln e RAD51 G135C claramente desempenham um papel na previsão da 
agressividade do tumor e sobrevivência dos doentes. Além disso, este estudo sugeriu os 
polimorfismos no gene TP53, Arg72Pro e PIN3 Ins16bp, como factores na previsão de 
metástases nos gânglios linfáticos. Por ultimo, demonstrou-se ainda que a expressão proteica da 
XRCC1, XRCC3 e P53 não se correlacionava com o respectivo polimorfismo estudado, nem em 
pacientes com cancro da mama nem em linhas celulares humanas de cancro da mama.      
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ATM Ataxia telangiectasia mutated protein 
CHEK or CHK Checkpoint kinase   
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coactivator 
EP300 E1A-binding protein 
COMT Catechol-O-methyl transferase 
CYP19 Aromatase (cytochrome P450 sub-family XIX) 
HSD17B2 Hydroxysteroid (17-beta) dehydrogenase 2 
EPHX Epoxide hydrolase protein 
UGT1A7 UDP glucuronosyltransferase 1 family, polypeptide A7 
GSTP1 Glutathione S-transferase pi 
Val Valine 
Leu Leucine 
His Histidine 
Gln Glutamine 
Gly Glycine 
Ser Serine 
Thr Threonine 
Met Methionine 
Ala Alanine 
Pro Proline 
Ile Isoleucine 
Arg Arginine 
Cys Cysteine 
C Cytosine 
T Thymine 
A Adenine 
G Guanine 
Tyr Tyrosine 
Lys Lysine 
UV Ultraviolet 
NER Nucleotide excision repair 
MMR Mismatch repair 
DSBR Double strand break repair 
HNPCC Hereditary non-polyposis colorectal cancer
Abbreviations 
 
FA Fanconi anemia 
AT Ataxia telangiectasia 
LFS Li-Fraumeni syndrome 
BS Bloom’s syndrome 
WS Werner’s syndrome 
NBS Nijmegen breakage syndrome 
XP Xeroderma pigmentosum syndrome 
CS Cockayne syndrome 
TTD Trichothiodystrophy 
MLH1 Human MutL homolog protein 
MSH Human MutS homolog protein 
PMS Postmeiotic segregation increased protein  
HRR Homologous recombination repair 
NHEJ Non homologous end joining 
GGR Global genomic repair 
XPA to XPG Xeroderma pigmentosum group A to G proteins 
ATR ATM and Rad23-related protein 
RAD51 Recombination protein 51 
FANCA to M Fanconi anemia A to M proteins 
MRE11 Meiotic recombination 11 
RAD50 Recombination protein 50 
NBS1 Nijmegen breakage syndrome 1 protein 
BLM Bloom helicase protein 
RPA or C Replication protein A or C 
WRN Werner syndrome helicase protein 
DSB Double strand break 
H2AX Histone family member X protein 
BER Base excision repair 
PCNA Proliferating cell nuclear antigen 
MDC1 DNA damage checkpoint 1 
Cdc Cell division cycle protein 
AP Abasic site 
dRP Abasic sugar phosphate 
DNA Pol DNA polymerase protein 
FEN1 Flap endonuclease protein 
XRCC X-ray repair complementing protein 
PARP-1 Poly ADP-ribose) polymerase-1 
TCR Transcription-coupled repair 
hHR23B Human Rad23B homolog 
ERCC Excision repair cross-complementing protein 
LIG Ligase protein 
CSA or B Cockayne syndrome A or B protein 
Ku Thyroid autoantigen subunit protein 
DNA-PK DNA protein kinase 
FEN-1 Flap structure-specific endonuclease 1 
OGG-1 8-oxoguanine DNA glycosylase 
SSBR Single strand break repair 
xxiv 
Abbreviations 
BRCT BRCA C-terminal domain 
Trp Tryptophan 
Asp Aspartic acid 
Asn Asparagine 
UTR Untranslated region 
Glu Glutamic acid 
Thr Threonine 
IVS Intron intervining sequence 
bp Base pair 
IPO Oncology Portuguese Institute 
EDTA Ethylene diamine tetracetic acid 
PCR Polymerase chain reaction 
RFLP Restriction fragment length polymorphism 
OR Odds ratio 
CI Confidence interval 
SD Standard deviation 
OS Overall survival 
IHC Immunohistochemistry 
TMA Tissue microarray 
IPATIMUP Institute of Molecular Pathology and Immunology of the University of Porto 
PBS Phosphate buffer solution 
RT Room temperature 
WB Western blot 
IDV Intensity density value 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxv 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aims 
xxix 
AIMS 
 
A number of risk factors have been associated with susceptibility to breast cancer 
development, including endogenous and exogenous factors responsible for the production of a 
wide range of DNA damage, causing genome instability. Furthermore, some studies have been 
demonstrated a strong association of higher levels of DNA damage and lower DNA repair 
capacity in breast cancer patients. Several reports showed the presence of polymorphic alleles in 
DNA damage signalling/repair genes. Previous studies suggested an influence of gene variants in 
different DNA sigannling/repair mechanisms, as well as in its capacity to promote DNA repair 
and/or fidelity, maintaining the original sequence. Therefore, polymorphisms in these genes may 
contribute to breast cancer susceptibility. 
 
GENERAL AIM 
 
The general aim of this thesis was to understand the role of DNA damage signalling and repair 
genetic polymorphisms in breast cancer susceptibility, in familial and sporadic breast cancer, 
from a Portuguese population. 
 
To achieve our research aim, the work was divided as follows: 
 
1. COLLECTION OF PERIPHERIC BLOOD AND DNA EXTRACTION FROM SEVERAL GROUPS OF WOMEN  
We collected peripheric blood from 3 different groups of women: 
 - 84 unrelated familial breast cancer cases were obtained from S. João Hospital at Porto 
and General Hospital at Vigo; 
- 201 unrelated sporadic breast cancer cases were recruited from IPO-Porto (Oncology 
Portuguese Institute); 
- 442 healthy women were randomly selected from blood banks during the same time 
period as the cases were collected.  
DNA used for genotyping was extracted from peripheric blood lymphocytes.  
 
Aims 
2. GENOTYPING OF XRCC1 ARG399GLN, XPD LYS751GLN, RAD51 G135C, XRCC3 THR241MET, TP53 
ARG72PRO AND TP53 PIN3 INS16BP 
Polymorphisms were chosen based on theoretical effects on biological function of the protein, 
and an allelic frequency higher than 0.1. We selected the following polymorphisms: XRCC1 
Arg399Gln, XPD Lys751Gln, RAD51 G135C, XRCC3 Thr241Met, TP53 Arg72Pro and TP53 PIN3 
Ins16bp, and evaluated their genotypic frequencies in previous groups: familial and sporadic 
breast cancer patients and healthy women with no breast cancer family history, in a Portuguese 
population. 
 
3. CORRELATION OF THE SELECTED POLYMORPHISMS WITH BREAST CANCER SUSCEPTIBILITY AND CLINICAL 
PATHOLOGICAL FEATURES OF PATIENTS 
We applied appropriate statistical analysis to assess correlations between the genotyped 
polymorphisms with breast cancer susceptibility. Furthermore, we analysed associations of these 
genotypes and breast cancer features, as histological type and grade, axillary lymph node status, 
estrogen receptor status and survival and recurrence at last follow-up. 
 
4. CHARACTERIZATION OF XRCC1, XRCC3 AND P53 PROTEIN EXPRESSIONS IN BREAST CANCER PATIENTS AND 
HUMAN BREAST CANCER CELL LINES 
The characterization of XRCC1, XRCC3 and P53 immunohistochemical expressions were 
performed in paraffin embedded tissue microarrays from normal breast, benign breast lesions, in 
situ and invasive breast carcinomas. 
 
5. CORRELATION BETWEEN XRCC1, XRCC3 AND P53 PROTEIN EXPRESSIONS IN BREAST CANCER PATIENTS AND 
HUMAN BREAST CANCER CELL LINES WITH THEIR POLYMORPHIC STATUS 
We compared the expression profiles from breast cancer patients and from a series of human 
breast cancer cell lines with its respective genetic polymorphic status. We also evaluated the 
association of its expression with clinical-pathological factors, such as family history, histological 
grade, lymph node status and estrogen receptor status, and correlations between expressions of 
the different proteins. 
xxx 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THESIS PLANNING 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thesis Planning 
xxxiii 
THESIS PLANNING 
 
The present thesis is organized in six different Chapters: 
- In Chapter 1, a general introduction to the thesis theme is presented, including a review 
of the literature focused in the breast cancer epidemiology, risk factors and 
carcinogenesis, as well as the importance of DNA damage signalling/repair pathways 
and polymorphisms within these mechanisms in breast cancer.  
- In Chapter 2, the work “DNA repair polymorphisms might contribute differentially on 
familial and sporadic breast cancer susceptibility: a study on a Portuguese population” is 
presented, showing the importance of XRCC1 Arg399Gln and XRCC3 Thr241Met DNA 
repair polymorphisms as biomarkers to sporadic breast cancer susceptibility, as well as, 
RAD51 G135C polymorphism in familial breast cancer cases. 
- In Chapter 3, the study “XRCC1 Arg399Gln and RAD51 5’UTR G135C polymorphisms 
and their outcome in tumor aggressiveness and survival of Portuguese breast cancer 
patients” clearly underling the role of the above mentioned polymorphisms in the 
prediction of breast tumor aggressiveness and patients’ survival. 
- In Chapter 4, our findings regarding TP53 Arg72Pro and PIN3 Ins16bp polymorphisms 
and association with breast cancer susceptibility and clinical-pathological features are 
shown in the work “Importance of TP53 codon 72 and intron 3 duplication 16bp 
polymorphisms in prediction of susceptibility on breast cancer and presence of lymph 
node metastases”. 
- In Chapter 5, a characterization of XRCC1, XRCC3 and P53 protein expression profiles is 
demonstrated in the study “Immunohistochemical expression profile of XRCC1, XRCC3 
and P53 proteins in breast cancer: correlation with genetic polymorphic status”. 
- In last chapter, Chapter 6 is presented the discussion outline of the present thesis, as 
well as main conclusions of this work. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1 – GENERAL INTRODUCTION
 
 

1.1. Breast Cancer 
3  
1.1. BREAST CANCER 
 
Breast Cancer is an extraordinarily important disease all over the world. Over 1,2 million of 
women are diagnosed each year worldwide, and almost 411,000 of them will die of breast 
cancer (1). This disease affects not only the survival rate of these women but also their 
psychological and physical well-being, also influencing the people with close relation with them. 
Over the last 30 to 40 years, significant progress has been made in the diagnosis and 
treatment of this disease. Breast cancer presents a multifactor etiology, leading to a variety of 
genetic changes that result in variable biological behaviours from one patient to the other. 
Remarkable efforts have been developed to define the risk factors that help to identify those 
women expected to develop breast cancer and the genetic factors that contribute for this risk.  
 
1.1.1. BREAST NORMAL DEVELOPMENT, ANATOMY AND HISTOLOGY 
 
In order to understand the changes that the human breast undergoes in normal and 
especially abnormal situations, it is important to know how its normal breast development 
occurs, its anatomy and histology. 
Breasts begin developing in the embryo about 7 to 8 weeks after conception. They are 
unrecognizable at this stage consisting only of a thickening or ridge of tissue. From weeks 12 to 
16, the various sub-components become more defined. Tiny groups of cells begin to branch out 
laying the foundation for future ducts and milk producing glands. Other tissues develop into 
muscle cells which will form the nipple (the protruding point of the breast) and areola (the 
darkened tissue surrounding the nipple). In the later stages of pregnancy, the mother's 
hormones, which cross the placenta into the fetus, cause breast cells to organize into branching 
tube-like structures, thus forming the ducts. In the last 8 weeks, lobules (milk producing glands) 
mature and actually begin to secrete a liquid substance called colostrum. In both female and 
male newborns, swellings underneath the nipples and areola can easily be felt and a clear liquid 
discharge, colostrum, can be seen. These represent the effect of the mother's hormones and 
collapse in the first few weeks of life (2,3). 
Up until the onset of puberty, the breasts are much the same in males and females and their 
internal structure is similar – a collection of branching ducts ending in terminal ducts, with 
1. General Introduction 
minimal lobule formation. With the beginning of female menarche, the breast tissue responds to 
the release of female sex hormones, estrogen and progesterone. These stimulate the formation 
of lobules from the pre-existing terminal ducts, designed terminal duct-lobular unit (Figure 1B), 
leading to an increase in volume and elasticity of the connective tissue, the deposition of adipose 
tissue and the increase in vascularity (Figure 1A) (3-5). 
 
 
Figure 1 – Normal female breast. Macroscopic diagram (A), a microscopic low magnification 
of a terminal duct-lobular unit (B) and a microscopic high magnification of a intralobular terminal 
duct showing clear separation of epithelial (arrows) and myoepithelial cells (arrow heads).  
 
Histologically, the epithelium of intralobular terminal ducts presents essentially 2 layers: an 
inner layer presenting a epithelium constituted by a continuous surface of epithelial cells with 
oval-like nuclei, and an outer discontinuous layer of prominent myoepithelial cells presenting a 
clear cytoplasm (Figure 1C) (5). 
 During each menstrual cycle there is a number of morphologic changes that happen in 
the breast. In the first half of the cycle, the lobules are relatively quiescent. After ovulation, under 
the enhancement of hormone levels, an increased cell proliferation and number of acini per 
lobule and vacuolization of epithelial cells take place. When menstruation occurs, falling hormone 
levels there are epithelial cells apoptosis, loss of the stromal edema and regression in lobules 
size (4).  
Complete maturation of the breast tissue only occurs with lactation. The morphological 
alterations during pregnancy include increase of lobules number and size, so that in the end of 
the phase almost all the breast is composed of lobules with a slight amount of stroma, increase 
of melanin pigmentation in areola and vascularization of the nipple. After birth, the breast first 
produce the colostrum, and, with the decrease of progesterone levels, change to milk. After 
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ending lactation, the breast size diminished and the lobules regress and atrophy, but never to the 
appearance of the nulliparous breast (3,5). 
As women age, especially with the loss of estrogen at menopause, the lobules involute and in 
some areas disappear, remaining only the ducts. The fibrous connective component of the 
stroma also diminishes, whereas stromal adipose tissue accumulation increases (2,3).  
 
1.1.2. EPIDEMIOLOGY AND RISK FACTORS  
 
Breast cancer is the leading cause of death among women in developing countries. According 
to the World Health Organization, more than 1.2 million people worldwide will be diagnosed with 
breast cancer each year and nearly 320.000 cases in Europe (31% of all cancers in women) 
(1,6) (Figure 2).  
 
 
Figure 2 – Incidence rates of female breast cancer worldwide (per 100,000; all ages), 
according to GLOBOCAN 2002 (1). 
 
In Portugal, it presents the highest incidence and mortality rates between the women diseases 
(1,7) (Figure 3). However, in the last decade, breast cancer mortality have been declined, in 
Portugal as well as in developing countries, due to multiple factors, including improvements in 
cancer screening and novel and more effective treatment regimens (3,8,9).  
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Figure 3 - Incidence and mortality rates of common cancer types in Portugal (per 100,000; all 
ages), according to GLOBOCAN 2002 (1). 
 
As result of numerous epidemiological studies, several risk factors have been pointed out as 
well-established and probable in breast cancer, both as harmful or protective factors (Table 1). 
 
Table 1 – Summary of breast cancer risk factors. 
Risk Factor Effect 
Increasing Age  ↑↑ 
Early menarche ↑ 
Late menopause ↑↑ 
Nulliparity ↑ 
Early age of first birth ↓↓ 
Breastfeeding ↓ 
High serum of sex hormones (oestradiol, 
prolatin and insulin-like growth factor-1) 
↑↑ 
Prolonged HRT ↑ 
History of benign breast disease ↑↑ 
High breast density ↑↑ 
Obesity postmenopausal ↑ 
Obesity premenopausal ↓ 
Physical activity ↓ 
Fat intake and well-done food ↑ 
Vegetables and fruit intake  ↓ 
Alcohol consumption  ↑ 
Radiation exposure (child and young adulthood) ↑↑ 
Family history  ↑↑ 
Mutations in high penetrance genes (BRCA1, 
BRCA2, TP53, ATM, CHEK2) 
↑↑ 
Polymorphism in low penetrance genes ↑↓ 
↑ - low to moderate increased risk; ↑↑ - moderate to high increased risk; ↓ - low to moderate decreased 
risk; ↓↓ - moderate to high decreased risk 
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Breast cancer incidence is very low before age 25, except in certain familial cases, but 
increases with age, doubling every 10 years until the menopause, reaching its highest incidence 
rates in women over 50 years old (3,9). In menopause women the incidence rates slows 
dramatically (9), which suggests the important involvement of reproductive hormones in breast 
cancer etiology. 
Mortality and, mainly, incidence rates of breast cancer shows significantly differences between 
more developed countries, which present high rates, and less developed countries and Japan, 
with low rates (9). Studies of migrants from low to high risk countries have shown that women 
assume the rate of the host country within one or two generations, indicating the relevance of the 
environmental and lifestyle factors as breast cancer risks (8,9). 
The lifetime exposure to endogenous sex hormones has been described, for almost half a 
century, as the most well-established risk factor to breast cancer. This factor is determined by 
several variables, including age at menarche, age at first full-term pregnancy, breastfeeding and 
age at menopause. Women who start menstruating early in life (less than 12 years of age) or 
who have a late menopause (after the age of 55 years) present an increase risk to breast cancer 
(3,10). These findings could be explained by a prolonged exposure of mammary gland epithelium 
to estrogens and progesterone due to earlier or long-standing regular ovulatory menstrual cycles 
(11). The time and/or occurrence of pregnancy seem to have dual effect on breast cancer risk. 
On one hand, early age of first full-term pregnancy (less than 20 years versus more than 30 
years) is a protective factor to breast cancer, independently of the number of pregnancies. In 
contrast, nulliparity or late age of first full-term birth represents increased risk factor (9,10). 
These findings are contradictory with the fact that high and continuous levels of estrogen are 
associated with increased risk to breast cancer, since during pregnancy the oestradiol reach high 
levels. However, this could be counteracted by the fact that other hormones are secreted during 
pregnancy, inhibiting the effect of estrogen, and the breasts at this time reach the differentiation 
maximum, reducing the probability of cancer development (12). Breastfeeding effect on breast 
cancer risk has been controversial. Recent studies have proved that it represents a protective 
factor only in women that experiment a prolonged lactation period time (more than 24 months), 
probably due to diminishing of ovulatory frequency (9,10). 
During the last decade, several studies have looked to the effect of endogenous serum 
concentrations of hormones and breast cancer risk. It has been demonstrated that high serum 
oestradiol concentrations represent an increased risk to postmenopause women to develop 
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breast cancer. Furthermore, other sex hormones, such as insulin-like growth factor-1 and 
prolactin, have been suggest also to contribute to an increased breast cancer risk (9,11). 
Recent studies aimed to elucidate the importance of hormone replacement therapy (HRT) in 
breast cancer risk. So far, it becomes clear that users of HRT (mainly, estrogen combined with 
progestin) have a higher increase risk of breast cancer after four to five years of therapy 
compared with women who never used HRT (9).   
The presence of history of benign breast disease is also known to increase the risk of 
developing breast cancer. The diagnosis of atypical hyperplasia or atypia in epithelial mammary 
cells has been correlated with an increased risk of breast cancer (9,10). 
Another consistent breast cancer risk factor is the breast density. Research studies have 
shown that higher breast density is linked with increased risk to breast cancer, both in pre- and 
postmenopausal women, especially nulliparious, where these two factors seem to act in synergy 
(10).  
Obesity and the weight gain seem to have contradictories effects on breast cancer risk 
depending on the menopause status of the women. Obese postmenopausal women present 
higher risk to breast cancer, in contrast to obese premenopausal women that have a decreased 
risk (13).  
Several studies have demonstrated that physical activity reduces breast cancer risk when 
performed during adolescence and young adulthood, since it could delay the age of menarche 
(10). 
Numerous epidemiological studies have tried to clarify the role of diet and lifestyle (i.e. 
smoking, alcohol) as breast cancer risks. High intake of fat in the diet seems to be weakly 
associated with breast cancer risk (14,15). Moreover, consumption of well-done meat also has 
been correlated with increased risk, since in overcooked food there is production of extremely 
mutagenic compounds, like heterocyclic aromatic amines, which can lead to DNA damage, 
mutation accumulation and cancer initiation (15,16). In contrast, the fruits and vegetables intake, 
rich sources of natural antioxidants, seems to have a protective effect in breast cancer, mainly in 
postmenopausal women (14,15). Furthermore, intake of soya or some other foods that presents 
high levels of phytoestrogens seems to have some protective effect in breast cancer, given that 
these substances may block the effects of endogenous estrogens. However, contradictory results 
have been shown, whereas these substances seems to have also breast cancer promoting effects 
(14). Concerning alcoholic habits, several studies have demonstrated that daily alcohol uptake 
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increases breast cancer risk (14,15). No association of smoking habit and breast cancer risk was 
obtained by the majority of the reports (14,15). 
Radiation exposed population has shown higher increase risk to breast cancer, mostly in 
women exposed before 40 years. However, low doses of radiation, including occupational and 
medical diagnostic exposures, remain uncertain in their effect to breast cancer risk (3).  
Approximately 10% of all breast cancer is inherited, exhibiting a familial pattern of incidence. 
Women with at least one affected first-degree relative have an increased risk to breast cancer. 
This risk enhance significantly when: a) there are more than one affected relative; b) the relatives 
are close; c) early age of onset of the disease; c) there are cases of bilateral disease in the 
affected women or among relatives (17).   
The family history (FH) as a risk factor to breast cancer indicates that genetic factors are 
important determinants of this disease risk. Mutations in BRCA1 and BRCA2 (Breast Cancer 1 
and 2), the most commonly implicated high-penetrance genes in hereditary breast cancer, 
account for around 25% of families with this disease (18). In addition to these genes, mutations 
in three others were considered to establish them as also high penetrance genes associated with 
a moderate breast cancer risk (10,17). TP53 mutations are rare events in breast cancer families; 
however, women carriers of them present significantly high risk of early onset breast cancer. 
Another gene that account to increased risk to hereditary breast cancer is ATM (Ataxia-
Telangiectasia), especially under the age of 50. More recently, a gene that has been associated 
with hereditary breast cancer is CHEK2, presenting a frequency of 0.5-2.0% in the European 
population (19,20).  
The high penetrance genes account for only 5-10% of all breast cancers. Therefore, the 
majority of breast cancer cases do not have any inherited or hereditary origin. In this way, 
identification of genes that are associated with a moderate or low cancer risk is an important step 
in defining breast cancer risk. It has been understandable that different genetic backgrounds due 
to the combination of subtle sequence variants or polymorphisms in the low-penetrance genes, in 
combination with endogenous and exogenous exposure, could explain the remaining familial and 
“sporadic” breast cancer risks. Numerous studies have been conducted to identify accurate low-
penetrance susceptibility genes in breast cancer, and promising results have been obtained in 
genes encoded proteins implicated in the DNA repair and cell signalling pathways and in the 
metabolism of estrogen or various carcinogens (21-25).    
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1.1.3. PATHOGENESIS AND ETIOLOGY 
 
Some years ago it was believed that breast cancer rose from mammary epithelium through a 
well-defined, but non-obligatory, sequence of histological changes, from normal epithelium 
through hyperplasia, atypical hyperplasia, in situ carcinoma and invasive malignant disease. 
However, new pathological findings and distinct genetic hereditary or somatic alterations have 
reflected a more complex, heterogenic and multi-step etiology for breast cancer. 
Nowadays, breast tumors classification are made concerning not only to the morphology of 
the lesion, but also to their molecular profile (8). A vast variety of benign and malignant breast 
diseases has been identified, reflecting the high complexity and heterogeneity of the disease. The 
most common breast tumors have an epithelial origin (nearly 95% of all breast diseases) (3), and 
could be divided in three main groups: benign lesions, in situ and invasive carcinomas.  
Benign tumors can be defined as well-differentiated tissue with similar origin morphology, 
usually with a slow growth rate and well demarcated areas of growth (3). The benign lesions may 
be divided in: a) nonproliferative lesions, including cysts, apocrine metaplasia and duct ectasia; 
b) proliferative lesions without atypia, such epithelial hyperplasia, sclerosing adenosis, complex 
sclerosing lesions, papillomas, and fibroadenoma; and c) proliferative lesions with atypia, as 
atypical lobular and ductal hyperplasia (3,8). Of the many types of benign lesions in human 
breast, only the atypical hyperplasias seem to present a pre-malignant phenotype, enclosing a 
relative loss of growth control, however, without the ability to invade and metastasize, features 
restricted to malignant lesions (3). Thus, malignant tumors are characterized by decreased levels 
of cellular differentiation presenting a loss of morphology regarding the origin tissue; with a 
disorganized growth and high proliferation rates, abnormal nuclei and several mitoses; with ability 
to invade adjacent tissues and metastasize to other organs (3).  
The in situ carcinomas are divided mainly in two types: ductal (DCIS) and lobular (LCIS). Both 
present proliferation of the epithelium combined with cellular features of malignancy but without 
the capacity to invade the adjacent tissue. These two types of carcinomas present similar cellular 
origins, such as origin in terminal duct-lobular unit and undistinguishable genetic alteration at 
various loci (26). However, only a minority of LCIS cases seem to progress to invasive disease, in 
contrast to DCIS, which represents a high risk factor for progression to invasive carcinomas (8). 
1.1. Breast Cancer 
The majority of the invasive carcinomas are referred as ductal (85-95%), encompassing a 
heterogeneous group of tumors with particular names, as tubular, medullary, mucinous, 
papillary, metaplastic, apocrine, secretory and lipid-rich, and others classified as “not otherwise 
specified” (3,8). The abundance of invasive lobular carcinomas varies from 5-15% and is a much 
more homogenous group.  
Recently, this morphological classification was totally remodelled using the expression profile 
analysis through cDNA microarrays. Perou et al (27) defined three groups of breast cancer that 
are related to different molecular features of mammary epithelial biology: the luminal (estrogen 
receptor (ER) positive), the epidermal growth factor-2 (HER-2) positive and the basal-like (ER and 
HER-2 negative). 
In the classical model of general tumorigenesis, genetic variation is provided primarily by 
genetic mutations, and natural selection acts on this variation to provide a net survival advantage 
to the phenotypes (and genotypes) that are best adapted to the environment. Tumour growth, by 
comparison, is initiated by one or more mutations that a selective growth advantage to a cell. The 
clone derived from that cell then expands. Successive useful mutations or epigenetic changes 
occur, and it is thought that each is followed by waves of clonal expansion. This model has been 
confirmed by numerous molecular studies (28-30), and it has been established that cells have to 
acquire several genetic changes to allow tumour growth, invasion and metastasis. However, the 
normal mutation rate is insufficient to provide the genetic variation that is required for tumour 
growth. So, it is often proposed that mutations causing genomic instability occur as the initiating 
events and driving force to tumorigenesis. In general, these theories assume that genomic 
instability is derived from mutations in genes that are involved in processes such as DNA repair 
and chromosomal segregation, and mutations in these genes have no direct selective advantage 
or disadvantage, only an effect on the mutation rates of other genes. Genomic instability may 
arise as an additional effect of a mutation that has a larger direct selective advantage. Similarly, 
mutagenic environments might favour cells that bypass slow DNA repair mechanisms and 
therefore speed up progress through the cell cycle (31). Under these conditions, selection for 
rapid cellular proliferation might again indirectly raise the mutation rate. Finally, genomic 
instability mutations might ‘hitch-hike’ with new advantageous mutations in the same genome, as 
long as the overall selective advantage for the tumour cell is maintained. 
The tumorigenesis model is also viable in breast organ. The transformation of normal breast 
epithelium into carcinoma is generally accepted as a multistep process, in which genetic changes 
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(either in tumour suppressor genes and oncogenes) (32), environmental factors, lifestyle and 
hormones exposure, may play a role (33), resulting in a very complicated picture (figure 4). 
However, most breast cancer encloses a complex, heterogenic and multifactorial origin. One 
consequence of this phenomenon implies that two or more groups of breast cancer cases may 
have been caused by different sets of events, or even different causes.  
 
 
Figure 4 – Schematic model of hypothetical multistep carcinogenesis in breast cancer. 
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Regarding epidemiological findings, it is clear that one of the hypotheses to breast cancer 
etiology is due to excessive and cumulative exposure to endogenous hormones at different stages 
of breast cancer development. Several evidences suggest the involvement of hormones through 
two distinct ways: as genotoxic estrogen metabolites, which are able to induce DNA damage and 
thus cause initiation and progression of breast carcinogenesis; and as estrogen receptor (ER) 
mediated genomic and non-genomic signalling, affecting cell proliferation and apoptosis in breast 
tissue (34-37).  
Importantly, estrogens by their mitotic effects on breast cells appear to control the growth of 
primary breast cancers by inducing estrogen-regulated proteins that function as autocrine and 
paracrine growth factors. Estrogens activate genes controlled by estrogen-responsive elements. In 
addition to these classical transcriptional effects, these ligands can also modulate other genes, 
not containing estrogen-responsive elements, via direct protein–protein interaction of ER with 
other transcription factors (35,37). The genes responsible for the mitogenic effect of estrogen 
probably include secreted growth factors, for example, epidermal growth factor and insulin-like 
growth factor-1 and their respective receptors (35,37). By contrast, the non-genomic effects of 
estrogens on signal transduction do not appear implicated in their mitogenic action, since all key 
events in cell cycle stimulation can occur in the presence of a mitogen-activated protein kinase-
activating inhibitor (38).  
Increasing evidences have suggested that estrogen metabolism produced mutagenic 
metabolites that may contribute to breast carcinogenesis. During the process of estrogen 
biotransformation and elimination several DNA damage, such as direct DNA adducts, lipids 
oxidative damage and production of reactive oxygen species, which can turn out multiple types of 
genetic insults contributing to the induction of genomic instability (39-41). In addition to the 
estrogen mutagenic potential, a number of environmental chemicals, resulting from lifestyle and 
environmental factors, are supposed to contribute to the initiation of breast cancer, through the 
accumulation of DNA mutations, arising presumably via DNA damage, in genes that normally 
function to guarantee genetic stability (15,42-44). Several studies have been performed to 
elucidate the role of DNA damage in breast cancer predisposition and initiation. Patel et al (45) 
showed that breast cancer patients and their first-degree relatives presented higher frequencies 
of chromatid breaks in peripheric blood lymphocytes compared with control women, following in 
vitro G2 phase X-irradiation. Regarding ionizing radiation (IR), various reports have demonstrated 
higher levels of DNA damage in breast cancer patients (with or without FH of breast cancer) 
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compared to healthy women, after in vitro and in vivo exposure to IR (46-48). Some studies have 
also demonstrated that familial breast cancer patients, as well as theirs relatives and the 
sporadic breast cancer patients presented higher cromatid break frequencies when compared 
with controls, using as mutagens bleomycin, doxorubicin and N-methyl N-nitro N-nitrosoguanidine 
(49-51). Another common type of DNA damage is the bulky DNA adducts, produced by a wide 
range of chemical, such as polycylic aromatic amines, heterocyclic aromatic amines and 
benzo(a)pyrene, commonly found in well-cooked food and cigarette smoke. Rundle et al (52) 
design a case-control study to analyse polycylic aromatic amines-DNA adducts in tumors and 
nontumoral breast tissue from patient cases and benign tissue from controls. They observed a 
mean adduct levels significantly higher for the tumour tissue samples when compared with 
benign tissue samples. Furthermore, DNA adduct levels was significantly associated with breast 
cancer risk. In resume, all these findings corroborate the important involvement of DNA damage, 
and, in consequence, all the cellular mechanisms unchain by it (such as DNA damage 
recognition, signalling and repair pathways), in breast cancer etiology. 
Some years ago, Adami et al (53) have proposed an etiological model with four key 
components. First, the probability of breast cancer occurrence depends on the number of 
proliferating cells, being supported by the evidence that breast density is a predictor of breast risk 
(10). Secondly, the number of target cells and their responsiveness to hormonal stimulation is 
determined early in life, since the prenatal period, the mammary gland is in an undifferentiated 
state that turns it to a “perfect place” for cancer initiation. Third, the occurrence of the first full-
term pregnancy leads to the generation of terminally differentiated glandular tissue, which 
presents a lower rate of proliferation conferring long-term protection. Fourth, exposure to sex 
hormones, like estrogens, progesterone, prolactin and insulin-like growth factor 1, affect breast 
cancer risk by increasing the cellular proliferation, influencing clonal expansion and modulating 
growth enhancement of sub-clinical tumors (53). 
A more recent theory to breast cancer etiology, gaining more and more recognition, is based 
on the stem cell concept (54). In summary, the epithelial stem cells are the primary targets of 
tumorigenesis in the adult mammary gland, are long-lived and have large replication potential, 
allowing them to accumulate the mutations required for malignant potential. According to Dontu 
et al (54), ER positive and negative stem cells or progenitor cells of normal breast epithelium are 
the founding cells of breast tumors. The transformed mutated cells become the cancer stem cells 
that maintain the functional properties of differentiation present in normal stem cell. This concept 
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would provide an explanation for the heterogeneity of breast cancer phenotypes. These last two 
theories could be consider to be linked, since the four components of the first one represent 
steps in a single biologic process that point the mammary gland stem cells as the core 
determinant of breast cancer risk (55).   
 
1.1.4. GENETIC POLYMORPHISMS AS RISK FACTOR 
 
Polymorphisms have been historically classified as commonly occurring (>1%) genetic 
variations in the general population. Compared to mutations, polymorphisms have been 
perceived as functionally insignificant, however, current evidence emphasizes that a considerable 
fraction affects the intrinsic properties and proteins function to a variable degree (56,57).  
Low-penetrance susceptibility alleles are defined as polymorphic genes with specific alleles 
that are associated with an altered risk for disease susceptibility. Usually, the variants in these 
genes are common within general population. Therefore, although each variant may be 
associated with a small increased risk for breast cancer in an individual, the attributable risk in 
the population as a whole and the genetic effect of combinations of relevant polymorphisms may 
additively or synergistically be higher than for rare, high-penetrance susceptibility genes.  
Several reports have demonstrated the importance of polymorphisms in several cellular 
mechanisms, like estrogen and carcinogen detoxification metabolisms, cell cycle, apoptosis, cell 
signalling, growth factors and receptors molecules, cell adhesion, angiogenesis, DNA damage 
signalling and DNA repair, on breast cancer susceptibility (21,58-64). Polygenic models have also 
been proposed to explain the joint effect of many susceptibility alleles on breast cancer, but 
without considering specifically their possible interactions (65-68). Some examples of recent 
studies regarding this issue are shown in Table 2. Besides, these genetic variants might function 
through interactions with different genes and with behavioural, environmental and other external 
risk factors.   
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Table 2 – Studies of association of polymorphisms in different cellular mechanisms with 
breast cancer risk. 
 
Gene Name 
 
Polymorphism 
Name 
Breast cancer risk 
(OR; 95% CI)# 
Reference 
XbaI 2.61 (0.65-10.49) 
PvuII 0.95 (0.43-2.08) 
(69) 
XbaI 1.18 (0.73-1.89) 
PvuII 1.30 (0.86-1.97) 
(70) 
XbaI 0.69 (0.46-1.03) 
ER α 
PvuII 0.92 (0.69-1.21) 
(71) 
Val660Leu 1.69 (0.87-3.28) (72) 
Val660Leu 1.47 (0.06-37.5) 
H770H 1.43 (0.06-35.3) 
Q886Q 1.54 (0.20-11.8) 
(73) 
PRG 
 
Val660Leu 1.40 (0.90–2.00) (74) 
Gly482Ser 0.90 (0.65-1.24) PPARGC1A 
Thr612Met 3.02 (0.78-11.7) 
Ala203Pro 1.78 (0.61-5.15) PPARGC1B 
Pro388Pro 1.43 (0.76-2.68) 
EP300 Ile997Val 0.95 (0.65-1.38) 
(75) 
3.72 (0.99-13.9) (69) 
1.04 (0.76-1.44) (76) 
1.20 (0.90-1.40) (74) 
COMT Val158Met 
1.10 (0.93-1.30) (66) 
Arg264Cys 2.07 (0.18-23.3) (69) CYP19 
3’UTR C>T 0.90 (0.70-1.00) (74) 
HSD17B2 Met226Val 
1.06 (0.49-2.29)  
1.14 (0.47-2.77) a)  
1.26 (0.47-3.41) b) 
(77) 
0.60 (0.43-0.84) (78) EPHX  Tyr113His 
1.42 (0.94-2.17) (76) 
1.20 (1.00-1.50) (74) SOD2 Val16Ala 
0.92 (0.66-1.27) (76) 
UGT1A7 Lys131Arg 1.00 (0.80-1.20) (74) 
GSTP1 Ile105Val 0.90 (0.66-1.25) (78) 
# Homozygote variant genotype vs homozygote wild type genotype; * Study not realized; a) homozygote wild type 
vs heterozygote genotype between breast cancer patients with two close relatives with breast cancer vs healthy 
women; b) homozygote wild type vs heterozygote genotype between hereditary breast cancer patients vs healthy 
women. 
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1.2. DNA DAMAGE SIGNALLING AND REPAIR 
 
“DNA is, in fact, so precious and so fragile that we now know that the cell has evolved a whole 
variety of repair mechanisms to protect its DNA from assaults by radiation, chemicals and other 
hazards. This is exactly the sort of thing that the process of evolution by natural selection would 
lead us to expect.” (79). 
 
As Crick postulated, multiple repair mechanisms have evolved in all organisms to minimize 
the consequences of cellular exposure to endogenous and exogenous agents that inflict 
deleterious alterations in DNA. 
DNA damage occurs spontaneously and constantly throughout the life of an organism and can 
be further enhanced by exogenous DNA damaging factors. Therefore, an efficient response to 
DNA damage is essential for cellular life. DNA damage results from exogenous factors, including 
chemical carcinogens, such as some presented in diet and environmental pollution, IR, ultraviolet 
(UV) rays, and chemotherapeutic drugs (15). Spontaneous errors in fundamental cellular 
processes, such as DNA replication, and DNA damage produced by endogenous metabolic 
processes together with exogenous factors induce a wide range of DNA lesions such as reactive 
oxygen species, oxidized bases, bulky DNA adducts and DNA strand breaks (41,80). 
The importance of DNA repair is underscored by DNA repair deficiency, that is associated with 
hypersensitivity to DNA-damaging agents leading to mutations accumulation in the genome (81), 
as well as with genomic instability syndromes, which dramatically increase cancer incidence 
(82). So far, several pathways that lead to genomic instability have been described, including the 
disruption of Nucleotide Excision Repair (NER), Double Strand Break Repair (DSBR), Mismatch 
Repair (MMR) and DNA damage signalling pathways. 
  
1.2.1. SYNDROMES AND CANCERS ASSOCIATED 
 
The acquisition of some form of inherent genomic instability is a hallmark to several diseases, 
most notably cancer. The failure in the maintenance of genomic integrity and DNA repair can 
predispose humans to some well described malignancies (83). Several DNA repair genes are 
linked to hereditary predisposition diseases, such as Hereditary Nonpolyposis Colon Cancer 
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(HNPCC), Hereditary Breast Cancer, Fanconi Anemia (FA), Ataxia Telangiectasia (AT), Li-
Fraumeni syndrome (LFS), Bloom’s Syndrome (BS), Werner’s Syndrome (WS), Nijmegen 
Breakage Syndrome (NBS), Xeroderma Pigmentosum Syndrome (XP), Cockayne Syndrome (CS) 
and Trichothiodystrophy (TTD). 
HNPCC syndrome, also termed as Lynch Syndrome, is the most common form of hereditary 
colorectal cancer counting for 1-3% of all colorectal cancer cases. Other cancers seen in HNPCC 
include small intestine, pancreas, brain, hepatobiliary tract, and urinary tract. This hereditary 
disease is characterised by germline mutations in any of five DNA MMR genes (MLH1, MSH2, 
MSH6, PMS1 and PMS2) causing errors in DNA replication, known as microsatellite instability. 
These deficiencies in MMR instead of causing malignant transformation create the background 
that permits mutations to accumulate in other growth regulatory genes (84).  
Hereditary breast cancer syndrome is the most common form of inherited breast cancer and 
is caused by germline mutations in BRCA1 and BRCA2 (85). Although a great proportion of the 
familial risk cases is not explained by germ line mutations in BRCA1/2, no other susceptibility 
genes exclusively associated with increased risk of breast cancer have been identified so far, 
except CHEK2, whose variant allele 1100delC has been associated with a moderate increase in 
breast cancer risk in specific populations (86). BRCA1, BRCA2 and CHEK2 present important 
functions within the cellular network that responds to DNA damage and protects genomic 
integrity. BRCA1 protein seems to enclose multiple functions: acts directly in Homologous 
Recombination Repair (HRR), a sub-pathway of DSBR, through association and co-localization 
with RAD51 protein; promotes precise Non-Homologous End Joining (NHEJ) repair sub-pathway 
of DSBR, reducing the mutagenic potential of it; coordinates some roles of DNA replication; 
enhances Global Genome Repair (GGR) sub-pathway of NER by inducing genes of these 
machinery (Xeroderma Pigmentosum C (XPC) and others); is a phosphorylated downstream 
protein by protein kinases ATR (ATM- and Rad3-related) and ATM, having important roles in the 
various cell cycle checkpoints (87). The functions of BRCA2 protein are not well known, but it has 
an unquestionably role in HRR, since it interacts directly with the DNA recombination protein A 
(RAD51), being responsible for the transport of it to the nucleus and sites of DNA damage (87). 
Concerning CHEK2 protein, it has a role in DNA damage signalling, with direct impact on 
downstream effectors within cell cycle checkpoints, DNA repair and apoptosis machineries (86). 
  Fanconi Anemia is a rare recessive disorder characterized clinically by congenital defects, 
bone marrow failure, and cancer predisposition. Patients are diagnosed early in life by certain 
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clinical hallmarks, particularly hematological abnormalities such as aplastic anemia, 
myelodysplastic syndrome, and acute myeloid leukaemia (88). Abnormalities may also be 
present in many other organ systems, and the most notable features include radial and thumb 
hypoplasia, abnormal skin pigmentation, short stature, and infertility (89). Patients with FA are 
also susceptible to solid tumors, such as head and neck squamous cell carcinoma, gynaecologic 
squamous cell carcinoma, esophageal carcinoma, liver, brain, skin, and renal tumors (89). At the 
cellular level, a distint and diagnostic feature of FA is chromosomal instability and cellular 
sensitivity resulting from exposure to DNA interstrand crosslinkers, such as mitomycin C. Upon 
exposure to these genotoxins, cells from FA patient’s exhibit increased chromosomal aberrations, 
including chromosomal breaks and tri-radial formations (88,89). So far, twelve complementation 
groups and responsible genes, named FANCA-FANCM, have been identified. A general model has 
become known for the FA pathway as an arm of the DNA-damage response following interstrand 
crosslinkers. Eight FA proteins (FANCA, B, C, E, F, G, L, and M) form a nuclear core complex 
with a putative DNA helicase (FANCM) and an E3 ubiquitin ligase (FANCL) subunit. Following 
DNA damage, the core complex is required for mono-ubiquitination of FANCD2, a downstream FA 
protein. Following modification, FANCD2 co-localizes to DNA damage foci, presumably DNA-
repair complexes, with BRCA1, BRCA2 and the MRE11-RAD50-NBS1 complex (88,89). 
Ataxia Telangiectasia is characterized by cerebellar degeneration, immunodeficiency, cancer 
predisposition, and acute sensitivity to IR. The affected individual has been found to be prone to 
develop T cell prolymphocytic leukemia, B cell chronic lymphocytic leukemia, as well as sporadic 
colon cancer with microsatellite instability (90). The ATM protein enlarges a central role in the 
cellular response to DNA damage. ATM is a nuclear serine/threonine protein kinase involved in 
activation of several cell cycle checkpoints (G1–S, S and G2–M by autophosphorylation after 
exposure of cells to DNA damage, as IR, and through phosphorylation of several substrates, such 
as BRCA1, NBS1 and P53. ATM also has a role in phosphorylating proteins that are recruited to 
the sites of DNA double strand breaks and this results in enhanced cell survival (90). 
Li-Fraumeni syndrome originally was described as a familial cancer syndrome with an 
autosomal-dominant pattern of inheritance of early onset sarcomas of the soft tissues and bone, 
carcinomas of the breast and adrenal cortex, brain tumors, and leukemias. The underlying 
genetic defect in the majority of LFS families was identified as a germline mutation in the p53 
tumor-suppressor gene (91). 
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Bloom’s Syndrome is an autosomal recessive disorder characterized by growth retardation, 
sunlight sensitivity and a predisposition to the development of cancer. At the cellular level, BS is 
associated with inherent genomic instability. In comparison with cells isolated from unaffected 
individuals, BS cells show an increased frequency of several types of chromosomal aberrations, 
including breaks and translocations. BS is a result of mutations in a RecQ helicase gene, BLM. 
BLM seems to develop important roles to maintain the genomic stability. This protein interacts 
physically and functionally with a number of other nuclear factors in human cells. Most notably, 
BLM binds directly to topoisomerase IIIα, to RAD51 and to RPA (replication protein A), the major 
ssDNA (single-stranded DNA)-binding protein in human cells (92). 
Werner’s syndrome is an autosomal recessive disorder manifested by premature onset of age-
related phenotypes (such as short stature, premature greying of the hair, progressive hair loss, 
mild diabetes and cataract formation), including cancer. In WS cells, the genomic instability 
appears as spontaneous chromosomal abnormalities: chromosome breaks, complex 
rearrangements and deletions. A striking characteristic of WS cells is the expansion of different 
structural chromosome rearrangements in different clones from the same cell line. Another sign 
of genomic instability is abnormal fluctuation of telomere length. Along with spontaneous 
genomic instability, cells from WS individuals show a delayed S phase and a hypersensitivity to 
agents that interfere with DNA replication. The mutated gene responsible for WS is WRN, a RecQ 
helicase family member. WRN protein has been found to physically interact and/or co-localize 
with several proteins involved in DNA replication or control of genetic stability during S phase, 
enclosing an important role in recombinatorial repair and replication fork (93). 
NBS1 protein was the first component of the complex NBS1/MRE11/RAD50 to be associated 
with a genetic disease, the Nijmegen Breakage Syndrome. NBS is characterized by 
developmental defects, immune deficiency and a high incidence of cancer. NBS cells present 
genomic instability in the form of chromosome breaks and fail to arrest DNA synthesis following 
DNA damage. Furthermore, NBS cells are also sensitive to DNA-damaging agents causing 
replication fork stall. NBS1 protein forms a complex with MRE11/RAD50 and recruits them to 
sites of double strand breaks (DSBs). Recent knowledge showed that H2AX is phosphorylated by 
ATM in response to radiation and hence, ATM regulates this recruitment of the 
NBS1/MRE11/RAD50 complex through interaction of NBS1 with H2AX phosphorilated. 
Moreover, NBS1 is involved in signal transduction for cell-cycle checkpoints as a substrate of 
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ATM kinase and, when this mechanism is defective, induces impaired G2 checkpoint control and 
also allows continued DNA synthesis in the presence of DSBs (94). 
The presence of defects in some NER proteins is responsible for three rare recessive 
syndromes: Xeroderma Pigmentosum Syndrome, Cockayne Syndrome and Trichothiodystrophy. 
The more common clinical manifestations of XP are freckling in sun-exposed areas, followed by 
other pigmentation changes, loss of elasticity and multiple skin cancers including basal and 
squamous cell carcinomas and malignant melanomas. XP can result from defects in any of eight 
genes (XPA-XPG) (82). The clinical features of CS have little in common with XP. However, they 
share some mutated genes responsible for the diseases, which in the case of CS are XPB, XPD 
and XPG. CS patients have many developmental defects including severe physical and mental 
retardation, microcephaly, long limbs, bird-like face, pigmented retinopathy, gait defects and sun 
sensitivity (82). The defining feature of TTD is sulphur-deficient brittle hair caused by a reduced 
level of cysteine-rich matrix proteins. Associated features include small stature, mental 
retardation, ichthyotic skin, β-thalassaemia trait, unusual facial features, and in many cases 
photosensitivity. Most photosensitive patients have mutations in the XPD gene, but there are 
patients mutated in XPB and others in another group, TTD, which gene has not yet been 
identified (82). 
 
1.2.2. PATHWAYS 
 
Approximately 150 human DNA repair genes were cloned and sequenced. DNA repair genes 
can be divided into 2 sub-groups: genes associated with signalling and regulation of DNA repair, 
and the genes associated with distinct repair mechanisms, such as Base Excision Repair (BER), 
NER, DSBR and MMR (95-97). 
Next we will focus on the DNA repair pathways more related with breast cancer initiation and 
progression, namely BER, NER and DSBR and DNA damage signalling and regulation. 
 
1.2.2.1. DNA DAMAGE SIGNALLING 
 
The fidelity of eukaryotic genome is maintained by coordinated actions of cellular 
pathways, including DNA repair, chromatin remodelling, apoptosis, and cell cycle check-
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points. The checkpoint pathways are signal-transduction pathways, responsible mainly for the 
control of cell cycle arrest, control of the activation of DNA repair mechanisms, movement of 
DNA repair proteins to sites of DNA damage, activation of transcriptional programmes and 
induction of cell death by apoptosis (98). These DNA damage control mechanisms minimize 
the risk of DNA to be converted to inheritable mutations, and are believed to be of critical 
importance in the prevention of carcinogenesis.  
As in all signal-transduction processes, the DNA checkpoint pathways involve sensors, 
responsible for DNA damage recognition and signal initiation, transducers, being in charge of 
transmitting and amplifying the signal, and effectors molecules, that control the biological 
consequences of triggering the pathway. 
In Figure 5, we visualized a schematic diagram of DNA damage signalling. In mammalian 
systems, the proteins responsible for the sensing and initiation of DNA damage responses, 
caused by various genotoxic agents, are two protein kinases of the PI-3-kinase-like kinase 
family: ATM and ATR. The kinase activity of ATM is activated when DNA DSBs occur 
(99,100). A crucial sensor for the ATM pathway seems to be the MRE11-NBS1-RAD50 
complex. This complex is required for the damage-induced chromatin association of ATM and 
for efficient ATM autophosphorilation after damage (100). In contrast to ATM, the ATR 
responds to damage rather than DSB, such that caused by hydroxyurea and UV-light (98). 
Activation of the ATR kinase requires its associated protein ATR-interacting protein and two 
protein complexes, that seem to be the trimeric proliferating cell nuclear antigen (PCNA) and 
the replication factor C (RFC) (100).  
Some proteins, the transducers, are crucial to the activation of specific subsets of ATM or 
ATR substrates. ATR-dependent pathway requires the function of several proteins including 
BRCA1, Claspin and mediator of DNA damage checkpoint 1 (MDC1). In the case of ATM, 
P53 binding protein-1 and MDC1 also appear to be critical for the phosphorilation of many 
ATM substrates (100).  
With the help of mediators, checkpoint signals are transmitted, in the form of protein 
phosphorylation, to two major signal-transducing checkpoints kinases—CHK1 and CHK2. 
These two kinases in their turn regulate downstream targets, such as the phosphatases 
(Cdc25A, Cdc25C), and P53, controlling cell cycle progression and DNA synthesis. CHK2 
is the kinase target of ATM, and seems to phosphorilate P53 and BRCA1 (98,101). On the 
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other side, CHK1 is the target of ATR-dependent pathway and responsible for Cdc25 
phosphorilation (100,101). 
 
 
Figure 5 - Simplified scheme of DNA damage signalling. 
 
1.2.2.2. BASE EXCISION REPAIR 
 
Base excision repair pathway is the main mechanism to repair DNA damage with an 
endogenous origin, mainly DNA oxidation by reactive oxygen species which are generated by a 
wide range of normal metabolism and spontaneous deamination of DNA bases, and with an 
exogenous origin, including ionising radiation and long-wave UV light, as already mentioned 
(102). 
Briefly, BER is initiated by a DNA glycosylase that releases the target base to form an abasic 
site (AP) in the DNA (Figure 6). AP endonuclease (APE1) is the second enzyme in the pathway 
and hydrolyses the phosphosdiester bond 5’ to the abasic sugar phosphate (dRP) site to generate 
a nick. The insertion of the first nucleotide is performed by DNA polymerase β (DNA Polβ) (103). 
The removal of 5’dRP upon the insertion of the first nucleotide is the critical step in the decision 
between the two sub-pathways in BER: short-patch and long-patch. Besides polymerisation 
activity, DNA Polβ also exerts lyase activity in the hemiacetal form of 5’-dRP residues from 
incised AP sites. In contrast, oxidised or reduced AP sites are resistant to β elimination by DNA 
Polβ. Upon dissociation of DNA Polβ from damaged DNA, strand displacement and DNA 
synthesis is accomplished by DNA Polε and DNA Polδ together with PCNA and RFC, resulting in 
longer repair patches of up to 10 nucleotides. The removal of deoxyribosephosphate flap 
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structure is executed by flap endonuclease (FEN1) stimulated by PCNA. The ligation is performed 
by ligase I, in interaction with PCNA and Polβ, in long-patch BER, and by ligase III, that interact 
with X-ray repair complementing 1 (XRCC1), Polβ and PARP-1 [poly(ADP-ribose) polymerase-1], 
in short-patch BER (97,103). 
 
 
Figure 6 - Simplify diagram of BER pathway. 
 
1.2.2.3. NUCLEOTIDE EXCISION REPAIR 
 
The NER is the most versatile and flexible DNA repair pathway and is the major repair system 
for removing bulky DNA lesions, such as UV-light-induced photolesions and cyclobutane 
pyrimidine dimers, intrastrand cross-links, large chemical adducts, bulky adducts, generated 
from exposure to genotoxic agents and oxidative damage (104,105).  
This pathway consists of 2 distinct sub-pathways designated GGR and transcription-coupled 
repair (TCR) (Figure 7). GGR seems to be responsible for the repair of the non-transcribed 
domains of the genome. In contrast, TCR removes lesions from the transcribed strand of active 
genes. The first step involved in NER is the recognition of damaged residues and bubble 
formation, performed by XPC-hHR23B (human Rad23B homolog) and the nine subunits of 
transcription factor-IIH (TFIIH), XPA and RPA, respectively. The dual incision of the damaged DNA 
strands 5’ and 3’ to the lesion is executed by 2 endonucleases, XPG and ERCC1(excision repair 
cross-complementing)-XPF. DNA Polδ and Polε jointly with the sliding clamp PCNA, the 
pentameric clamp loader RFC and DNA ligase I (LIG I), are responsible for the release of an 
oligonucleotide containing the damage, synthesis and ligation of the resulting gap. With the 
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exception of XPC-hHR23B, all the genes involved in GGR are also required for TCR. In addition, 
TCR requires other genes, including CSA and CSB genes, also responsible for the Cockayne 
Syndrome (97,103). 
 
 
Figure 7 - Elementary illustration of NER pathway. 
 
1.2.2.4. DOUBLE STRAND BREAK REPAIR 
 
Double-strand break is the most dangerous type of DNA damage in the cells. DSB could result 
from exogenous agents, such as IR and certain chemotherapeutic agents, from endogenous 
origin, for instance reactive oxygen species, mechanical stress on chromosomes and replication 
errors (99). Several genes described as breast cancer susceptibility genes are important DSBR 
genes and for DSBR pathway, such as BRCA1, BRCA2, ATM, P53 and CHEK2 (99). 
The repair of DSB involves 2 types of pathways (Figure 8): HRR and NHEJ mechanisms, 
which are error-free and error-prone, respectively. The occurrence of HRR or NHEJ depends on 
the cell cycle phase. HRR occurs during the late S and G2 phases, whereas NHEJ occurs mainly 
in G0/G1 phases (97). 
HRR pathway uses extensive regions of DNA homology as coding information. The 
homologous DNA is usually the sister cromatid and may also be the homologous chromosome. 
The first step in HRR is the nucleolytic resection of the DSB in the 5’-3’ direction by the MRE11-
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Rad50-NBS1 complex. The resulting 3’ single-stranded DNA is bound by a heptameric ring 
complex formed by Rad52 proteins. The search for a homologous template and the formation of 
the joint molecules are performed by Rad51 nucleoprotein filament, which reunion is facilitated 
by five different paralogues of Rad51 (Rad51B, C and D, XRCC2 and XRCC3). The BRCA2 
interacts directly with RAD51, through its BRC repeats and through a domain in this carboxyl 
terminus (85,106). The interaction between these molecules is essential to RAD51 nucleoprotein 
filament formation (107). Furthermore, the BRCA1, having important functions in DNA damage 
checkpoints, seems to be important to RAD51 functions, but the nature of this interaction is still 
unknown. After strand exchange, the resulting structures are resolved according to the classical 
model of Holliday (108). 
In contrast to HRR, NHEJ is a conceptually simple pathway that involves the religation of 
broken ends and does not require a homologous template (109). NHEJ is initiated by the binding 
of a heterodimer complex consisting of the Ku (thyroid autoantigen) 70 and Ku80 proteins to the 
damaged DNA, protecting DNA from exonucleases digestion. The Ku heterodimer associates with 
the catalytic subunit of DNA protein kinase (DNA-PK). One of the targets of DNA-PKs is XRCC4 
which forms a stable complex with DNA ligase IV (LIG IV), which binds to the ends of DNA 
molecules and links duplex DNA molecules with complementary but non-ligatable ends. The 
XRCC4-LIG IV complex cannot directly re-ligate most DSB, being these processed first. The 
processing of DSB is mainly performed by MRE11-Rad50-NBS1 complex. Two other proteins that 
seem to be involved in the removal of 5’ and 3’ overhang are FEN1 and Artemis (109). 
 
 
Figure 8 - Simplified diagram of DSBR pathway. 
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1.2.3. GENETIC POLYMORPHISMS, DNA REPAIR CAPACITY AND BREAST CANCER RISK 
 
The DNA damage signalling and repair pathways are essential mechanism to the genome 
viability. The important role of DNA repair in the maintenance of a normal cellular genotype and a 
cancer-free state is obvious in cancer with family history, in which the presence of rare variant 
alleles but highly penetrance at a number of loci is associated with a high risk for cancer. 
A huge number of common polymorphisms have been described in DNA damage signalling 
and repair genes (110-112). Observations of inter-individual differences in measurements of DNA 
damage suggest that these polymorphisms may alter the functional properties of DNA repair 
enzymes. For all the evidences, it seems of great importance to define the meaning of DNA 
damage signalling and repair polymorphisms in the context of protein and pathway functions and 
their contribution to breast cancer risk. 
Several BER genes as been described to present polymorphic regions, namely, APE1, XRCC1, 
glycosylases (8-oxoguanine DNA glycosylase - OGG1), LIG I and LIG III (112). Several studies 
have been conducted with the aim of determine the influence of BER polymorphisms in breast 
cancer risk (Table 3). Until today, more than 200 polymorphisms have been identified in the NER 
pathway (111,112) and several studies have been performed to associate them with breast 
cancer risk. In Table 4, we show reports associating breast cancer susceptibility and NER 
polymorphisms. Cells evolved two sub-pathways to repair DSB lesions: NHEJ and HRR. Some 
polymorphisms have been demonstrated in some NHEJ and HRR genes (110), several of them 
have been examined in case-control studies for breast cancer risk (Table 5). An overview of the 
different studies associating breast cancer and DNA signalling polymorphic genes is presented in 
Table 6. From the analysis of the tables above, we can conclude that there are a lack of 
consistent findings between polymorphisms and breast cancer risk. Several points could be 
responsible for these differing reports. First of all, breast cancer is a heterogeneous disease, but 
the majority of the analysis treats it as one, using in the same analysis different types of tumors. 
Secondly, risk factors of breast cancer behind the genetic factors, such as environmental, 
lifestyle, endogenous metabolism, are very difficult to identify, and therefore so complicated to be 
included in case-control studies. Third, although it has been shown that >95% of genetic variation 
is shared across populations and that <10% is specific to a single population (113), it is also well 
known that prevalence of the allele variants differs across racial/ethnic groups (114). This is 
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phenomenon which adds considerable importance to studies that comprise a diverse group of 
racial/ethnic groups or populations with different ancestry. 
 
 
 
 
 
Table 3 – Studies of association of BER genetic polymorphisms with breast cancer risk and 
functional phenotype. 
Gene Name 
 
Polymorphism 
Name 
Breast cancer risk 
(OR; 95% CI)# 
DNA repair 
capacity/environment 
interaction 
Reference 
0.98 (0.52-1.86) * Vogel et al, 2003 (115) OGG1 
 
Ser326Cys 
1.3 (0.92-1.93) * Choi et al, 2003 (116) 
Arg194Trp 1.61 (0.10-26.1) No 
Arg399Gln 1.00 (0.57-1.76) No 
Moullan et al, 2003 
(117) 
Arg194Trp 
2.24 (0.91-5.53)a) 
2.46 (0.98-6.17)b) 
1.58 (0.39-6.39)c) 
* 
Arg399Gln 
0.92 (0.53-1.58)a) 
0.57 (0.32-1.02)b) 
0.74 (0.31-1.72)c) 
* 
Smith et al, 2003 (118) 
1.05 (0.59-1.87) * Smith et al, 2003 (119) 
1.20 (0.85-1.69) Yes Shu et al, 2003 (120) Arg399Gln 
1.03 (0.77-1.37) No 
Gln632Gln 0.90 (0.69-1.16) No 
Han et al, 2003 (121) 
0.89 (0.46-1.72) * Forsti et al, 2004 (122) 
0.88 (0.57-1.37) Yes 
Figueiredo et al, 2004 
(123) Arg399Gln 
1.27 (0.62-2.61) * 
Deligezer et al, 2004 
(124) 
Arg194Trp 2.78 (0.82-9.40) * 
Arg280His 1.69 (0.29-9.63) * 
2.69 (1.10-6.57) * 
Chacko et al, 2005 
(125) 
XRCC1 
Arg399Gln 
0.97 (0.73-1.29) Yes Shen et al, 2005 (126) 
Lys289Met 3.76 (1.87-7.56) * DNA Pol β 
Pro242Arg 1.96 (1.15-3.34) d) * 
Sliwinski e tal, 2007 
(127) 
# Homozygote variant genotype vs homozygote wild type genotype; * study not realized; ** visualized in the test; a) 
variant genotypes vs wild type genotype between healthy women with FH vs healthy women without FH; b) variant 
genotypes vs wild type genotype between breast cancer patients without FH vs healthy women without FH; c) variant 
genotypes vs wild type genotype between breast cancer patients with FH vs healthy women without FH; d) 
homozygote wild type genotype vs heterozygote genotype. 
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Table 4 – Studies of association of NER genetic polymorphisms with breast cancer risk and 
functional phenotype. 
Gene 
Name 
Polymorphism 
Name 
Breast cancer risk 
(OR; 95% CI)# 
DNA repair 
capacity/environment 
interaction 
Reference 
0.91 (0.47-1.73) * Försti et al, 2004 (122) XPC Lys939Gln 
0.91 (0.47-1.73) * Zhang et al, 2005 (128) 
XPG Asp1104His 1.19 (0.57-2.50) No Kumar et al, 2003 (129) 
Asp312Asn 0.51 (0.27-0.94) * 
Lys751Gln 1.00 (0.57-1.77) * 
Försti et al, 2004 (122) 
Asp312Asn 2.06 (0.63-6.69)a) Yes 
Lys751Gln 1.49 (0.46-4.86)a) Yes 
Shi et al, 2004 (130) 
Asp312Asn 2.06 (1.39-3.07)b) * 
1.32 (0.94-1.86)b) * 
Justenhoven et al, 2004 
(131) 
Lys751Gln 
1.18 (0.91-1.53)a) Yes Terry et al, 2004 (132) 
0.80 (0.12-3.23) * Lee et al, 2005 (133) 
Asp312Asn 
1.38 (1.11-1.73)b) * 
Lys751Gln 1.01 (0.82-1.25)b) * 
10.2 (0.77-1.36)b) * 
XPD 
Asp312Asn 
0.77 (0.54-1.10)b) * 
Kuschel et al, 2005 (134) 
3’UTR C8092A 0.58 (0.38-0.89)c) No 
ERCC1 
C354T 1.08 (0.84-1.39)a) Yes 
Lee et al, 2005 (135) 
 
XPF T835C 1.30 (0.57-2.74) * Lee et al, 2005 (133) 
# Homozygote variant genotype vs homozygote wild type genotype; * study not realized; a) Variant genotypes vs 
wild type genotype between breast cancer patients vs healthy women; b) homozygotes variant genotype vs wild type 
genotype between breast cancer patients vs healthy; c) homozygote variant genotype vs wild type and heterozygote 
genotypes between breast cancer patients vs healthy women. 
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Table 5 – Studies of association of DSBR genetic polymorphisms with breast cancer risk. 
Gene Name Polymorphism Name 
Breast cancer risk 
(OR; 95% CI)# 
Reference 
0.70 (0.39-1.28) Försti et al, 2004 (122) 
NBS1 Glu185Gln 
0.70 (0.39-1.28) Zhang et al, 2005 (128) 
0.69 (0.27-1.80) Webb et al, 2005 (136) 5’UTR G135C 
0.89 (0.67-1.17)a) RAD51 
5’UTR G172T 0.84 (0.56-1.26)a) 
RAD52  3’UTR C2259T 1.33 (1.02-1.75)a) 
Lee et al, 2005 (135) 
1.12 (0.88-1.44)a) Han et al, 2004 (23) 
XRCC2 Arg188His 
1.01 (0.77-1.33)a) Webb et al, 2005 (136) 
1.48 (0.64-3.43) Smith et al, 2003 (118) 
0.98 (0.67-1.41)a) Smith et al, 2003 (119) Thr241Met 
1.72 (0.94-3.15)b) 
0.74 (0.34-1.60)c) 
Försti et al, 2004 (122) 
5’UTR A4541G 1.10 (1.00-1.20)a) 
IVS5-14 A>G 1.04 (0.87-1.25) a) 
0.92 (0.76-1.11) a) 
Han et al, 2004 (23) 
1.47 (1.00-2.15)a) Figueiredo et al, 2004 (123) 
0.84 (0.64-1.09)a) Webb et al, 2005 (136) 
XRCC3 
Thr241Met 
1.79 (0.98-3.26) Zhang et al, 2005 (128) 
Asn372His 1.65 (0.36-7.58) 
Met784Val 2.03 (1.07-3.87)a) 
Ishitobi et al, 2003 (137) 
BRCA2 
Thr1915Met 
2.20 (0.20-23.7)d) 
5.40 (1.20-24.6)e) 
Górski et al, 2005 (138) 
# Homozygote variant genotype vs homozygote wild type genotype; a) Variant genotypes vs wild type genotype; b) 
Finish population; c) Polish population; d) under age 40 years; e) above age 41 years. 
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Table 6 – Studies of association between DNA damage signalling genetic polymorphisms with 
breast cancer risk.  
Gene Name Polymorphism Name 
Breast cancer risk 
(OR; 95% CI) 
Reference 
IVS22-77 T>C 1.67 (1.00-2.81) 
IVS48+238 C>G 1.66 (1.00-2.76) 
G5557A 1.07 (0.35-3.24) 
Angéle et al, 2003 (139) 
-5144 A>T 1.13 (0.92-1.39)a) 
IVS21+1049 T>C 1.39 (1.09-1.77)a) 
IVS33-55 T>C 1.19 (0.96-1.47) a) 
IVS34+60 G>A 1.29 (1.04-1.60) a) 
ATM 
3393 T>G 1.24 (1.00-1.54) a) 
Lee et al, 2005 (140) 
PIN3 Ins16bp 
5.30 (1.10-25.6)a)b) 
1.20 (0.90-1.60)a) 
Arg72Pro 
2.30 (0.70-7.60)a)b) 
1.10 (0.80-1.40)a) 
MspI Intron6 
2.80 (0.80-19.3)a)b) 
1.20 (0.90-1.50)a) 
Wang-Gohrke et al, 2002 (141) 
2.14 (1.21-3.79) Huang et al, 2003 (142) 
TP53 
Arg72Pro 
1.26 (0.96–1.67) Cox et al, 2007 (143) 
´# Homozygote variant genotype vs homozygote wild type genotype; a) Variant genotypes vs wild type genotype 
between breast cancer patients vs healthy women; b) breast cancer patients with FH. 
 
 
1.2.4. XRCC1, XPD, RAD51, XRCC3 AND TP53 POLYMORPHIC GENES AS GOOD 
CANDIDATES TO EVALUATE INDIVIDUAL BREAST CANCER SUSCEPTIBILITY 
 
XRCC1 protein is thought to act as scaffold protein for both single-strand break repair (SSBR) 
and BER activities (144). Three domains have been identified within its 633 amino acid protein: 
the NH2-terminal domain (residues 1–183), which interacts with DNA Pol-β and DNA containing 
a single-strand break; a central BRCA C-terminal (BRCT)-I domain (residues 315–403), which 
interacts with PARP-1; and the COOH-terminal BRCT-II (residues 538–633), which interacts with 
the COOH-terminal domain of DNA LIG III. XRCC1 is responsible for the assembly of these 
proteins in lesion area (144). Several polymorphisms have been found in XRCC1 gene and some 
have been linked with a variety of cancers (145). A common XRCC1 polymorphism, Arg399Gln, 
located in exon 10, results in an amino acid substitution from arginine to glutamine (Arg→Gln), 
within the BRCT-I domain, where PARP-1 binds, therefore affecting complex assembly and the 
repair efficiency of BER (146).  
XPD protein is a DNA helicase, being a subunit of the TFIIH complex and presenting important 
roles both in transcription and NER pathway. XPD participates in the locally unwind of DNA helix 
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allowing RNA transcription machinery to access the promoter and to permit the NER machinery 
access to the lesion (104). XPD is a highly polymorphic gene and correlation of its 
polymorphisms and cancer risk have been intensively studied (147,148). One of the most 
common XPD polymorphism, Lys751Gln, has been associated with a differential DNA repair 
capacity (149-151). This polymorphism, located in exon 23, is characterized by an A to T 
substitution causing a lysine to glutamine amino acid exchange (Lys→Gln) at codon 751. 
Lys751Gln is situated in the important domain of interaction between XPD protein and its 
helicase activator, inside the TFIIH complex, suggesting a biological importance in XPD function 
(152). 
In the HRR pathway, RAD51 is an important protein in DSBR pathway promoting DNA 
homologous pairing and strand exchange, in association with other proteins of the heterodimer 
complex with several other genes (such as XRCC2, XRCC3, BRCA2 and others) (153). In cultured 
mammalian cells, RAD51 is involved in spontaneous gene conversion as well as in HRR induced 
by radiation, alkylating agents and replication elongation inhibitors. More precisely, RAD51 
controls DSB repair via gene conversion associated or not with crossing over (154). RAD51 also 
partly participates in induced sister chromatid exchange in mammalian cells. RAD51 gene 
presents a low rate of polymorphisms and the majority of them are described in UTRs, such as 
5’UTR G135C polymorphism, occurring in the 5’UTR region at 135 position by a substitution of a 
guanine by a cytosine. The biological effect of this polymorphism is currently unknown. However, 
in two studies, an elevated breast cancer risk associated with RAD51 135C allele was reported in 
BRCA2 mutation carriers, but not in BRCA1 mutation carriers (155,156). 
Another important HRR protein is XRCC3, that interacts directly with RAD51, helping in the 
assembly of the nucleofilament protein and in the selection and interaction with appropriate 
recombination substrates (157), being required for genomic stability. The XRCC3 Thr241Met 
polymorphism, located in exon 7, is a very common variant in the general population, and results 
from the substitution of a C to a T, which induces in an amino acid substitution of a threonine by 
a methionine (Thr→Met) at codon 241. Some findings have demonstrated that this 
polymorphism may affect the enzyme’s function and/or its interaction with other proteins 
involved in DNA damage and repair (158). Some functional studies have shown that XRCC3 
241Met variant present a decreased DNA repair function and some deficiencies in mitotic events 
(158,159). Molecular epidemiological studies have linked this XRCC3 polymorphism to increased 
risk of some types of cancer, among them breast cancer (123,160). 
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The TP53 tumour suppressor gene, also designated the “guardian of the genome”, is 
essential in the preservation of genome integrity. From the numerous biological functions of p53 
protein, inhibition of cell cycle progression, DNA repair and apoptosis are the major cellular 
pathways where it is involved (161). TP53 gene mutations are widely detected in breast cancer, 
being correlated with specific clinical phenotypes (162,163).  Furthermore, several 
polymorphisms have been identified within TP53 gene, both in non-coding and coding regions 
(164). One of the most well studied TP53 gene polymorphism is Arg72Pro, located in codon 72 
on exon 4, leading to arginine-proline substitution (Arg→Pro), which in its turn results in a 
structural alteration of the protein giving rise to variants with distinct electrophoretic mobility 
(165). This polymorphism occurs in a proline-rich region of p53, which is known to be important 
for the growth suppression and apoptotic functions of this protein (165). Another common 
polymorphism is 16 base pair (bp) duplication in intron 3 of the TP53 gene (PIN3 Ins16bp). 
However, until now only a single report has shown an altered mRNA expression linked to the 
presence of this polymorphism (166). Consistent with this altered functional activity, several 
studies have correlated the intron 3 duplication with an increased risk of various cancers, 
including breast cancer (167-169). 
33 
1. General Introduction 
 34 
1.3. REFERENCES 
 
 1.  Ferlay, J., Bray, F., Pisani, P., Parkin, D.M. GLOBOCAN 2002 - Cancer incidence 
mortality and prevalence worlwide. nº5. IARCPress, Lyon (2004). 
 2.  Hayes, D.F. Atlas of Breast Cancer.  Mosby International, London (2000). 
 3.  Kumar, V., Abbas, A.K., Fausto, N. Robbins and Cotran Pathologic Basis of Disease. 7th. 
Elsevier, Philaphelphia, PA (2005). 
 4.  Russo, J., Hu, Y.F., Yang, X., Russo, I.H. Developmental, cellular, and molecular basis of 
human breast cancer. J Natl Cancer Inst Monogr 2000; 17-37. 
 5.  Stevens, A., Lowe, J. Human Histology. 3rd. Elsevier, Philaphelphia, PA (2005). 
 6.  Bray, F., Sankila, R., Ferlay, J., Parkin, D.M. Estimates of cancer incidence and mortality 
in Europe in 1995. Eur J Cancer 2002; 38: 99-166. 
 7.  Pinheiro, P.S., Tycznski, J.E., Bray, F., Amado, J., Matos, E., Parkin, D.M. Cancer 
Incidence and mortality in Portugal. Eur J Cancer 2003; 39: 2507-2520. 
 8.  Tavassoli, F.A., Devilee, P. Pathology and Genetics - Tumours of the Breast and Female 
Genital Organs.  IARC Press, Lyon (2003). 
 9.  Key, T.J., Verkasalo, P.K., Banks, E. Epidemiology of breast cancer. Lancet Oncol 2001; 
2: 133-140. 
10.  Dumitrescu, R.G., Cotarla, I. Understanding breast cancer risk -- where do we stand in 
2005? J Cell Mol Med 2005; 9: 208-221. 
11.  Muti, P. The role of endogenous hormones in the etiology and prevention of breast 
cancer. Ann N Y Acad Sci 2004; 1028: 273-282. 
1.3. References 
12.  Wiseman, R. Breast cancer: critical data analysis concludes that estrogens are not the 
cause, however lifestyle changes can alter risk rapidly. J Clin Epidemiol 2004; 57: 766-772. 
13.  Lorincz, A.M., Sukumar, S. Molecular links between obesity and breast cancer. Endocr 
Relat Cancer 2006; 13: 279-292. 
14.  Gerber, B., Müller, H., Reimer, T., Krause, A., Friese, K. Nutrition and lifestyle factors on 
the risk of developing breast cancer. Breast Cancer Res Treat 2003; 79: 265-276. 
15.  DeBruin, L.S., Josephy, P.D. Perspectives on the chemical etiology of breast cancer. 
Environ Health Perspect 2002; 110 Suppl 1: 119-128. 
16.  Felton, J.S., Knize, M.G., Salmon, C.P., Malfatti, M.A., Kulp, K.S. Human exposure to 
heterocyclic amine food mutagens/carcinogens: relevance to breast cancer. Environ Mol 
Mutagen 2002; 39: 112-118. 
17.  Arver, B., Du, Q., Chen, J., Luo, L., Lindblom, A. Hereditary breast cancer: a review. 
Semin Cancer Biol 2000; 10: 271-288. 
18.  Ford, D., Easton, D.F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D.T., 
Weber, B., Lenoir, G., Chang-Claude, J., Sobol, H., Teare, M.D., Struewing, J., Arason, A., 
Scherneck, S., Peto, J., Rebbeck, T.R., Tonin, P., Neuhausen, S., Barkardottir, R., Eyfjord, J., 
Lynch, H., Ponder, B.A., Gayther, S.A., Zelada-Hedman, M., . Genetic heterogeneity and 
penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast 
Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-689. 
19.  Meijers-Heijboer, H., van den, O.A., Klijn, J., Wasielewski, M., de Snoo, A., Oldenburg, R., 
Hollestelle, A., Houben, M., Crepin, E., Veghel-Plandsoen, M., Elstrodt, F., van Duijn, C., Bartels, 
C., Meijers, C., Schutte, M., McGuffog, L., Thompson, D., Easton, D., Sodha, N., Seal, S., 
Barfoot, R., Mangion, J., Chang-Claude, J., Eccles, D., Eeles, R., Evans, D.G., Houlston, R., 
Murday, V., Narod, S., Peretz, T., Peto, J., Phelan, C., Zhang, H.X., Szabo, C., Devilee, P., 
Goldgar, D., Futreal, P.A., Nathanson, K.L., Weber, B., Rahman, N., Stratton, M.R. Low-
penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or 
BRCA2 mutations. Nat Genet 2002; 31: 55-59. 
35 
1. General Introduction 
20.  Vahteristo, P., Bartkova, J., Eerola, H., Syrjakoski, K., Ojala, S., Kilpivaara, O., 
Tamminen, A., Kononen, J., Aittomaki, K., Heikkila, P., Holli, K., Blomqvist, C., Bartek, J., 
Kallioniemi, O.P., Nevanlinna, H. A CHEK2 genetic variant contributing to a substantial fraction of 
familial breast cancer. Am J Hum Genet 2002; 71: 432-438. 
21.  Mitrunen, K., Hirvonen, A. Molecular epidemiology of sporadic breast cancer. The role of 
polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutat Res 2003; 544: 9-
41. 
22.  Fu, Y.P., Yu, J.C., Cheng, T.C., Lou, M.A., Hsu, G.C., Wu, C.Y., Chen, S.T., Wu, H.S., Wu, 
P.E., Shen, C.Y. Breast cancer risk associated with genotypic polymorphism of the 
nonhomologous end-joining genes: a multigenic study on cancer susceptibility. Cancer Res 2003; 
63: 2440-2446. 
23.  Han, J., Hankinson, S.E., Ranu, H., De, V., I, Hunter, D.J. Polymorphisms in DNA double-
strand break repair genes and breast cancer risk in the Nurses' Health Study. Carcinogenesis 
2004; 25: 189-195. 
24.  Weiss, J.M., Goode, E.L., Ladiges, W.C., Ulrich, C.M. Polymorphic variation in hOGG1 
and risk of cancer: a review of the functional and epidemiologic literature. Mol Carcinog 2005; 
42: 127-141. 
25.  Zhang, Y., Newcomb, P.A., Egan, K.M., Titus-Ernstoff, L., Chanock, S., Welch, R., 
Brinton, L.A., Lissowska, J., Bardin-Mikolajczak, A., Peplonska, B., Szeszenia-Dabrowska, N., 
Zatonski, W., Garcia-Closas, M. Genetic polymorphisms in base-excision repair pathway genes 
and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 353-358. 
26.  Schneider, H.P., Böcker, W. Hormones and progeny of breast tumor cells. Climacteric 
2006; 9: 88-107. 
27.  Perou, C.M., Sorlie, T., Eisen, M.B., van de, R.M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., 
Ross, D.T., Johnsen, H., Akslen, L.A., Fluge, O., Pergamenschikov, A., Williams, C., Zhu, S.X., 
Lonning, P.E., Borresen-Dale, A.L., Brown, P.O., Botstein, D. Molecular portraits of human breast 
tumours. Nature 2000; 406: 747-752. 
 36 
1.3. References 
28.  Stoler, D.L., Chen, N., Basik, M., Kahlenberg, M.S., Rodriguez_Bigas, M.A., Petrelli, N.J., 
Anderson, G.R. The onset and extent of genomic instability in sporadic colorectal tumor 
progression. Proc Natl Acad Sci U S A 1999; 96: 15121-15126. 
29.  Lijovic, M., Frauman, A.G. Toward an understanding of the molecular genetics of 
prostate cancer progression. J Environ Pathol Toxicol Oncol 2003; 22: 1-15. 
30.  Fearon, E.R., Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 
759-767. 
31.  Rubin, H. The role of selection in progressive neoplastic transformation. Adv Cancer Res 
2001; 83: 159-207. 
32.  Kenemans, P., Verstraeten, R.A., Verheijen, R.H. Oncogenic pathways in hereditary and 
sporadic breast cancer. Maturitas 2004; 49: 34-43. 
33.  Beckmann, M.W., Niederacher, D., Schnurch, H.G., Gusterson, B.A., Bender, H.G. 
Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med 1997; 75: 429-
439. 
34.  Yager, J.D. Endogenous estrogens as carcinogens through metabolic activation. J Natl 
Cancer Inst Monogr 2000; 67-73. 
35.  Yager, J.D., Davidson, N.E. Estrogen carcinogenesis in breast cancer. N Engl J Med 
2006; 354: 270-282. 
36.  Platet, N., Cathiard, A.M., Gleizes, M., Garcia, M. Estrogens and their receptors in breast 
cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 
2004; 51: 55-67. 
37.  Dickson, R.B., Stancel, G.M. Estrogen Receptor-Mediated Processes in Normal and 
Cancer Cells. J Natl Cancer Inst Monographs 2000; 27: 135-145. 
38.  Caristi, S., Galera, J.L., Matarese, F., Imai, M., Caporali, S., Cancemi, M., Altucci, L., 
Cicatiello, L., Teti, D., Bresciani, F., Weisz, A. Estrogens do not modify MAP kinase-dependent 
37 
1. General Introduction 
nuclear signaling during stimulation of early G(1) progression in human breast cancer cells. 
Cancer Research 2001; 61: 6360-6366. 
39.  Cavalieri, E., Rogan, E. A unifying mechanism in the initiation of cancer and other 
diseases by catechol quinones. Ann N Y Acad Sci 2004; 1028: 247-257. 
40.  Castagnetta, L., Granata, O.M., Cocciadiferro, L., Saetta, A., Polito, L., Bronte, G., Rizzo, 
S., Campisi, I., Agostara, B., Carruba, G. Sex steroids, carcinogenesis, and cancer progression. 
Ann N Y Acad Sci 2004; 1028: 233-246. 
41.  Cavalieri, E., Frenkel, K., Liehr, J.G., Rogan, E., Roy, D. Estrogens as endogenous 
genotoxic agents--DNA adducts and mutations. J Natl Cancer Inst Monogr 2000; 27: 75-93. 
42.  Gorlewska-Roberts, K., Green, B., Fares, M., Ambrosone, C.B., Kadlubar, F.F. 
Carcinogen-DNA adducts in human breast epithelial cells. Environ Mol Mutagen 2002; 39: 184-
192. 
43.  Phillips, D.H., Martin, F.L., Williams, J.A., Wheat, L.M., Nolan, L., Cole, K.J., Grover, P.L. 
Mutagens in human breast lipid and milk: the search for environmental agents that initiate breast 
cancer. Environ Mol Mutagen 2002; 39: 143-149. 
44.  Wogan, G.N., Hecht, S.S., Felton, J.S., Conney, A.H., Loeb, L.A. Environmental and 
chemical carcinogenesis. Semin Cancer Biol 2004; 14: 473-486. 
45.  Patel, R.K., Trivedi, A.H., Arora, D.C., Bhatavdekar, J.M., Patel, D.D. DNA repair 
proficiency in breast cancer patients and their first-degree relatives. Int J Cancer 1997; 73: 20-
24. 
46.  Alapetite, C., Thirion, P., de la, R.A., Cosset, J.M., Moustacchi, E. Analysis by alkaline 
comet assay of cancer patients with severe reactions to radiotherapy: defective rejoining of 
radioinduced DNA strand breaks in lymphocytes of breast cancer patients. Int J Cancer 1999; 
83: 83-90. 
47.  Buchholz, T.A., Wu, X. Radiation-induced chromatid breaks as a predictor of breast 
cancer risk. Int J Radiat Oncol Biol Phys 2001; 49: 533-537. 
 38 
1.3. References 
48.  Smith, T.R., Miller, M.S., Lohman, K.K., Case, L.D., Hu, J.J. DNA damage and breast 
cancer risk. Carcinogenesis 2003; 24: 883-889. 
49.  Jyothish, B., Ankathil, R., Chandini, R., Vinodkumar, B., Nayar, G.S., Roy, D.D., 
Madhavan, J., Nair, M.K. DNA repair proficiency: a potential marker for identification of high risk 
members in breast cancer families. Cancer Lett 1998; 124: 9-13. 
50.  Rajeswari, N., Ahuja, Y.R., Malini, U., Chandrashekar, S., Balakrishna, N., Rao, K.V., 
Khar, A. Risk assessment in first degree female relatives of breast cancer patients using the 
alkaline Comet assay. Carcinogenesis 2000; 21: 557-561. 
51.  Blasiak, J., Arabski, M., Krupa, R., Wozniak, K., Rykala, J., Kolacinska, A., Morawiec, Z., 
Drzewoski, J., Zadrozny, M. Basal, oxidative and alkylative DNA damage, DNA repair efficacy and 
mutagen sensitivity in breast cancer. Mutat Res 2004; 554: 139-148. 
52.  Rundle, A., Tang, D., Hibshoosh, H., Estabrook, A., Schnabel, F., Cao, W., Grumet, S., 
Perera, F.P. The relationship between genetic damage from polycyclic aromatic hydrocarbons in 
breast tissue and breast cancer. Carcinogenesis 2000; 21: 1281-1289. 
53.  Adami, H.O., Persson, I., Ekbom, A., Wolk, A., Pontén, J., Trichopoulos, D. The aetiology 
and pathogenesis of human breast cancer. Mutat Res 1995; 333: 29-35. 
54.  Dontu, G., Liu, S., Wicha, M.S. Stem cells in mammary development and carcinogenesis. 
Stem Cell Rev 2005; 1: 207-213. 
55.  Trichopoulos, D., Lagiou, P., Adami, H.O. Towards an integrated model for breast cancer 
etiology - The crucial role of the number of mammary tissue-specific stem cells. Breast Cancer 
Research 2005; 7: 13-17. 
56.  Chakravarti, A. It's raining SNPs, hallelujah? Nature Genetics 1998; 19: 216-217. 
57.  Collins, F.S., Guyer, M.S., Chakravarti, A. Variations on a theme: Cataloging human DNA 
sequence variation. Science 1997; 278: 1580-1581. 
39 
1. General Introduction 
58.  Nathanson, K.L., Weber, B.L. "Other" breast cancer susceptibility genes: searching for 
more holy grail. Hum Mol Genet 2001; 10: 715-720. 
59.  Lymberis, S.C., Parhar, P.K., Katsoulakis, E., Formenti, S.C. Pharmacogenomics and 
breast cancer. Pharmacogenomics 2004; 5: 31-55. 
60.  Pinto, D., Vasconcelos, A., Costa, S., Pereira, D., Rodrigues, H., Lopes, C., Medeiros, R. 
HER2 polymorphism and breast cancer risk in Portugal. Eur J Cancer Prev 2004; 13: 177-181. 
61.  Coughlin, S.S., Piper, M. Genetic polymorphisms and risk of breast cancer. Cancer 
Epidemiology Biomarkers & Prevention 1999; 8: 1023-1032. 
62.  Dunning, A.M., Healey, C.S., Pharoah, P.D.P., Teare, M.D., Ponder, B.A.J., Easton, D.F. 
A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiology 
Biomarkers & Prevention 1999; 8: 843-854. 
63.  Fletcher, O., Gibson, L., Johnson, N., Altmann, D.R., Holly, J.M.P., Ashworth, A., Peto, J., 
Silva, I.D. Polymorphisms and circulating levels in the insulin-like growth factor system and risk of 
breast cancer: A systematic review. Cancer Epidemiology Biomarkers & Prevention 2005; 14: 2-
19. 
64.  Vogl, F.D., Taioli, E., Maugard, C., Zheng, W., Pinto, L.F.R., Ambrosone, C., Parl, F.F., 
Nedelcheva-Kristensen, V., Rebbeck, T.R., Brennan, P., Boffetta, P. Glutathione S-transferases 
M1, T1, and P1 and breast cancer: A pooled analysis. Cancer Epidemiology Biomarkers & 
Prevention 2004; 13: 1473-1479. 
65.  Setiawan, V.W., Cheng, I., Stram, D.O., Giorgi, E., Pike, M.C., van den, B.D., Pooler, L., 
Burtt, N.P., Marchand, L.L., Altshuler, D., Hirschhorn, J.N., Henderson, B.E., Haiman, C.A. A 
Systematic Assessment of Common Genetic Variation in CYP11A and Risk of Breast Cancer. 
Cancer Res 2006; 66: 12019-12025. 
66.  Gaudet, M.M., Chanock, S., Lissowska, J., Berndt, S.I., Peplonska, B., Brinton, L.A., 
Welch, R., Yeager, M., Bardin-Mikolajczak, A., Garcia-Closas, M. Comprehensive Assessment of 
 40 
1.3. References 
Genetic Variation of Catechol-O-Methyltransferase and Breast Cancer Risk. Cancer Res 2006; 66: 
9781-9785. 
67.  Chen, C., Huang, Y., Li, Y., Mao, Y., Xie, Y. Cytochrome P450 1A1 (CYP1A1) T3801C 
and A2455G polymorphisms in breast cancer risk: a meta-analysis. J Hum Genet 2007; 52: 423-
435. 
68.  Wagner, K., Hemminki, K., Forsti, A. The GH1/IGF-1 axis polymorphisms and their 
impact on breast cancer development. Breast Cancer Res Treat 2007; -10.1007/s10549-006-
9411-9. 
69.  Hu, Z., Song, C.-G., Lu, J.-S., Luo, J.-M., Shen, Z.-Z., Huang, W., Shao, Z.-M. A multigenic 
study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and 
CYP19 in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected 
relatives. J Cancer Res Clin Oncol 2007; 10.1007/s00432-007-0244-7: -10.1007/s00432-007-
0244-7. 
70.  González-Zuloeta, A.M., Vásquez, A.A., Rivadeneira, F., Siemes, C., Hofman, A., Stricker, 
B.H., Pols, H.A., Uitterlinden, A.G., Duijn, C.M. Estrogen receptor alpha polymorphisms and 
postmenopausal breast cancer risk. Breast Cancer Res Treat 2007; -10.1007/s10549-007-
9562-3. 
71.  Wang, J., Higuchi, R., Modugno, F., Li, J., Umblas, N., Lee, J., Lui, L.-Y., Ziv, E., Tice, 
J.A., Cummings, S.R., Rhees, B. Estrogen recpetor alpha haplotypes and breast cancer risk in 
older Caucasian women. Breast Cancer Res Treat 2007; -10.1007/s10549-007-9497-8. 
72.  Fernandez, L.P., Milne, R.L., Barroso, E., Cuadros, M., Arias, J.I., Ruibal, A., Benitez, J., 
Ribas, G. Estrogen and progesterone receptor gene polymorphisms and sporadic breast cancer 
risk: a Spanish case-control study. International Journal of Cancer 2006; 119: 467-471. 
73.  Johnatty, S.E., Spurdle, A.B., Beesley, J., Chen, X., Hopper, J.L., Du, Q., Duffy, D.L., 
Chenevix-Trench, G. Progesterone receptor polymorphisms and risk of breast cancer: results 
from two Australina breast cancer studies. Breast Cancer Res Treat 2007; -DOI 
10.1007/s10549-007-9627-3. 
41 
1. General Introduction 
74.  Ralph, D.A., Zhao, L.P., Aston, C.E., Manjeshwar, S., Pugh, T.W., DeFreese, D.C., 
Gramling, B.A., Shimasaki, C.D., Jupe, E.R. Age-specific Association of Steroid Hormone Pathway 
Gene Polymorphisms With Breast Cancer Risk. Cancer 2007; 109: 1940-1948. 
75.  Wirtenberger, M., Tchatchou, S., Hemminki, K., Schmutzhard, J., Sutter, C., Schmutzler, 
R.K., Meindl, A., Wappenschmidt, B., Kiechle, M., Arnold, N., Weber, B.H.F., Niederacher, D., 
Bartram, C.R., Burwinkel, B. Associations of genetic variants in the estrogen receptor coactivators 
PPARGC1A, PPARGC1B and EP300 with familial breast cancer. Carcinogenesis 2006; 27: 2201-
2208. 
76.  Justenhoven, C., Hamann, U., Schubert, F., Zapatka, M., Pierl, C.B., Rabstein, S., 
Selinski, S., Mueller, T., Ickstadt, K., Gilbert, M., Ko, Y.-D., Baisch, C., Illig, T., Eils, R., Dippon, J., 
Brauch, H. Breast cancer: a candidate gene approach across the estrogen metabolic pathway. 
Breast Cancer Res Treat 2007; -10.1007/s10549-007-9586-8. 
77.  Jansson, A., Carlsson, J., Olsson, A., Storm, P., Margolin, S., Gunnarsson, C., Srenmark-
Askmalm, M., Lindblom, A., Persson, B., Stal, O. A new polymorphism in the coding region of 
exon four in HSD17B2 in relation to risk of sporadic and hereditary breast cancer. Breast Cancer 
Res Treat 2007; -10.1007/s10549-006-9477-4. 
78.  Spurdle, A.B., Chang, J.-H., Byrnes, G.B., Chen, X., Dite, G.S., McCredie, M., Giles, G.G., 
Southey, M.C., Chenevix-Trench, G., Hopper, J.L. A Systematic Approach to Analysing Gene-Gene 
Interactions: Polymorphisms at the Microsomal Epoxide Hydrolase EPHX and Glutathione S-
transferase GSTM1, GSTT1, and GSTP1 Loci and Breast Cancer Risk. Cancer Epidemiol 
Biomarkers Prev 2007; 16: 769-774. 
79.  Crick, F. Double Helix - A Personal View. Nature 1974; 248: 766-769. 
80.  Johnson-Thompson, M.C., Guthrie, J. Ongoing research to identify environmental risk 
factors in breast carcinoma. Cancer 2000; 88: 1224-1229. 
81.  Hoeijmakers, J.H. Genome maintenance mechanisms for preventing cancer. Nature 
2001; 411: 366-374. 
 42 
1.3. References 
82.  de Boer, J., Hoeijmakers, J.H. Nucleotide excision repair and human syndromes. 
Carcinogenesis 2000; 21: 453-460. 
83.  Heinen, C.D., Schmutte, H., Fishel, R. DNA repair and tumorigenesis - Lessons from 
hereditary cancer syndromes. Cancer Biology & Therapy 2002; 1: 477-485. 
84.  Chung, D.C., Rustgi, A.K. The hereditary nonpolyposis colorectal cancer syndrome: 
Genetics and clinical implications. Ann Intern Med 2003; 138: 560-570. 
85.  Narod, S.A., Foulkes, W.D. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 
2004; 4: 665-676. 
86.  Nevanlinna, H., Bartek, J. The CHEK2 gene and inherited breast cancer susceptibility. 
Oncogene 2006; 25: 5912-5919. 
87.  Gudmundsdottir, K., Ashworth, A. The roles of BRCA1 and BRCA2 and associated 
proteins in the maintenance of genomic stability. Oncogene 2006; 25: 5864-5874. 
88.  Taniguchi, T., D'Andrea, A.D. Molecular pathogenesis of Fanconi anemia: recent 
progress. Blood 2006; 107: 4223-4233. 
89.  Mathew, C.G. Fanconi anaemia genes and susceptibility to cancer. Oncogene 2006; 25: 
5875-5884. 
90.  Taylor, A.M.R., Byrd, P.J. Molecular pathology of ataxia telangiectasia. J Clin Pathol 
2005; 58: 1009-1015. 
91.  Varley, J.M., Evans, D.G.R., Birch, J.M. Li-Fraumeni syndrome - A molecular and clinical 
review. Br J Cancer 1997; 76: 1-14. 
92.  Ellis, N.A., German, J. Molecular genetics of Bloom's syndrome. Hum Mol Genet 1996; 
5: 1457-1463. 
93.  Ostler, E.L., Wallis, C.V., Sheerin, A.N., Faragher, R.G.A. A model for the phenotypic 
presentation of Werner's syndrome. Exp Gerontol 2002; 37: 285-292. 
43 
1. General Introduction 
94.  Iijima, K., Komatsu, K., Matsuura, S., Tauchi, H. The Nijmegen breakage syndrome gene 
and its role in genome stability. Chromosoma 2004; 113: 53-61. 
95.  Ronen, A., Glickman, B.W. Human DNA repair genes. Environ Mol Mutagen 2001; 37: 
241-283. 
96.  Yu, Z., Chen, J., Ford, B.N., Brackley, M.E., Glickman, B.W. Human DNA repair systems: 
an overview. Environ Mol Mutagen 1999; 33: 3-20. 
97.  Christmann, M., Tomicic, M.T., Roos, W.P., Kaina, B. Mechanisms of human DNA repair: 
an update. Toxicology 2003; 193: 3-34. 
98.  Zhou, B.B., Elledge, S.J. The DNA damage response: putting checkpoints in perspective. 
Nature 2000; 408: 433-439. 
99.  Khanna, K.K., Jackson, S.P. DNA double-strand breaks: signaling, repair and the cancer 
connection. Nat Genet 2001; 27: 247-254. 
100. Li, L., Zou, L. Sensing, signaling, and responding to DNA damage: organization of the 
checkpoint pathways in mammalian cells. J Cell Biochem 2005; 94: 298-306. 
101. Kastan, M.B., Bartek, J. Cell-cycle checkpoints and cancer. Nature 2004; 432: 316-323. 
102. Fortini, P., Pascucci, B., Parlanti, E., D'Errico, M., Simonelli, V., Dogliotti, E. The base 
excision repair: mechanisms and its relevance for cancer susceptibility. Biochimie 2003; 85: 
1053-1071. 
103. Scharer, O.D. Chemistry and biology of DNA repair. Angew Chem Int Ed Engl 2003; 42: 
2946-2974. 
104. Friedberg, E.C. How nucleotide excision repair protects against cancer. Nat Rev Cancer 
2001; 1: 22-33. 
105. Hanawalt, P.C. Subpathways of nucleotide excision repair and their regulation. 
Oncogene 2002; 21: 8949-8956. 
 44 
1.3. References 
106. Yoshida, K., Miki, Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, 
transcription, and cell cycle in response to DNA damage. Cancer Sci 2004; 95: 866-871. 
107. Masson, J.Y., Tarsounas, M.C., Stasiak, A.Z., Stasiak, A., Shah, R., McIlwraith, M.J., 
Benson, F.E., West, S.C. Identification and purification of two distinct complexes containing the 
five RAD51 paralogs. Genes Dev 2001; 15: 3296-3307. 
108. Constantinou, A., Davies, A.A., West, S.C. Branch migration and Holliday junction 
resolution catalyzed by activities from mammalian cells. Cell 2001; 104: 259-268. 
109. Critchlow, S.E., Jackson, S.P. DNA end-joining: from yeast to man. Trends Biochem Sci 
1998; 23: 394-398. 
110. Kuschel, B., Auranen, A., McBride, S., Novik, K.L., Antoniou, A., Lipscombe, J.M., Day, 
N.E., Easton, D.F., Ponder, B.A., Pharoah, P.D., Dunning, A. Variants in DNA double-strand break 
repair genes and breast cancer susceptibility. Hum Mol Genet 2002; 11: 1399-1407. 
111. Shen, M.R., Jones, I.M., Mohrenweiser, H. Nonconservative amino acid substitution 
variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 
1998; 58: 604-608. 
112. Mohrenweiser, H.W., Xi, T., Vazquez-Matias, J., Jones, I.M. Identification of 127 amino 
acid substitution variants in screening 37 DNA repair genes in humans. Cancer Epidemiol 
Biomarkers Prev 2002; 11: 1054-1064. 
113. Rosenberg, N.A., Pritchard, J.K., Weber, J.L., Cann, H.M., Kidd, K.K., Zhivotovsky, L.A., 
Feldman, M.W. Genetic structure of human populations. Science 2002; 298: 2381-2385. 
114. Mathonnet, G., Labuda, D., Meloche, C., Wambach, T., Krajinovic, M., Sinnett, D. 
Variable continental distribution of polymorphisms in the coding regions of DNA-repair genes. J 
Hum Genet 2003; 48: 659-664. 
115. Vogel, U., Nexo, B.A., Olsen, A., Thomsen, B., Jacobsen, N.R., Wallin, H., Overvad, K., 
Tjonneland, A. No association between OGG1 Ser326Cys polymorphism and breast cancer risk. 
Cancer Epidemiol Biomarkers Prev 2003; 12: 170-171. 
45 
1. General Introduction 
116. Choi, J.Y., Hamajima, N., Tajima, K., Yoo, K.Y., Yoon, K.S., Park, S.K., Kim, S.U., Lee, 
K.M., Noh, D.Y., Ahn, S.H., Choe, K.J., Han, W., Hirvonen, A., Kang, D. hOGG1 Ser326Cys 
polymorphism and breast cancer risk among Asian women. Breast Cancer Res Treat 2003; 79: 
59-62. 
117. Moullan, N., Cox, D.G., Angele, S., Romestaing, P., Gerard, J.P., Hall, J. Polymorphisms 
in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy. Cancer 
Epidemiol Biomarkers Prev 2003; 12: 1168-1174. 
118. Smith, T.R., Miller, M.S., Lohman, K., Lange, E.M., Case, L.D., Mohrenweiser, H.W., Hu, 
J.J. Polymorphisms of XRCC1 and XRCC3 genes and susceptibility to breast cancer. Cancer Lett 
2003; 190: 183-190. 
119. Smith, T.R., Levine, E.A., Perrier, N.D., Miller, M.S., Freimanis, R.I., Lohman, K., Case, 
L.D., Xu, J., Mohrenweiser, H.W., Hu, J.J. DNA-repair genetic polymorphisms and breast cancer 
risk. Cancer Epidemiol Biomarkers Prev 2003; 12: 1200-1204. 
120. Shu, X.O., Cai, Q., Gao, Y.T., Wen, W., Jin, F., Zheng, W. A Population-Based Case-
Control Study of the Arg399Gln Polymorphism in DNA Repair Gene XRCC1 and Risk of Breast 
Cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 1462-1467. 
121. Han, J., Hankinson, S.E., De, V., I, Spiegelman, D., Tamimi, R.M., Mohrenweiser, H.W., 
Colditz, G.A., Hunter, D.J. A prospective study of XRCC1 haplotypes and their interaction with 
plasma carotenoids on breast cancer risk. Cancer Res 2003; 63: 8536-8541. 
122. Forsti, A., Angelini, S., Festa, F., Sanyal, S., Zhang, Z., Grzybowska, E., Pamula, J., 
Pekala, W., Zientek, H., Hemminki, K., Kumar, R. Single nucleotide polymorphisms in breast 
cancer. Oncol Rep 2004; 11: 917-922. 
123. Figueiredo, J.C., Knight, J.A., Briollais, L., Andrulis, I.L., Ozcelik, H. Polymorphisms 
XRCC1-R399Q and XRCC3-T241M and the risk of breast cancer at the Ontario site of the Breast 
Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 2004; 13: 583-591. 
 46 
1.3. References 
124. Deligezer, U., Dalay, N. Association of the XRCC1 gene polymorphisms with cancer risk 
in Turkish breast cancer patients. Exp Mol Med 2004; 36: 572-575. 
125. Chacko, P., Rajan, B., Joseph, T., Mathew, B.S., Radhakrishna, P.M. Polymorphisms in 
DNA repair gene XRCC1 and increased genetic susceptibility to breast cancer. Breast Cancer Res 
Treat 2005; 89: 15-21. 
126. Shen, J., Gammon, M.D., Terry, M.B., Wang, L., Wang, Q., Zhang, F., Teitelbaum, S.L., 
Eng, S.M., Sagiv, S.K., Gaudet, M.M., Neugut, A.I., Santella, R.M. Polymorphisms in XRCC1 
modify the association between polycyclic aromatic hydrocarbon-DNA adducts, cigarette smoking, 
dietary antioxidants, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005; 14: 336-
342. 
127. Sliwinski, T., Ziemba, P., Morawiec, Z., Kowalski, M., Zadrozny, M., Blasiak, J. 
Polymorphisms of the DNA polymerase ß gene in breast cancer. Breast Cancer Res Treat 2007; 
103: 161-166. 
128. Zhang, L., Zhang, Z., Yan, W. Single nucleotide polymorphisms for DNA repair genes in 
breast cancer patients. Clin Chim Acta 2005; 359: 150-155. 
129. Kumar, R., Hoglund, L., Zhao, C., Forsti, A., Snellman, E., Hemminki, K. Single 
nucleotide polymorphisms in the XPG gene: determination of role in DNA repair and breast 
cancer risk. Int J Cancer 2003; 103: 671-675. 
130. Shi, Q., Wang, L.E., Bondy, M.L., Brewster, A., Singletary, S.E., Wei, Q. Reduced DNA 
repair of benzo(a)pyrene diol epoxide-induced adducts and common XPD polymorphisms in 
breast cancer patients. Carcinogenesis 2004. 
131. Justenhoven, C., Hamann, U., Pesch, B., Harth, V., Rabstein, S., Baisch, C., Vollmert, 
C., Illig, T., Ko, Y.D., Bruning, T., Brauch, H. ERCC2 Genotypes and a Corresponding Haplotype 
Are Linked with Breast Cancer Risk in a German Population. Cancer Epidemiol Biomarkers Prev 
2004; 13: 2059-2064. 
47 
1. General Introduction 
132. Terry, M.B., Gammon, M.D., Zhang, F.F., Eng, S.M., Sagiv, S.K., Paykin, A.B., Wang, Q., 
Hayes, S., Teitelbaum, S.L., Neugut, A.I., Santella, R.M. Polymorphism in the DNA Repair Gene 
XPD, Polycyclic Aromatic Hydrocarbon-DNA Adducts, Cigarette Smoking, and Breast Cancer Risk. 
Cancer Epidemiol Biomarkers Prev 2004; 13: 2053-2058. 
133. Lee, S.A., Lee, K.M., Park, W.Y., Kim, B., Nam, J., Yoo, K.Y., Noh, D.Y., Ahn, S.H., 
Hirvonen, A., Kang, D. Obesity and genetic polymorphism of ERCC2 and ERCC4 as modifiers of 
risk of breast cancer. Exp Mol Med 2005; 37: 86-90. 
134. Kuschel, B., Chenevix-Trench, G., Spurdle, A.B., Chen, X., Hopper, J.L., Giles, G.G., 
McCredie, M., Chang-Claude, J., Gregory, C.S., Day, N.E., Easton, D.F., Ponder, B.A., Dunning, 
A.M., Pharoah, P.D. Common polymorphisms in ERCC2 (Xeroderma pigmentosum D) are not 
associated with breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005; 14: 1828-1831. 
135. Lee, K.M., Choi, J.Y., Kang, C., Kang, C.P., Park, S.K., Cho, H., Cho, D.Y., Yoo, K.Y., 
Noh, D.Y., Ahn, S.H., Park, C.G., Wei, Q., Kang, D. Genetic polymorphisms of selected DNA 
repair genes, estrogen and progesterone receptor status, and breast cancer risk. Clin Cancer Res 
2005; 11: 4620-4626. 
136. Webb, P.M., Hopper, J.L., Newman, B., Chen, X., Kelemen, L., Giles, G.G., Southey, 
M.C., Chenevix-Trench, G., Spurdle, A.B. Double-strand break repair gene polymorphisms and 
risk of breast or ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 319-323. 
137. Ishitobi, M., Miyoshi, Y., Ando, A., Hasegawa, S., Egawa, C., Tamaki, Y., Monden, M., 
Noguchi, S. Association of BRCA2 polymorphism at codon 784 (Met/Val) with breast cancer risk 
and prognosis. Clin Cancer Res 2003; 9: 1376-1380. 
138. Gorski, B., Narod, S.A., Lubinski, J. A common missense variant in BRCA2 predisposes 
to early onset breast cancer. Breast Cancer Res 2005; 7: R1023-R1027. 
139. Angele, S., Romestaing, P., Moullan, N., Vuillaume, M., Chapot, B., Friesen, M., 
Jongmans, W., Cox, D.G., Pisani, P., Gerard, J.P., Hall, J. ATM haplotypes and cellular response 
to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res 
2003; 63: 8717-8725. 
 48 
1.3. References 
140. Lee, K.M., Choi, J.Y., Park, S.K., Chung, H.W., Ahn, B., Yoo, K.Y., Han, W., Noh, D.Y., 
Ahn, S.H., Kim, H., Wei, Q., Kang, D. Genetic polymorphisms of ataxia telangiectasia mutated 
and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005; 14: 821-825. 
141. Wang-Gohrke, S., Becher, H., Kreienberg, R., Runnebaum, I.B., Chang-Claude, J. Intron 
3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer 
by the age of 50 years. Pharmacogenetics 2002; 12: 269-272. 
142.  Huang, X.E., Hamajima, N., Katsuda, N., Matsuo, K., Hirose, K., Mizutani, M., 
Iwata, H., Miura, S., Xiang, J., Tokudome, S., Tajima, K. Association of p53 codon Arg72Pro and 
p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. 
Breast Cancer 2003; 10: 307-311. 
143. Cox, D.G., Deer, D., Guo, Q., Tworoger, S.S., Hankinson, S.E., Hunter, D.J., De Vivo, I. 
The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses' 
health studies. Cancer Causes Control 2007; 18: 621-625. 
144. Izumi, T., Wiederhold, L.R., Roy, G., Roy, R., Jaiswal, A., Bhakat, K.K., Mitra, S., Hazra, 
T.K. Mammalian DNA base excision repair proteins: their interactions and role in repair of 
oxidative DNA damage. Toxicology 2003; 193: 43-65. 
145. Hung, R.J., Hall, J., Brennan, P., Boffetta, P. Genetic Polymorphisms in the Base 
Excision Repair Pathway and Cancer Risk: A HuGE Review. Am J Epidemiol 2005; 162: 925-942. 
146. Callebaut, I., Mornon, J.P. From BRCA1 to RAP1: a widespread BRCT module closely 
associated with DNA repair. FEBS Lett 1997; 400: 25-30. 
147. Clarkson, S.G., Wood, R.D. Polymorphisms in the human XPD (ERCC2) gene, DNA 
repair capacity and cancer susceptibility: An appraisal. DNA Repair (Amst) 2005; 4: 1068-1074. 
148. Benhamou, S., Sarasin, A. ERCC2 /XPD gene polymorphisms and lung cancer: a HuGE 
review. Am J Epidemiol 2005; 161: 1-14. 
49 
1. General Introduction 
149. Seker, H., Butkiewicz, D., Bowman, E.D., Rusin, M., Hedayati, M., Grossman, L., Harris, 
C.C. Functional significance of XPD polymorphic variants: attenuated apoptosis in human 
lymphoblastoid cells with the XPD 312 Asp/Asp genotype. Cancer Res 2001; 61: 7430-7434. 
150. Qiao, Y., Spitz, M.R., Shen, H., Guo, Z., Shete, S., Hedayati, M., Grossman, L., 
Mohrenweiser, H., Wei, Q. Modulation of repair of ultraviolet damage in the host-cell reactivation 
assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis 2002; 23: 295-299. 
151. Au, W.W., Salama, S.A., Sierra-Torres, C.H. Functional characterization of 
polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 
2003; 111: 1843-1850. 
152. Coin, F., Marinoni, J.C., Rodolfo, C., Fribourg, S., Pedrini, A.M., Egly, J.M. Mutations in 
the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and 
the p44 subunit of TFIIH. Nat Genet 1998; 20: 184-188. 
153. Thompson, L.H., Schild, D. Homologous recombinational repair of DNA ensures 
mammalian chromossome stability. Mutat Res 2001; 477: 131-153. 
154. Daboussi, F., Dumay, A., Delacote, F., Lopez, B.S. DNA double-strand break repair 
signalling: the case of RAD51 post-translational regulation. Cell Signal 2002; 14: 969-975. 
155. Levy-Lahad, E., Lahad, A., Eisenberg, S., Dagan, E., Paperna, T., Kasinetz, L., Catane, 
R., Kaufman, B., Beller, U., Renbaum, P., Gershoni-Baruch, R. A single nucleotide polymorphism 
in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci U 
S A 2001; 98: 3232-3236. 
156. Wang, W.W., Spurdle, A.B., Kolachana, P., Bove, B., Modan, B., Ebbers, S.M., Suthers, 
G., Tucker, M.A., Kaufman, D.J., Doody, M.M., Tarone, R.E., Daly, M., Levavi, H., Pierce, H., 
Chetrit, A., Yechezkel, G.H., Chenevix-Trench, G., Offit, K., Godwin, A.K., Struewing, J.P. A single 
nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among 
BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2001; 10: 955-960. 
 50 
1.3. References 
157. Jackson, S.P. Sensing and repairing DNA double-strand breaks. Carcinogenesis 2002; 
23: 687-696. 
158. Matullo, G., Palli, D., Peluso, M., Guarrera, S., Carturan, S., Celentano, E., Krogh, V., 
Munnia, A., Tumino, R., Polidoro, S., Piazza, A., Vineis, P. XRCC1, XRCC3, XPD gene 
polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. 
Carcinogenesis 2001; 22: 1437-1445. 
159. Lindh, A.R., Rafii, S., Schultz, N., Cox, A., Helleday, T. Mitotic defects in XRCC3 variants 
T241M and D213N and their relation to cancer susceptibility. Hum Mol Genet 2006; 15: 1217-
1224. 
160. Costa, S., Pinto, D., Pereira, D., Rodrigues, H., Cameselle-Teijeiro, J., Medeiros, R., 
Schmitt, F. DNA repair polymorphisms might contribute differentially on familial and sporadic 
breast cancer susceptibility: a study on a Portuguese population. Breast Cancer Res Treat 2007; 
103: 209-217. 
161. Feki, A., Irminger-Finger, I. Mutational spectrum of p53 mutations in primary breast and 
ovarian tumors. Crit Rev Oncol Hematol 2004; 52: 103-116. 
162. Xu, Y., Yao, L., Ouyang, T., Li, J., Wang, T., Fan, Z., Lin, B., Lu, Y., Xie, Y. p53 Codon 72 
polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with 
breast cancer. Clin Cancer Res 2005; 11: 7328-7333. 
163. Tommiska, J., Eerola, H., Heinonen, M., Salonen, L., Kaare, M., Tallila, J., Ristimaki, A., 
von, S.K., Aittomaki, K., Heikkila, P., Blomqvist, C., Nevanlinna, H. Breast cancer patients with 
p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 2005; 11: 5098-5103. 
164. Olivier, M., Eeles, R., Hollstein, M., Khan, M.A., Harris, C.C., Hainaut, P. The IARC TP53 
database: new online mutation analysis and recommendations to users. Hum Mutat 2002; 19: 
607-614. 
165. Pietsch, E.C., Humbey, O., Murphy, M.E. Polymorphisms in the p53 pathway. Oncogene 
2006; 25: 1602-1611. 
51 
1. General Introduction 
166. Gemignani, F., Moreno, V., Landi, S., Moullan, N., Chabrier, A., Gutierrez-Enriquez, S., 
Hall, J., Guino, E., Peinado, M.A., Capella, G., Canzian, F. A TP53 polymorphism is associated 
with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 2004; 
23: 1954-1956. 
167. Weston, A., Pan, C.F., Ksieski, H.B., Wallenstein, S., Berkowitz, G.S., Tartter, P.I., 
Bleiweiss, I.J., Brower, S.T., Senie, R.T., Wolff, M.S. p53 haplotype determination in breast 
cancer. Cancer Epidemiol Biomarkers Prev 1997; 6: 105-112. 
168. Wang-Gohrke, S., Rebbeck, T.R., Besenfelder, W., Kreienberg, R., Runnebaum, I.B. p53 
germline polymorphisms are associated with an increased risk for breast cancer in German 
women. Anticancer Res 1998; 18: 2095-2099. 
169. Powell, B.L., van Staveren, I.L., Roosken, P., Grieu, F., Berns, E.M., Iacopetta, B. 
Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic 
features of breast cancer. Carcinogenesis 2002; 23: 311-315. 
 
 
 52 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 – DNA REPAIR POLYMORPHISMS MIGHT CONTRIBUTE 
DIFFERENTIALLY ON FAMILIAL AND SPORADIC BREAST CANCER 
SUSCEPTIBILITY: A STUDY ON A PORTUGUESE POPULATION 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results presented on this chapter were published as: 
 
Costa, S., Pinto, D., Pereira, D., Rodrigues, H., Cameselle-Tejeiro, J., Medeiros, R. and 
Schmitt, F. DNA repair polymorphisms might contribute differentially on familial and sporadic 
breast cancer susceptibility: a study on a Portuguese population. Breast Cancer Res Treat 2007; 
103: 209-217. 
 
   
 
2.1. Introduction  
57 
ABSTRACT 
 
The purpose of this study was to evaluate the role of polymorphisms in DNA repair genes as 
genetic indicators of susceptibility to familial and sporadic breast cancer. We analysed DNA 
samples from 285 breast cancer patients and 442 control subjects, for XRCC1 Arg399Gln, XPD 
Lys751Gln, RAD51 G135C and XRCC3 Thr241Met polymorphisms using PCR-RFLP. We 
observed that women carriers of XRCC1 399Gln genotypes and without FH of breast cancer have 
a protective effect concerning this disease (OR= 0.54 95% CI 0.35-0.84; p=0.006). Furthermore, 
we found that carriers of XRCC3 241Met genotypes without FH have an increased susceptibility 
of breast cancer (OR= 2.21 95% CI 1.42-3.44; p<0.001). Additionally, we verified an increased 
risk of breast cancer in women with FH and carrying RAD51 135C genotypes (OR= 2.17 95% CI 
1.19-3.98; p=0.012). Our results suggest XRCC1 Arg399Gln and XRCC3 Thr241Met DNA repair 
polymorphisms as important biomarkers to sporadic breast cancer susceptibility, as well as, 
RAD51 G135C polymorphism as a real risk modifier in familial breast cancer cases. 
 
2.1. INTRODUCTION 
 
Breast cancer is the leading cause of death among women in developing countries. In 
Portugal, it presents the highest incidence and mortality rates among women diseases (1). It is a 
disease caused by a complex combination of genetic and environmental factors. Well-established 
risk factors have been described to breast cancer, such as early menarche, late menopause, age 
of first child’s birth, nulliparity and family history (2). Family history of breast cancer is a 
particularly important high risk factor for this disease. Two genes were identified as the major 
susceptibility genes in high risk families, namely BRCA1 and BRCA2. However, these genes 
account for only a minority of the overall family risk of breast cancer (3). Furthermore, 
approximately only 10% of all breast cancer cases exhibit a familial pattern of incidence (4). In 
this way, the identification of genetic susceptibility factors that account from low to moderate 
breast cancer risk is an important step in the definition of individual risk to this malignancy.  
Many environmental factors have been associated with risk of breast cancer development, 
such as ionized radiation and chemical carcinogens, such as some presented in diet and 
environment (5). These mutagens sources, together with endogenous and exogenous estrogens, 
2. DNA repair polymorphisms and breast cancer susceptibility  
 
produce a wide range of DNA lesions such as reactive oxygen species, oxidized bases, bulky DNA 
adducts and DNA strand breaks (6,7). Mammalian cells have evolved distinct pathways to repair 
different types of DNA damage in order to maintain genome integrity. Therefore, DNA repair 
capacity determines cellular susceptibility to endogenous and exogenous substances. Some 
studies have demonstrated a strong association of higher levels of DNA damage and lower DNA 
repair capacity in breast cancer patients and in healthy women with a positive family history of 
breast cancer (8,9). Genetic polymorphisms in DNA repair genes are very common events (10-
12), and some studies have shown a significant effect of some of these polymorphisms in DNA 
repair capacity (13-15).  
XRCC1 protein is thought to act as scaffold protein for both single-strand break repair and 
BER activities (16). It has been shown that XRCC1 interacts with DNA Polβ, DNA LigIII and APE1, 
through a BRCT-I domain at the C-terminus (16). Several polymorphisms have been found in 
XRCC1 gene and some have been linked with a variety of cancers (17). One common XRCC1 
polymorphism, Arg399Gln, located in exon 10, lies within the BRCT-1 domain (18). 
Another important DNA repair protein is XPD protein is a subunit of the TFIIH complex and 
has important roles in transcription and NER pathway. XPD participates in the locally unwind of 
DNA helix to allow RNA transcription machinery to access the promoter and to permit the NER 
machinery to access the lesion (19). XPD is a highly polymorphic gene and correlation of its 
polymorphisms and cancer risk have been intensively studied (14,20). One common XPD 
polymorphism, Lys751Gln, has been associated with a differential DNA repair capacity (21-23). 
This polymorphism, located in exon 23, is situated in the important domain of interaction 
between XPD protein and its helicase activator, inside the TFIIH complex (24). 
Double strand break damage is the most injurious lesions observed because it causes cell 
death or loss of genetic material. HRR and NHEJ are two distinct mechanisms in the repair of 
DSB in mammalian cells. In the HRR pathway, RAD51 is an important protein in DSBR pathway 
that forms a heterodimer with several genes (such as XRCC2, XRCC3, BRCA2) playing central 
role in strand exchange (25). The majority of RAD51 polymorphisms described are in UTRs, such 
as 5’UTR G135C. Another HRR protein is XRCC3, that interact directly with RAD51, helping in 
the assembly of the nucleofilament protein and in the selection and interaction with appropriate 
recombination substrate (26). The XRCC3 Thr241Met polymorphism, located in exon 7, could 
affect the enzyme function and/or its interaction with other proteins involved in DNA damage and 
repair (15). 
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We hypothesize that those common polymorphisms of DNA repair genes could modify either 
DNA repair capacity or fidelity, which may contribute to familial and sporadic breast cancer 
susceptibility. In a case-control study, we analysed polymorphisms of genes involved in different 
DNA repair pathways, since the DNA damage produced by breast mutagens are repaired by 
different pathways (6,7): XRCC1 Arg399Gln in BER, XPD Lys751Gln in NER and RAD51 5’UTR 
G135C and XRCC3 Thr241Met in HRR. 
 
2.2. MATERIALS AND METHODS 
 
Study Population 
We analysed a total of 727 DNA samples. From 285 breast cancer cases, 84 unrelated 
familial breast cancer cases were selected from S. João Hospital at Porto and General Hospital at 
Vigo, and 201 unrelated sporadic breast cancer cases were recruited from IPO-Porto (Oncology 
Portuguese Institute), during 1998-2003, form patients that were receiving treatment. All cases 
were histological confirmed at the Departments of Pathology. Familial case group presented a 
mean age of 41.05, with an age range of 21-77 years. The high-risk family history of breast 
cancer group included women with the follow features, based on the Breast Cancer Linkage 
Consortium criteria (27): early onset (≤40 years) and/or bilaterality; or more than three cases of 
breast cancer in the family; or more than one case of ovarian cancer in the family; or more than 
two first-degree relatives involved; or male breast cancer. Sporadic cases group presented a 
mean age of 53.56, with an age range of 41-88 years. Control women were randomly selected 
from blood banks in the same region during the same time period as the cases were collected. 
The selection criteria include no prior history of cancer, and controls were frequency matched to 
the cases by age (±5 years). 442 healthy women, presenting a median age of 42.29 and an age 
range of 21-85 years, were used as control group of familial breast cancer cases. 226 healthy 
women, with a median age of 53.05 and an age range of 41-85, were selected according to age 
of diagnosis higher than 40 years, and it was used as control group of sporadic breast cancer 
cases. All participants provided informed consent. 
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Genotyping  
Blood samples from all study participants were collected in tubes with EDTA as an 
anticoagulant. Genomic DNA was isolated from buffy coat using Puregene® DNA Purification Kit 
by Gentra Systems. All the polymorphisms were assessed by PCR-RFLP technique. The PCR and 
RFLP conditions to perform genotyping are presented in Table 1. 
 
Table 1 – Primers, amplification parameters and PCR product fragments weight used as PCR 
conditions, and specific restriction enzymes and corresponding digestion product fragments 
weight used as RFLP conditions, for the polymorphisms studied. 
Polymorphism 
PCR Conditions  
XRCC1 Arg399Gln XPD Lys751Gln RAD51 G135C XRCC3 Thr241Met 
Primers     
Forward 
5’-CAA GTA CAG CCA GGT 
CCT AG-3’ 
5’-CTG CTC AGC 
CTG GAG CAG CTA 
GAA TCA GAG GAG 
ACG CTG-3’ 
5’-TGG GAA CTG 
CAA CTC ATC 
TGG-3’ 
5’-GCC TGG TGG 
TCA TCG ACT C-3’ 
Reverse 
5’-CCT TCC CTC ATC TGG 
AGT AC-3’ 
5’-AAG ACC TTC TAG 
CAC CAC CG-3’ 
5’-GCG CTC CTC 
TCT CCA GCA G-3’ 
5’-ACA GGG CTC 
TGG AAG GCA CTG 
CTC AGC TCA 
CGC ACC-3’ 
Annealing 
temperature  
58ºC/30 seconds 60ºC/30 seconds 53ºC/30 seconds 60ºC/30 seconds 
Number of cycles 32 32 32 32 
PCR product (bp) 268 161 159 136 
RFLP Conditions     
Restriction enzyme  Bcn I (Fermentas) Pst I (Fermentas) 
Mva III 
(Fermentas) 
Nla III (New 
England Biolabs) 
         Digestion 
products (bp) 
    
W 91 and 177 161 71 and 88 136 
M 268 41 and 120 159 35 and 101 
 
Statistical Analysis 
Analysis of data was performed using the computer software SPSS version 14.0. Chi-square 
(χ2 test) analysis was used to compare categorical variables. A 5% level of significance was used 
in the analysis. The Odds Ratio (OR) and its 95% confidence interval (CI) were calculated to 
measure the association between polymorphic variants and breast cancer risk. Logistic 
regression analysis was used to calculate the adjusted OR and 95% CI for the influence of 
different genotypes in the risk of breast cancer, adjusted for age. Whenever appropriate, the 
observed number of each genotype in control groups were compared with that expected for a 
population in the Hardy-Weinberg Equilibrium by using a goodness of fit χ2 test. We hypothesized 
that DNA repair genotypes may alter the onset of disease in these cases, as performed before by 
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Medeiros et al (28). We therefore considered the waiting time for the onset of disease as the 
interval between the time of initial exposure to the risk factor (DNA repair genotypes) and the 
time of onset of disease. We estimated the cumulative probabilities for having disease 
(cumulative hazard function plots) by the Kaplan–Meier methodology. The primary analysis of 
time-to-event end points for waiting time for the onset of disease was performed with the use of a 
two-sided log-rank test at the 5% level of significance. 
 
2.3. RESULTS 
 
The genotypic and allelic frequencies of DNA repair polymorphisms studied for cases, familial 
and sporadic breast cancer, and controls are presented in Table 2.  
 
Table 2 – Allelic and genotype frequencies of polymorphisms in XRCC1, XPD, RAD51 and 
XRCC3 genes and familial and sporadic breast cancer cases and controls. 
Polymorphisms 
Genotype or 
Allele 
Familial Risk 
Cases n (%) 
Controls 
n (%) 
Sporadic 
Cases n (%) 
Controls 
n (%) 
XRCC1 Arg399Gln      
PHWE=0.781 Arg/Arg 28 (34.6) 153 (34.7) 84 (48.0) 75 (34.1) 
 Arg/Gln 42 (51.9) 222 (50.3) 67 (38.3) 116 (52.7) 
 Gln/Gln 11 (13.6) 66 (15.0) 24 (13.7) 29 (13.2) 
 Arg  98 (60.5) 528 (59.9) 235 (67.1) 266 (60.5) 
 Gln  64 (39.5) 354 (40.1) 115 (32.9) 174 (39.5) 
XPD Lys751Gln      
PHWE=0.415 Lys/Lys 34 (42.0) 216 (48.9) 93 (46.3) 115 (52.8) 
 Lys/Gln 41 (50.6) 179 (40.5) 84 (41.8) 81 (37.2) 
 Gln/Gln 6 (7.4) 47 (10.6) 24 (11.9) 22 (10.1) 
 Lys  109 (67.2) 611 (69.1) 270 (67.2) 311 (71.3) 
 Gln  53 (32.7) 273 (30.9) 132 (32.8) 125 (28.7) 
RAD51 5’UTR G135C      
PHWE=0.842 GG 64 (78.0) 381 (87.6) 152 (83.1) 177 (83.9) 
 GC 18 (22.0) 53 (12.2) 27 (14.8) 33 (15.6) 
 CC 0 (0.0) 1 (0.2) 4 (2.2) 1 (0.5) 
 G  146 (89.0) 815 (93.7) 331 (90.4) 387 (91.7) 
 C  18 (11.0) 55 (6.3) 35 (9.6) 35 (8.3) 
XRCC3 Thr241Met      
PHWE=0.002 Thr/Thr 40 (49.4) 225 (52.2) 68 (38.6) 121 (57.3) 
 Thr/Met 29 (35.8) 140 (32.5) 77 (43.8) 61 (28.9) 
 Met/Met 12 (14.8) 66 (15.3) 31 (17.6) 29 (13.7) 
 Thr  109 (67.3) 590 (68.4) 213 (60.5) 303 (71.8) 
 Met  53 (32.7) 272 (31.6) 139 (39.5) 119 (28.2) 
 
We tested each polymorphism for association with breast cancer risk in two breast cancer 
subgroups: negative presence of FH of breast cancer, designated as sporadic cancer, and 
positive FH of breast cancer, family risk cases, and the results are presented in Table 3. 
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Concerning XRCC1 Arg399Gln polymorphism, 399Gln genotypes were observed in lower 
frequency in all breast cancer cases (56.3%) and sporadic breast cancer cases (52.0%) 
compared with the respective control group (65.3% and 65.9%, respectively). The 399Gln 
genotypes showed a protective effect to sporadic breast cancer risk (p=0.006; OR= 0.54, 95% CI 
0.35-0.84). However, no statistically significant difference was observed regarding familial breast 
cancer risk (p=0.932; OR= 1.02, 95% CI 0.61-1.71). 
No statistically significant associations were found between the XPD Lys751Gln polymorphism 
and risk of familial and sporadic breast cancer risk (table 3). 
Regarding RAD51 G135C polymorphism, our results showed that carriers of variant 135C 
present an increased risk of familial breast cancer (p=0.012; OR=2.17, 95% CI 1.19-3.98), while 
no statistically significant correlation was observed with sporadic breast cancer risk (p= 0.477; 
OR= 1.22, 95% CI 0.70-2.14).  
The XRCC3 241Met genotypes carriers with negative FH were at a 2.21-fold (95% CI = 1.42–
3.44; p<0.001) increased risk of breast cancer compared with the respective control group. No 
statistically significant differences were observed in genotypes frequencies comparing positive FH 
breast cancer cases and respective control group. 
 
Table 3 – Polymorphisms in DNA repair genes as biomarkers of breast cancer susceptibility in 
presence or absence of family risk. 
Familial Risk Cases Sporadic Cases 
Polymorphism 
OR (95% CI)* P value OR (95% CI)* P value 
XRCC1 Arg399Gln 1.02 (0.61-1.71) 0.932 0.54 (0.35-0.84) 0.006 
Gln carriers     
XPD Lys751Gln 1.31 (0.80-2.15) 0.278 1.45 (0.95-2.19) 0.082 
Gln carriers     
RAD51 G135C 2.17 (1.19-3.98) 0.012 1.22 (0.70-2.14) 0.477 
C carriers     
XRCC3 Thr241Met 1.16 (0.71-1.89) 0.558 2.21 (1.42-3.44) <0.001 
Met carriers     
* OR adjusted for age among variant carriers vs wild type carriers (logistic regression analysis) 
 
Regarding the waiting time-to-onset of disease, the cumulative probabilities of having familial 
and sporadic breast cancer according to the presence or absence of the variants genotypes are 
shown in Figure 1 and 2. We observed statistically significant differences in the mean waiting 
time-to-onset of sporadic breast cancer for carriers of the 399Gln genotypes (Figure 2 (a)) and for 
carriers of the 241Met genotypes (Figure 2 (d)) in comparison for non-carriers (log-rank test: 
p=0.028 and p<0.001, respectively). 
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Figure 1 - Association between XRCC1 Arg399Gln (a), XPD Lys751Gln (b), RAD51 G135C (c) 
and XRCC3 Thr241Met (d) polymorphisms and the waiting time-to-onset on familial breast 
cancer cases. Cumulative hazard function plots by the Kaplan–Meier methodology and Log-rank 
test. 
 
 
Figure 2 - Association between XRCC1 Arg399Gln (a), XPD Lys751Gln (b), RAD51 G135C (c) 
and XRCC3 Thr241Met (d) polymorphisms and the waiting time-to-onset on sporadic breast 
cancer cases. Cumulative hazard function plots by the Kaplan–Meier methodology and Log-rank 
test. 
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2.4. DISCUSSION 
 
The individual susceptibility to the development of cancer may be influenced by several 
factors. Increasing evidences suggest that genetic polymorphisms may have an important 
contribution on cancer susceptibility and tumour behaviour, particularly in hormone related 
cancers (28-31). 
Maintenance of the genomic integrity by DNA repair genes is an essential step in normal 
cellular growth and differentiation (32). There is increasing data supporting the hypothesis that 
genetic polymorphisms in various DNA repair genes result in reduced DNA repair capacity, in this 
way, being associated with increased susceptibility to various human solid tumours (13-
15,17,20-23).  
In our study, the allelic frequencies for the different polymorphisms were in accordance with 
earlier reports from European populations (33,34). The genotype frequencies in the controls are 
in agreement with those expected under Hardy-Weinberg equilibrium, except for XRCC3 
Thr241Met polymorphism genotypes. Hardy-Weinberg equilibrium depends on a series of 
features about the tested population, including, for example, the sample population size, random 
mating, no migration, no genetic drift and no selection taking place (35). As the discrimination of 
the other genotypes for this assay was good, this deviation could be due to chance or violation of 
these assumptions, rather than to genotyping errors. 
In this case-control study we investigated the role of polymorphisms of DNA repair genes 
involved in BER, NER and HRR. Our findings suggest a protective effect of the 399Gln genotypes 
of XRCC1 polymorphism to development of breast cancer in women with no FH.  These results 
are consistent with those from previous studies of XRCC1 polymorphisms and cancer risk, that 
reported a protective association between the 399Gln carriers and cancer (34,36,37). However, 
previous studies, performed in breast cancer, observed a positive, specially when gene-exposure 
interactions were considered (38-40), or no association (41,42) between the 399Gln carriers and 
breast cancer risk, also concerning in some studies the presence of FH of breast cancer (43-46). 
Functional studies of XRCC1 suggest that the 399Gln allele may be associated with higher levels 
of different types of DNA damage in some cancers (15,47,48). These contradictory effects of 
399Gln genotypes could be explained by two points. First, the gene variants could independently 
confer particular function to XRCC1 protein, since the effects of XRCC1 alleles could potentially 
depend upon competing biochemical pathways operating in the tissue being analyzed (49), as 
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well as the effects of any given genetic variant will depend upon other genetic and environmental 
factors that interact with that variant (50). Secondly, these variants could diminish the efficiency 
of the protein but still provide decreased cancer risk, since, in the presence of excessive damage, 
cells carriers of these variants would have decreased ability to repair and might be more likely to 
undergo apoptosis. 
In this study, we did not find an association between the XPD Lys751Gln polymorphism and 
breast cancer. To date, the results evaluating XPD Lys751Gln polymorphism are controversial. 
Our results are in agreement with other studies where no correlation was found between this 
polymorphism and breast cancer risk, among women without FH (38,51,52) and with FH of 
breast cancer (43,44). In contrast, significant association between XPD 751Gln allele and breast 
cancer risk was seen in recent studies (53). Furthermore, the functional significance of XPD 
polymorphism seems to be dependent from environmental factors that interact with that variant. 
Some studies showed that 751Gln allele was associated with reduced DNA repair efficiency of 
UV-light DNA damage, while others showed a suboptimal repair of X-ray-induced DNA damage 
related with 751Lys allele (47,54). 
Regarding RAD51 5’UTR G135C polymorphism, our results showed an association of RAD51 
135C genotypes and increased breast cancer risk only among women with FH of breast cancer, 
suggesting that this polymorphism contributed to the familial breast cancer in the Portuguese 
population, in opposition to reported results in the Brazilian population (44). Other studies have 
reported an association of RAD51 genotypes with familial breast cancer risk, only in women 
carriers of BRCA2 mutations (55-57). Since the number of BRCA1 and/or BRCA2 mutations 
detected in our familial breast cancer cases were too small (58), it was not possible to perform a 
separate analysis. The biological effect of the RAD51 G135C polymorphism is currently unknown. 
This polymorphism could affect mRNA splicing, regulation of transcription, translation or mRNA 
stability by association of 5’UTR region with regulatory elements (59). Furthermore, linkage 
disequilibrium could occur between RAD51 gene with another sequence change in a regulatory 
region of the gene or with another nearby gene affecting the incidence of breast cancer in familial 
breast cancer. Concerning sporadic breast cancer risk, similar results to our findings were 
obtained by others studies in the Australian women (60) and in the Anglo-Saxon population(10), 
where no association was obtained.  
Our results demonstrate a strong association of increased breast cancer susceptibility in 
women carriers of XRCC3 241Met genotypes and negative FH of breast cancer. This is 
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consistent with an earlier report in the United Kingdom (10). Functional data supporting the 
hypothesis of damaging consequences due to XRCC3 Thr241Met polymorphism supports our 
results. The 241Met variant has been associated with higher levels of bulky DNA adducts, mitotic 
defects and lower DNA repair capacities of X-ray-induced DNA damage (15,61). However, other 
studies report no risk association (44,45,60,62-64).  
The variance in results of association in different case-control studies on XRCC1, XPD, RAD51 
and XRCC3 polymorphisms may be connected to variation in genetic/ethnic origin and different 
carcinogenic exposures of the studied populations. Too small sample size and/or the inadequate 
controlling for certain confounders such as age and family history of breast cancer may also 
contribute to differing results. 
The natural history of breast cancer can be influenced by several factors. We hypothesize that 
under the influence of genetic polymorphisms, chronic exposure to higher levels of several 
endogenous (e.g. estrogens) and exogenous breast carcinogens resulting in consequent higher 
accumulation of DNA damage during an individual’s lifetime, may alter the waiting-time-to onset 
of disease. Moreover, it has been suggested that DNA repair genes are associated to age related 
disease (65). Our results are consistent with this hypothesis that XRCC1 Arg399Gln and XRCC3 
Thr241Met polymorphisms seem to influence directly the waiting time-to-onset of sporadic breast 
cancer.  
In conclusion, our findings suggest the RAD51 G135C polymorphism as a real risk modifier in 
familial breast cancer cases. Furthermore, we point out that XRCC1 Arg399Gln and XRCC3 
Thr241Met polymorphisms as important biomarkers to sporadic breast cancer susceptibility. A 
possible interpretation for different associations depending on presence of FH may be that FH 
broadly represents shared genes and environmental factors, and the presence of a single 
polymorphism, with likely weak effects on the individual phenotype, may not be measurable 
except in the context of these supporting factors. Among individuals without a familial 
predisposition, the effect may be hidden by sum effects of other unidentified genetic and 
environmental factors (45). Further evidence from other studies and functional data is required to 
confirm the real significance of the results observed by us in breast cancer risk. 
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3.1. Letter 
 
3. LETTER TO THE EDITOR 
 
Breast cancer is the most common type of cancer in female, including Portugal, where this 
disease presents the highest incidence and mortality rates (1). Breast cancer risk factors, like 
prolonged exposure to estrogen and/or IR, BRCA1, BRCA2, TP53, ATM and CHEK2 mutations 
(2,3), are related with an increased chance of DNA damage, acting as initiators of cellular 
alterations. DNA repair pathways are critical processes in order to maintain genome integrity. 
Therefore, genetic polymorphisms in DNA repair genes are common events (4). We previously 
showed correlations of some of these genetic variations, as XRCC1 Arg399Gln, RAD51 5’UTR 
G135C and XRCC3 Thr241Met, with changeable breast cancer susceptibility (5). 
In the present study, we aimed to investigate the possible correlations between DNA repair 
polymorphisms with breast cancer clinical-pathological phenotypes, identifying subgroups of 
patients according to their genetic background. 
We analysed DNA from 165 breast cancer patients, including 33 unrelated FH and 132 
sporadic breast cancer cases from Surgical Departments of S. João Hospital and the IPO, at 
Porto. All participants provided informed consent. Patients presented a mean age of 51.01 years 
(standard deviation (SD) ±12.68).  
We determined XRCC1 Arg399Gln, RAD51 5’UTR G135C and XRCC3 Thr241Met genotypes 
by PCR-RFLP technique, as previously described (6). 
Chi-square (χ2 test) analysis was used to compare different variables. Logistic regression 
analysis was applied to calculate the adjusted p value for age and FH in identification of 
subgroups of patients according to genotypes. The Kaplan-Meier method was used to estimate 
overall survival (OS). OS was defined as minimal 60 months follow-up, from clinical diagnosis 
until death or censorship (were alive at the end of the follow-up time period). Differences on OS 
were obtained by Log Rank test.  
The correlation of the analysed DNA repair polymorphisms with some clinical-pathological 
features is presented in Table 1. According to our results, XRCC1 Gln/Gln genotype seems to be 
associated with less aggressive tumors, since this genotype was correlated with well 
differentiated tumors (p=0.022 adjusted for age and breast cancer FH, using logistic regression 
analysis). Deficient efficiency of the XRCC1 protein has been described in XRCC1 Gln variant 
(7,8). Furthermore, repair of more complex base lesions (9-11) by BER pathway can potentially 
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convert non-lethal lesion into lethal DSBs (12,13). Thus, deficiency in BER, by low efficiency of 
XRCC1, may actually reflect a well differentiated nature of the tumor cells in less aggressive 
tumors, since less lethal lesions are produced.  
We also observed that RAD51 C135 genotypes show a relationship with more aggressive 
tumors and also with a poorer OS, since we found a significant association of RAD51 C135 
genotypes with moderate to poor differentiated grade (p=0.011, adjusted for age and breast 
cancer FH, using logistic regression analysis).  
 
Table 1 – Correlation between DNA repair polymorphisms and clinical-pathological 
parameters in Portuguese breast cancer patients. 
XRCC1 Arg399Gln RAD51 G135C XRCC3 Thr241Met 
Parameters 
Gln/Gln Others GC or CC GG Met/Met Others 
Histological Type       
Invasive ductal  23 (92.0) 115 (86.5) 32 (91.4) 113 (86.9) 23 (88.5) 120 (88.2) 
Invasive lobular  0 (0.0) 3 (2.3) 0 (0.0) 3 (2.3) 1 (3.8) 2 (1.5) 
Others 2 (8.0) 15 (11.3) 3 (8.6) 14 (2.3) 2 (7.7) 14 (10.3) 
P value 0.654  0.606  0.665  
Histological Grade       
I 5 (23.8) 8 (7.1) 6 (18.2) 9 (8.3) 1 (4.0) 14 (12.4) 
II 6 (28.6) 61 (54.0) 21 (63.6) 51 (47.2) 11 (44.0) 57 (50.4) 
III 10 (47.6) 44 (38.9) 6 (18.2) 48 (44.4) 13 (52.0) 42 (37.2) 
P value 0.021*  0.017**  0.269  
Axillary lymph node 
status 
      
Negative 10 (41.7) 52 (40.0) 12 (40.0) 54 (41.5) 8 (32.0) 57 (43.5) 
Positive 14 (58.3) 78 (60.0) 18 (60.0) 76 (58.5) 17 (68.0) 74 (56.5) 
P value 0.878  0.877  0.285  
Estrogen receptor 
status 
      
Negative 1 (33.3) 9 (31.0) 2 (28.6) 7 (25.9) 1 (33.3) 8 (27.6) 
Positive 2 (66.7) 20 (69.0) 5 (71.4) 20 (74.1) 2 (66.7) 21 (72.4) 
P value 0.935  0.888  0.833  
Survival status at  
last follow-up 
      
Death 3 (15.0) 13 (12.5) 2 (8.3) 15 (14.0) 1 (4.0) 16 (15.4) 
Alive 17 (85.0) 91 (87.5) 22 (91.7) 92 (86.0) 24 (96.0) 88 (84.6) 
P value 0.760  0.454  0.131  
Recurrence at last 
follow-up 
      
No 14 (77.8) 74 (82.2) 19 (86.4) 74 (80.4) 20 (87.0) 72 (80.0) 
Yes 4 (22.2) 16 (17.8) 3 (13.6) 18 (19.6) 3 (13.0) 18 (20.0) 
P value 0.658  0.519  0.444  
* p value= 0.022, adjusted for age and history family of breast cancer to compare the influence of different 
genotypes in histological grade (I vs II/III grade), using logistic regression analysis. ** p value= 0.011, adjusted for 
age and history family of breast cancer to compare the influence of different genotypes in histological grade (I/II vs 
III grade), using logistic regression analysis. 
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Additionally, assessment of OS demonstrated that patients with RAD51 C135 genotypes 
(102.87 months mean OS) presented a poorer survival compared with others genotypes (136.36 
months mean OS) (Figure 1). These results can be explained by the location of this 
polymorphism in the UTRs, may be affecting mRNA stability and/or translation efficiency, leading 
to altered RAD51 protein levels (14). Thus, RAD51, the key factor of homologous recombination 
process, can disturb the activity of the multi protein DNA repair complex, including BRCA1, 
BRCA2 and XRCC3, contributing to high levels of genetic instability (15), and as a result, being 
correlated with more aggressive breast tumors and poor survival.  
 
 
Figure 1 – Kaplan-Meier overall survival curve in breast cancer patients relating with RAD51 
G135C polymorphism. Log-rank test for statistical analysis. 
 
We had previously showed XRCC1 Arg399Gln and RAD51 5’UTR G135C as important 
polymorphism to predict breast cancer risk (16). According to the present results, we clearly 
underlie the role of these same polymorphisms in the prediction of breast tumor aggressiveness 
and patients’ survival. 
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ABSTRACT 
 
TP53 is one of major tumour suppressor genes, also known as the guardian of the genome, 
being essential in preservation of genome integrity. Two very common polymorphisms have been 
demonstrated to contribute to cancer susceptibility and tumour behaviour. The purpose of this 
study was to evaluate the role of Arg72Pro and PIN3 Ins16bp polymorphisms in TP53 gene as 
genetic susceptibility and predictive markers to breast cancer. We analysed DNA samples from 
264 breast cancer patients and 440 controls. We observed that women with A2A2 genotype have 
increased risk for developing breast cancer, either in women with or without FH of the disease 
(OR=4.40, 95% CI 1.60-12.0; p=0.004; OR=3.88, 95% CI 1.18-12.8; p=0.026, respectively). In 
haplotype analysis, statistically significant differences were found betweenTP53 Arg-A2 haplotype 
frequencies and familial breast cancer cases and the respective control group (OR=2.10, 95% CI 
1.08-4.06; p=0.028). Furthermore, both TP53 polymorphisms are associated with higher 
incidence of lymph node metastases. Our findings suggest PIN3 Ins16bp polymorphism as a risk 
modifier in breast cancer disease, with evidence for relative differential effect by family history. 
Moreover, Arg72Pro and PIN3 Ins16bp polymorphisms are suggested as predictive factors of 
lymph node metastases. 
 
4.1. INTRODUCTION 
 
Breast cancer disease have been associated with well-established risk factors, such as high 
estrogen exposure, many environmental factors (e. g. diet and ionizing radiation) and family 
history (1,2). Family history of breast cancer is a particularly important high risk factor for this 
disease. Two genes were identified as the major susceptibility genes in high risk families, namely 
BRCA1 and BRCA2. However, these genes account for only a minority of the overall family risk of 
breast cancer (3). Furthermore, approximately only 10% of all breast cancer cases exhibit a 
familial pattern of incidence (4,5). In this way, the remaining familial and sporadic risk may be 
due to common low to moderate penetrance genetic variants, which are also referred as genetic 
polymorphisms. One strong candidate for genetic susceptibility factor to familial and/or sporadic 
breast cancer is the TP53 gene. This gene is frequently somatically mutated in breast cancer 
(6,7) and TP53 germline mutations are associated with increased risk for developing diverse 
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malignancies, including 25–30% of hereditary breast cancer cases (8). Furthermore, based on its 
pivotal role in DNA damage repair and its physical and functional interactions with BRCA1 and 
BRCA2 proteins (9,10), TP53 seems to be a strong candidate breast cancer predisposition. 
The TP53 tumour suppressor gene, also designated the guardian of the genome, is essential 
in preservation of genome integrity. From the numerous biological functions of p53 protein, 
inhibition of cell cycle progression, DNA repair and apoptosis are the major cellular pathways 
where it is involved (6).  
TP53 gene mutations are widely detected in breast cancer, being correlated with specific 
clinical phenotypes (11,12).  
Predisposition to several human cancers has been associated with genetic polymorphisms, 
which may represent an important contribution to cancer susceptibility and tumour behaviour 
(13-16). Several polymorphisms have been identified within TP53 gene, both in non-coding and 
coding regions (17). One of the most well studied TP53 gene polymorphism is Arg72Pro, located 
in codon 72 on exon 4, leading to arginine-proline substitution, which in its turn results in a 
structural alteration of the protein (18). Another common polymorphism is 16 base pair (bp) 
duplication in intron 3 of the TP53 gene (PIN3 Ins16bp).  
In this case-control study, we hypothesize that the two common polymorphisms of TP53 gene 
play a role either apoptosis, cell cycle control efficiency, as well as DNA repair capacity, which 
ultimately may contribute to an increase of breast cancer susceptibility within familial and/or 
sporadic cases, as well as represent an additional tool for prognosis prediction. 
 
4.2. MATERIALS AND METHODS 
 
Study Population 
We analysed a total of 264 DNA breast cancer cases: 73 unrelated familial breast cancer 
cases were selected from the Oncology and Surgical Departments from S. João Hospital at Porto 
and Vigo Hospital, and 191 unrelated sporadic breast cancer cases were recruited from IPO-
Porto, during 1998-2003, from patients that were receiving treatment. All cases were histological 
confirmed at the Department of Pathology. Clinical-pathological parameters were obtained when 
possible from hospital clinical records. Familial case group presented a mean age of 42.07 
years, with an age range of 24-77 years. The high-risk familial breast cancer group, also 
4.2. Materials and Methods 
  
designated by us as family history (FH) breast cancer cases, included women with the follow 
features, based on the Breast Cancer Linkage Consortium criteria (19): early onset (≤40 years) 
and/or bilaterality; or more than three cases of breast cancer in the family; or more than one 
case of ovarian cancer in the family; or more than two first-degree relatives involved; or male 
breast cancer. These high-risk breast cancer cases are BRCA1/BRCA2 mutations non-carriers 
(20). Sporadic cases group (with no presence of FH) presented a mean age of 53.41 years, with 
an age range of 41-88 years. Control women were randomly selected from blood banks in the 
same region during the same time period as the cases were collected. The selection criteria 
include no prior history of cancer, and controls were frequency matched to the cases by age (±5 
years). A total of 440 healthy women presenting a median age of 42.29 years and an age range 
of 21-85 years, were used as control group of familial breast cancer cases. From the above 
control group 216 healthy women were selected according to age of diagnosis higher than 40 
years, with a median age of 53.05 and an age range of 41-85, being used as control group of 
sporadic breast cancer cases. All participants provided informed consent. 
 
Laboratory Methods 
Genomic DNA was isolated from lymphocytes of peripherical blood using Puregene® DNA 
Purification Kit (Gentra Systems, Minneapolis, USA). All the polymorphisms were assessed by 
PCR-RFLP technique. TP53 Arg72Pro polymorphism (rs1042522) was detected by amplifying 
genomic DNA with the forward primer 5’-GAA GAC CCA GGT CCA GAT GA-3’ and the reverse 
primer 5’-CTG CCC TGG TAG GTT TTC TG-3’. The PCR amplification parameters were 32 cycles 
each of 30 sec at 94°C, 30 sec at 54°C, and 30 sec at 72°C. The 152bp PCR product was 
digested with Bsh1236I (Fermentas, Ontario, Canada) at 37°C overnight. Digested products 
were separated by electrophoresis in a 3% agarose gel (Seakem® LE Agarose, Rockland, USA) 
and visualized by ethidium bromide staining. Wild type alleles resulted in 50 and 102bp 
fragments and the variant alleles resulted in 152bp fragment following restriction enzyme 
digestion. TP53 PIN3 Ins16bp polymorphism (rs17878362) was detected by amplifying genomic 
DNA with the forward primer 5’-CTG AAA ACA ACG TTC TGG TA-3’ and the reverse primer 5’-AAG 
GGG GAC TGT AGA TGG GTG-3’. The PCR amplification parameters were 32 cycles each of 30 
sec at 94°C, 30 sec at 60°C, and 30 sec at 72°C. The PCR product was separated by 
electrophoresis in a 4% agarose gel (Seakem® LE Agarose, Rockland, USA) and visualized by 
ethidium bromide staining. Wild type alleles, designated A1 allele (no duplication) resulted in 
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119bp fragment and the variant alleles, designated A2 allele (with 16bp duplication) resulted in 
135bp fragment.  
To ensure quality control of all genotyping results, one percent of the samples was randomly 
selected and sequenced using an ABI automated sequencer. 
    
Statistical Analysis 
Analysis of data was performed using the computer software SPSS version 14.0 (SPSS Inc., 
Chicago, USA). Chi-square (χ2 test) analysis was used to compare categorical variables. 
Whenever necessary, the Fisher test was used when number of samples was equal or inferior to 
5. A 5% level of significance was used in the analysis. The OR and its 95% CI were calculated to 
measure the association between TP53 polymorphic genotypes and breast cancer risk. Logistic 
regression analysis was used to calculate the adjusted OR and 95% CI for the influence of TP53 
genotypes in the risk of breast cancer, adjusted for age and/or FH. Whenever appropriate, the 
observed number of each genotype in control groups were compared with that expected for a 
population in the Hardy-Weinberg Equilibrium by using a goodness of fit χ2 test. The frequencies 
of expected haplotypes were estimated by using the statistical methodologies implemented by 
HPlus software (21). The nonparametric test, Kruskal-Wallis test, was used to compare mean age 
of diagnostic between the different genotype polymorphisms. The Kaplan-Meier method was also 
used to estimate OS. OS was defined as time (months) from clinical registration until death or 
censorship (were alive at the end of the follow-up time period). A follow-up period of at least 60 
months was considered. The Log rank test was applied to evaluate effect of the TP53 
polymorphisms on OS. The OS analysis was conducted only in a group of sporadic breast cancer 
patients were it was possible to get these data. 
 
4.3. RESULTS 
 
The distribution of the genotype frequencies in both Arg72Pro and PIN3 Ins16bp 
polymorphisms among control group and subgroup (Table 1) is in agreement with those 
expected under Hardy-Weinberg equilibrium, excepted for Arg72Pro in the control group.  
 
4.3. Results 
  
Table 1 – TP53 Arg72Pro and PIN3 Ins16bp genotypic and allelic frequencies. Association 
with familial and sporadic breast cancer risk. 
TP53 
Polymorphism 
Genotype 
Positive 
FH Cases 
Controls OR* (95% CI) 
Negative 
FH Cases 
Controls OR* (95% CI) 
Arg72Pro        
PHWE=0.223 Arg/Arg 39 (53.4) 256 (59.0) Reference 98 (56.0) 
124 
(58.5) 
Reference 
 Arg/Pro 25 (34.2) 142 (32.7) 1.19 (0.68-2.08) 61 (34.9) 70 (33.0) 1.26 (0.79-2.02) 
 Pro/Pro 9 (12.3) 36 (8.3) 1.58 (0.68-3.67) 16 (9.1) 18 (8.5) 1.35 (0.63-2.88) 
Alleles        
 Arg  103 (70.5) 654 (75.3) Reference 257 (73.4) 
318 
(75.0) 
Reference 
 Pro  43 (29.5) 214 (24.7) 1.28 (0.85-1.91) 93 (26.6) 
106 
(25.0) 
1.09 (0.78-1.52) 
PIN3 Ins16bp        
PHWE=0.889 A1A1 46 (65.7) 299 (68.0) Reference 122 (63.9) 
147 
(68.1) 
Reference 
 A1A2 15 (21.4) 130 (29.5) 0.80 (0.43-1.49) 56 (29.3) 65 (30.1) 1.07 (0.67-1.70) 
 A2A2 9 (12.9) 11 (2.5) 4.40 (1.60-12.0) 13 (6.8) 4 (1.9) 3.88 (1.18-12.8) 
Alleles        
 A1  107 (76.4) 728 (82.7) Reference 300 (78.5) 
359 
(83.1) 
Reference 
 A2  33 (23.6) 152 (17.3) 1.48 (0.94-2.31) 82 (21.5) 73 (16.9) 1.34 (0.93-1.94) 
* OR adjusted for age (logistic regression analysis); FH – family history; OR – odds ratio; CI-confidence interval. 
 
Concerning TP53 Arg72Pro polymorphism in the familial breast cancer cases, frequencies of 
Arg72Arg, Arg72Pro and Pro72Pro were 53.4%, 34.2% and 12.3%, respectively. In sporadic 
breast cancer, 56.0%, 34.9% and 9.1% were homozygous to 72Arg allele, heterozygous and 
homozygous to 72Pro allele, respectively. No statistically significant associations were found 
between the TP53 Arg72Pro polymorphism and risk of familial and sporadic breast cancer risk 
(Table 1).  
Frequencies of TP53 PIN3 Ins16bp polymorphism genotypes were 65.7% to A1A1, 21.4% to 
A1A2 and 12.9% to A2A2, in familial breast cancer cases. Regarding sporadic breast cancer 
group, we observed 63.9%, 29.3% and 6.8% frequencies for homozygous to A1 allele, 
heterozygous and homozygous to A2 allele, respectively. We observed that A2A2 genotype 
carriers with positive FH were at a 4.40-fold (95% CI = 1.60-12.0; p=0.004) increased risk of 
breast cancer compared with the respective control group. Moreover, statistically significant 
differences were observed in A2A2 genotype frequencies comparing negative FH breast cancer 
cases and respective control group (p=0.026). Our results showed that carriers of A2A2 genotype 
with no FH present an increased risk of breast cancer (OR=3.88, 95% CI 1.18-12.8). 
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We investigated haplotype effects of the two polymorphisms studied in breast cancer risk 
(Table 2). Compared the common TP53 Arg-A1 haplotype with the other expected haplotypes; we 
only observed statistically significant differences regarding TP53 Arg-A2 haplotype between the 
familial breast cancer cases and respective control group (p=0.028). Carriers of TP53 Arg-A2 
haplotype and presence of FH of breast cancer presented an increased risk of develop breast 
cancer (OR= 2.10; 95% CI 1.08-4.06).  
 
Table 2 – Expected haplotype frequencies between Arg72Pro and PIN3 Ins16bp 
polymorphisms. Association with familial and sporadic breast cancer risk. 
Haplotypes 
Positive 
FH Cases 
Controls OR (95% CI) 
Negative 
FH Cases 
Controls OR (95% CI) 
Arg-A1 0.607 0.711 Reference 0.695 0.705 Reference 
Arg-A2 0.091 0.041 2.10 (1.08-4.06) 0.048 0.045 1.06 (0.53-2.12) 
Pro-A1 0.150 0.111 1.49 (0.86-2.58) 0.098 0.119 0.80 (0.49-1.32) 
Pro-A2 0.151 0.137 1.27 (0.72-2.24) 0.160 0.131 1.27 (0.83-1.95) 
FH – family history; OR – odds ratio; CI- confidence interval 
 
We examined the relationship between age at onset and genotypes and found a positive 
correlation in the FH group. The mean age of FH patients group with A2A2 genotype was 33.43 
(±8.08) years, whereas the mean age of patients with A1A1 and A1A2 genotypes was 42.44 
(±12.14) and 44.80 (±10.85) years, respectively (Kruskal Wallis test p=0.056; Figure 1 b). 
Therefore, the carrier’s status of A2A2 genotype was associated with an earlier age at onset 
cancer with respect to the patients with A1 genotypes. However, this difference was in the 
frontier of statistically significant, possibly because of the smaller size of the group (7 patients to 
Pro/Pro genotype). No association was observed relating age at onset and Arg72Pro 
polymorphism (Kruskal Wallis test p=0.747; Figure 1 a). 
The analysis of the TP53 polymorphisms with respect to some clinical-pathological factors is 
presented in Table 3. No significant statistically association was found concerning histological 
type and grade and hormone receptor status. However, we found a significant association of Pro 
or A2 genotypes with the presence of lymph node metastases (p=0.009 and p<0.001, 
respectively, adjusted for age and breast cancer family history, using logistic regression 
analysis.). Patient carriers of Pro or A2 genotypes (69.7% and 78.6%, respectively) shown higher 
incidence of lymph node metastases than carriers of Arg/Arg or A1A1 genotypes (50.6% and 
50.5%, respectively).  
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Figure 1 - Association of age of familial and sporadic breast cancer age at onset with TP53 
Arg72Pro (a) and PIN3 Ins16bp (b) polymorphisms. 
 
Table 3 – Correlation between TP53 Arg72Pro and PIN3 Ins16bp polymorphisms and clinical-
pathological parameters in breast cancer patients. 
TP53 Arg72Pro TP53 PIN3 Ins16bp 
Parameters 
Arg/Arg Arg/Pro or Pro/Pro A1A1 A1A2 or A2A2 
Histological Type     
Invasive ductal carcinoma 68 (85.0%) 70 (92.1%) 88 (86.3%) 58 (90.6%) 
Invasive lobular carcinoma 3 (3.8%) 2 (2.6%) 5 (4.9%) 1 (1.6%) 
Others 9 (11.3%) 4 (5.3%) 9 (8.8%) 5 (7.8%) 
P value 0.359  0.510  
Histological Grade     
I 8 (12.1%) 6 (9.1%) 11 (12.6%) 4 (7.4%) 
II 33 (50.0%) 34 (51.5%) 45 (51.7%) 27 (50.0%) 
III 25 (37.9%) 26 (39.4%) 31 (35.6%) 23 (42.6%) 
P value 0.852  0.522  
Axillary lymph node status     
Negative 43 (49.4%) 20 (30.3%) 53 (49.5%) 12 (21.4%) 
Positive 44 (50.6%) 46 (69.7%) 54 (50.5%) 44 (78.6%) 
P value 0.017*  0.001**  
Oestrogen receptor status     
Negative 14 (18.7%) 14 (21.9%) 20 (21.3%) 9 (16.1%) 
Positive 61 (81.3%) 50 (78.1%) 74 (78.7%) 47 (83.9%) 
P value 0.638  0.435  
urvival status at last follow-up     
Alive 59 (86.8%) 52 (88.1%) 8 (88.9%) 114 (87.0%) 
Death 9 (13.2%) 7 (11.9%) 1 (11.1%) 17 (13.0%) 
P value 0.816  0.871  
ecurrence at last follow-up     
Yes  8 (13.3%) 12 (23.5%) 3 (37.5%) 21 (18.4%) 
No 52 (86.7%) 39 (76.5%) 5 (62.5%) 93 (81.6%) 
P value 0.164  0.189  
 * p value=0.009, adjusted for age and breast cancer family history, using logistic regression analysis; ** p 
value<0.001, adjusted for age and breast cancer family history, using logistic regression analysis. 
 
The overall survival analysis was performed in the patients where was possible to get follow-up 
of at least 60 months (Figure 2). The comparison of survival in patients with Pro/Pro vs Arg/Pro 
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vs Arg/Arg genotypes and A2A2 vs A1A2 vs A1A1 genotypes suggested a poorer survival in the 
first ones. However, these differences were not statistically significant, possibly because of the 
smaller size of the groups (7 patients to Pro/Pro and 5 patients to A2A2). 
 
 
Figure 2 – Kaplan-Meier overall survival curves in breast cancer patients relating with TP53 
Arg72Pro (a) and PIN3 Ins16bp (b) polymorphisms. Log-rank test for statistical analysis. 
 
4.4. DISCUSSION 
 
Breast cancer is an heterogeneous disease, as sustained by wide variable morphological 
appearance, many risks factors and distinct gene expression profile (2,22). Common genetic 
alterations (e.g. polymorphisms), with possible effects on function and/or protein expression, 
within genes involved in essential cellular pathways, such as carcinogen metabolism, DNA repair, 
cell cycle control and cell proliferation, could predispose individuals to cancer (15,23-25), 
including  breast cancer (15,26-29).  
The TP53 is one of the major tumour suppressor genes which carry out essential functions in 
preservation of genome integrity. Thus, when the cell is under stress, particularly stress which 
will involve DNA damage, p53 promotes growth arrest, allowing the cell to repair the DNA lesions. 
If the damage is excessively hazardous, then p53 will lead to cell apoptosis. Several genetic 
polymorphisms have been described in TP53 gene (18) and some of these variants seem to 
confer different  functions among the p53 (30-32).  
In the present study, we evaluated two separate TP53 polymorphisms, Arg72Pro and PIN3 
Ins16bp, in two groups of breast cancer, familial and sporadic cases, as well as in matching 
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control groups. The allelic frequencies of our control group for the different polymorphisms are in 
accordance with earlier reports from European populations (16,33). 
Concerning the codon 72 TP53 polymorphism (Arg72Pro), we did not find any association 
between this polymorphism and breast cancer. Our results are in agreement with other studies 
(33-35), however, the literature remains highly controversial regarding the role of this 
polymorphism in breast cancer risk (36-41). One study showed that TP53 72Pro variant induces 
transcription activation more efficiently than TP53 72Arg variant (39).  On the other hand, other 
authors revealed that TP53 72Pro variant induce cell cycle arrest better than 72Arg (31). Other 
studies have showed that TP53 72Arg variant is more efficient in inducing apoptosis (32,41). 
Beside apoptosis and cell cycle control, p53 protein seems to be crucial in the regulation of the 
different DNA repair pathways (42). A recent study demonstrated the influence of TP53 Arg72Pro 
in DNA repair capacity, showing that TP53 72Pro variant activates several TP53 dependent target 
genes involved in DNA repair and DNA damage repair much more efficiently than the 72Arg 
variant expressing cells (30). These contradictory results could be explained by the differential 
effects of this alteration in p53 function. Several in vitro evidences have demonstrated that both 
TP53 Arg72Pro variants may selectively regulate specific cellular functions. 
In TP53 PIN3 polymorphism, our findings suggest an association of A2A2 genotype and 
increased breast cancer risk among women with FH and sporadic breast cancer, suggesting that 
this polymorphism contributed to enhance susceptibility for breast cancer among Portuguese 
population, regardless of the presence of FH. Our results are supported by previously reported 
studies suggesting an association of PIN3 A2 genotypes with breast cancer risk (43). Although, 
the biological effect of the TP53 PIN3 Ins16bp polymorphism is currently unclear, theoretically, 
this polymorphism could affect mRNA splicing, altering the coding regions and therefore being 
implicated in regulation of gene expression and DNA-protein interactions, resulting in a defective 
protein (44,45). Until now, just a single study  had show PIN3 A2 allele presents reduced mRNA 
stability (46).  
The linkage disequilibrium between TP53 polymorphisms region could be an important factor 
affecting the incidence of cancer in general (47,48), and breast cancer, in particular (41,43,49). 
Thus, haplotype analysis would be important to confirm the significance of this variant on breast 
cancer susceptibility. A statistical significant association was found between Arg-A2 haplotype and 
breast cancer susceptibility among women with FH of breast cancer. On the other hand, a recent 
study has found that Pro-A1 haplotype individuals present increased breast cancer risk, however, 
99 
4. TP53 polymorphisms and prediction to breast cancer risk and lymph node metastases 
in women BRCA2 mutation carriers (41). Nevertheless, other reports have also demonstrated a 
positive association of Arg-A2 haplotype with cancer (43,47). Moreover, functional studies have 
shown that, in a specific haplotype combination, A2 allele is associated with decreased apoptotic 
and DNA repair capacity (33,47).  
Our findings suggest the Pro/Pro and A2A2 TP53 genotypes as predictor factors for the 
presence of lymph node metastases, being in agreement with previously functional studies in the 
biological consequences of these variations in P53 protein functions (39,46) 
The natural history of breast cancer can be influenced by several factors. We hypothesize that 
under the influence of TP53 genetic polymorphisms, chronic exposure to higher levels of several 
endogenous (e.g. estrogens) and exogenous breast carcinogens resulting in consequent higher 
accumulation of DNA damage during an individual’s lifetime, may alter the age at onset of 
disease. Moreover, it has been suggested that TP53 polymorphisms are associated to familial 
breast cancer by the age of 50 years (33). Our results are consistent with this hypothesis, since 
TP53 PIN3 Ins16bp polymorphism seems to influence directly the age to onset of familial breast 
cancer.  
In conclusion, our findings suggest TP53 PIN3 Ins16bp polymorphism as a real risk modifier 
in breast cancer disease, with evidence for relative differential effect by family history of breast 
cancer. Moreover, our results also suggest that PIN3 A2 allele in a haplotype combination confer 
increased breast cancer susceptibility among women carriers of FH of the disease. Subsequently, 
these results will be crucial in the characterization of the genetic breast cancer susceptibility 
profile, within familial breast cancer cases non-carriers of BRCA1/BRCA2 mutations. 
Furthermore, our findings suggest TP53 Arg72Pro and PIN3 Ins16bp polymorphisms as 
predictive factors of presence of lymph node metastases. 
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CHAPTER 5 – IMMUNOHISTOCHEMICAL EXPRESSION PROFILE OF XRCC1, 
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NOTE 
 
In our previous results, we showed that XRCC1 399Gln genotypes conferred a protective 
effect to the development of sporadic breast cancer. Furthermore, we also showed a strong 
association between increased breast cancer susceptibility in women carriers of XRCC3 241Met 
genotypes and sporadic breast cancer. Additionally, we demonstrated an association of RAD51 
135C genotypes and increased breast cancer risk among women with FH of breast cancer, 
suggesting that this polymorphism contributes to familial breast cancer in the Portuguese 
population. Moreover, our findings suggested that PIN3 A2 allele in a haplotype combination 
confer increased breast cancer susceptibility among women carriers of FH of the disease.  In 
order to understand the role of these polymorphisms, we decided to evaluate XRCC1, XRCC3, 
RAD51 and P53 protein expression profiles in a series of invasive ductal breast carcinoma and in 
a panel of human breast cancer cell lines, assessing the possible correlations between the 
different expression profiles and the genetic polymorphic status. 
The expression profiles were evaluated by immunohistochemical and western blot techniques 
and were studied to XRCC1, XRCC3 and P53 proteins. We excluded from this analysis the 
RAD51 protein screening due to technical reasons. After several attempts, using different 
antibodies and technical conditions, we did not find a RAD51 antibody that gives feasible results.  
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ABSTRACT 
 
The important role of DNA repair in the maintenance of a normal cellular genotype and a 
cancer-free state is obvious in familial hereditary breast cancer, demonstrated by increase risk 
related to important genes involved in DNA repair pathways, such as BRCA1, BRCA2, TP53, 
ATM, and NBS1 genes. Although, several DNA repair polymorphisms have been associated with 
differential DNA repair capacity and risk to breast cancer, such as XRCC1 Arg399Gln, XRCC3 
Thr241Met and TP53 PIN3 Ins16bp, nothing is known concerning the correlation between 
protein expression in breast cancer and their polymorphic status. Our aim was to evaluate 
XRCC1, XRCC3 and P53 protein expression profiles in a series of invasive ductal breast 
carcinoma and in a panel of human breast cancer cell lines and to assess the possible 
correlations between their respective genetic polymorphic status and clinical-pathological 
features. Our results showed that XRCC1 nuclear expression is a common event in human breast 
tissues, either in normal-like, benign lesions, DCIS and invasive carcinomas. Moreover, we 
showed that XRCC3 expression may be associated with the regulation of P53 and XRCC1 
expression in breast tumors and possibly an important factor in prediction of less aggressive 
breast tumors. Furthermore, we demonstrated that XRCC1, XRCC3 and P53 protein expressions 
do not correlate with their genetic polymorphisms status either in breast cancer patients or 
human breast cancer cell lines.  
 
5.1. INTRODUCTION 
 
Breast cancer is the leading cause of death among women in developing countries. In 
Portugal, it presents the highest incidence and mortality rates in women diseases (1). Well-
established risk factors have been described to breast cancer, such as early menarche, late 
menopause, age of first child’s birth and nulliparity (2), most of them reflecting a prolonged 
exposure to estrogen (3). However, these factors account for only half of the breast cancer cases. 
Several environmental factors have been associated with risk for breast cancer development, 
such as ionized radiation and chemical carcinogens (diet and environment) (4-6). These 
mutagens sources, together with endogenous and/or exogenous estrogens, produce a wide 
range of DNA lesions, such as reactive oxygen species, abasic sites, oxidized bases, bulky DNA 
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adducts and DNA strand breaks (7-9). However, during evolution, mammalian cells have 
developed distinct pathways to repair different types of DNA damage, in order to maintain the 
genome integrity. Therefore, DNA repair capacity determines cellular susceptibility to endogenous 
and exogenous substances and factors.  The crucial role of DNA repair in the maintenance of a 
normal cellular genotype and a “cancer-free” state is obvious in familiar hereditary breast cancer, 
demonstrated by the increased risk related to mutations in important genes involved in DNA 
repair pathways, such as BRCA1, BRCA2, TP53, ATM, and NBS1 genes (10). Interestingly, 
several DNA repair polymorphisms have been associated with differential risk to breast cancer 
and with differential DNA repair capacity (11,12). 
The XRCC1 and XRCC3 carry important functions in DNA repair; however, they work through 
distinct pathways. XRCC1 plays a central role in the BER mechanism, which is responsible for 
lesions repair from distinct origin, like oxidative and IR (13). On the other hand, XRCC3, another 
member of this family, is a HRR crucial player repairing DSBs produced by endogenous sources, 
like oxidative stress, mechanical stress on chromosomes and replication errors, and exogenous 
sources, such as IR and some chemicals. It has been shown that XRCC1 interacts with DNA 
Polβ, DNA Lig III and APE1, through a BRCT-I at the C-terminus (14). Several polymorphisms 
have been found in XRCC1 gene and some have been linked with a variety of cancers (15). 
Interestingly the most common XRCC1 polymorphism, Arg399Gln, located in exon 10, is known 
to lay within the BRCT-I domain (16). XRCC3 interacts directly with RAD51, helping in the 
assembly of the nucleofilament protein, as well as in the selection and interaction with 
appropriate recombination substrate (17). The XRCC3 Thr241Met polymorphism, located in exon 
7, is very common and seems to be responsible for a lower DNA repair capacity in healthy 
individuals, probably affecting the enzyme function and/or its interaction with other proteins 
involved in DNA damage and repair (18,19).   
An important protein interacting with DNA repair processes, such as BER and HRR, is P53 
(20-22). P53 is activated in response to a large range of stress, such as genotoxic damages (UV 
and IR radiation, chemical carcinogenesis and oxidative stress) and non-genotoxic damage, 
including hypoxia and oncogene activation (23). Its activation abolishes a wide variety of 
biological activities, including cell-cycle checkpoints, induction of apoptosis, DNA recombination, 
chromosomal segregation, cellular senescence and enhancement of DNA repair (20). Several 
polymorphisms have been identified within TP53 gene, both in non-coding and coding regions 
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(24), as the common polymorphism resulted from a 16 bp duplication in intron 3 (PIN3 
Ins16bp). However, information about its biological consequences is still scarce. 
Our previous results showed the importance of some DNA repair polymorphisms in breast 
cancer susceptibility (25). Although it is well established the crucial role of XRCC1 and XRCC3 
proteins in the maintenance of genomic integrity, there is no studies revealing their expression 
profile in normal and tumor tissues and its correlation with other DNA repair proteins, such as 
P53. 
Thus, the aim of the present work was to determine the XRCC1, XRCC3 and P53 expression 
profile in breast tissues, analysing normal, benign and neoplastic lesions (in situ and invasive 
ductal carcinomas) by immunohistochemistry (IHC) in tissue microarrays (TMA). We evaluated 
the correlation of their expression profiles and the respective genotypes and clinical-pathological 
features, such as family history, histological grade, nodal and ER status, as well as correlations 
between their expressions. We further performed a XRCC1, XRCC3 and P53 expression 
screening in a set of human breast cancer cell lines correlating it with the respective genetic 
polymorphic status. 
 
5.2. MATERIALS AND METHODS 
 
Study Population 
One hundred and eighty one breast tissue samples were obtained from the Hospital São João 
and Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), 
Porto, Portugal. Eight out of these were normal-like parenchima samples adjacent to the tumor, 
seven samples were classified as benign breast disease (such as fibroadenoma, adenosis, and 
typical ductal hyperplasia); thirteen samples were identified as DCIS and one hundred and fifty 
three samples were invasive ductal carcinomas. Patients with invasive breast carcinoma 
presented a mean age of 51.79 years (SD ± 14.08), ranging from 19 to 83 years. Clinical-
pathological features were obtained from hospital records when it was available. From the 
invasive ductal carcinomas, thirty nine presented clinical features of familial breast cancer based 
on the Breast Cancer Linkage Consortium criteria (26): early onset (≤40 years) and/or 
bilaterality; or more than three cases of breast cancer in the family; or more than one case of 
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ovarian cancer in the family; or more than two first-degree relatives involved; or male breast 
cancer. The remaining cases were considered sporadic breast cancer.  
From all invasive breast carcinoma, it was possible to obtain DNA from peripheric blood and 
tumor tissue samples for 49 patients, who were genotyped for the different polymorphisms in 
study.  
 
Cell lines and paraffin cell blocks 
The breast carcinoma cell lines, MDA-MB-231, MDA-MB-468, SKBr-3, BT-474, BT549, T47D, 
MCF-7, ZR-75-1, Hs578-T and MDA-MB-435 were kindly supplied by Elena P. Moiseeva (Cancer 
Biomarkers and Prevention Group, Leicester University, Leicester, United Kingdom); Eric W.-F. 
Lam (Cancer Research-United Kingdom Laboratories, Imperial College London, London, United 
Kingdom); and Mark Mareel (Laboratory of Experimental Cancerology, Department of 
Radiotherapy and Nuclear Medicine, VIB-Ghent University, Ghent, Belgium). All cell lines were 
cultured in Dulbecco’s Modified Eagles’ Medium supplemented with 10% (v/v) fetal bovine 
serum, 100 units/ml penicillin and 100 μg/ml streptomycin, at 37°C in humidified 5% CO2. To 
produce paraffin cell blocks, cell pellets from all cell lines were washed in phosphate buffer 
solution (PBS) 1x, fixed with 10% formalin during 20 min and then treated with 22% bovine 
serum albumin (BSA) solution and then incubated with ethanol 95%. The final pellets were then 
fixed overnight in 10% formalin, and then histologically processed. 
 
Genotyping 
Blood samples from all the study participants were collected in tubes with EDTA as an 
anticoagulant. Genomic DNA was isolated from buffy coat using Puregene® DNA Purification Kit 
from Gentra Systems. XRCC1 Arg399Gln, XRCC3 Thr241Met and TP53 PIN3 Ins16bp 
polymorphisms were assessed by PCR-RFLP technique, as already described (25). Briefly, 
fragments containing the specific polymorphisms were amplified by PCR, which were then 
digested with specific restriction endonuclease enzymes.  The results were obtained comparing 
different pattern fragments corresponding to specific genotypes, after fragment separation by 
electrophoresis in a 3% agarose gel. 
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Tissue Microarrays construction 
The TMA construction was conducted as previously described (27). Briefly, representative 
areas of different lesions/normal breast tissue were carefully selected on hematoxylin and eosin 
(H&E)-stained sections. Tissue cores (2 mm in diameter) were obtained from each selected area 
in the corresponding paraffin block and deposited into a recipient paraffin block using a TMA 
workstation (TMA builder ab1802, Abcam, Cambridge, United Kingdom). The H&E-stained slide 
from each block was performed to confirm the presence of the morphological representative 
area. 
 
Immunohistochemical analysis 
Immunostaining was carried out using the streptavidin-biotin-peroxidase technique in each set 
of glass slides containing the TMAs. Briefly, slides were deparaffinised and rehydrated and 
antigen retrieval was done incubating TMA slides in boiling (98ºC) 10 mM citrate buffer, pH 6.0, 
for 20 min followed by cooling at room temperature (RT) for 20 min. After washes in PBS, 
endogenous peroxidase activity was inactivated by incubation for 10 min in 3% (v/v) 
H2O2/methanol. Slides were then incubated with a blocking serum (LabVision Corporation, 
Fremont, USA) for 10 min, for blockage of non-specific protein binding, and then incubated with 
the primary antibody: XRCC1 monoclonal mouse antibody (clone 144, LabVision) diluted 1:150 
for 2 hours at RT; XRCC3 epitope specific rabbit antibody (LabVision) diluted 1:100 for 2 hours at 
RT; and P53 monoclonal mouse antibody (clone DO-7, Novocastra) diluted 1:100 for 2 hours at 
RT. After washes, the slides were incubated with biotinylated secondary antibody, following by 
streptavidin-conjugated peroxidase (LabVision Corporation, Fremont, USA). Diaminobenzidine 
was used as chromogen. Tissues were then counterstained with hematoxylin and covered with a 
mounting solution.  
The IHC staining was assessed independently by at least two of the authors, including one 
pathologist. In each run, a positive control was included (normal testis for XRCC1 and XRCC3, 
and breast carcinoma for P53). A negative control for each antibody was also included by 
replacing the primary antibody by PBS. 
The expression of XRCC1 and XRCC3 was classified by the absence (negative, 0) or presence 
of nuclear staining (positive, 1). XRCC3 was also evaluated by the intensity of its cytoplasmic 
stain, being graded as negative (0), low (1+), moderate (2+) or strong (3+). The cases 0/1+ were 
considered as negative and the 2+/3+ as positive. P53 nuclear expression was classified 
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according to a score already described (28): moderate or strong diffuse staining in more than 
50% of the neoplastic cells was considered positive. 
The same protocol was used to perform and evaluate IHC expression in paraffin cell block 
slides.  
 
Western-blot (WB) analysis 
All lysates were made from cell monolayers at 90% of confluence, which were washed twice 
with PBS. Cells were lysed with PBS containing 1% Triton X-100 (Sigma-Aldrich, St. Louis, USA), 
1% Nonidet P-40 (Sigma-Aldrich, St. Louis, USA), and 1:7 protease inhibitor cocktail (Roche 
Applied Science, Penzberg, Germany). After clearing the lysates, protein concentration was 
determined using the Rc Dc protein assay (BioRad, Richmond, USA). Total protein samples (75 
μg) were resolved by 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE), transferred to a nitrocellulose membrane (Hybond C) (Amersham Pharmacia Biotech, 
Piscataway, USA) and immunoblotted for 2 hours at RT using anti-XRCC1 monoclonal antibody 
(1:1000) (clone 144, Labvision, Fremont, USA), XRCC3 epitope specific rabbit antibody (1:250) 
(Labvision, Fremont, USA), P53 monoclonal antibody (1:10000) (clone DO-1, Novocastra, 
Newcastle, England), and goat anti-rabbit or anti-mouse antibodies (1:10000) (Santa Cruz 
Biotechnology, Santa Cruz, USA). Immunoreactive bands were then visualized by 
chemiluminescence (SuperSignal West Femto Maximun Sensitivity Substrate®, Pierce, Rockford, 
USA), following manufacturer’s instructions. The membrane was then stripped and re-probed 
with monoclonal mouse α-tubulin (1:10000) (Sigma-Aldrich, St. Louis, USA). Each immunoblot 
was done at least three times, and the selected are representative experiments. Protein 
expression was quantified using the AlphaImager analysing software (Alpha Innotech, San 
Leandro, USA. The final Intensity Density Value (IDV) for each cell line was normalised to the α-
tubulin levels. Protein expressions were classified based on IDV score established, being graded 
as negative (0) with an IDV range of 0-1000, low (1+) with an IDV range of 1001-5000, moderate 
(2+) with an IDV range of 5001-10000 or strong (3+) with an IDV range of >10000. The cases 
0/1+ were considered as negative and the cases 2+/3+ as positive. 
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Statistical analysis 
Data analysis was performed using the computer software SPSS version 14.0. Pearson’s Chi-
square test (χ2) test or Fisher’s exact test (when n<5) was used to analyse the relationship of 
protein expressions with genetic polymorphic status and with clinical-pathological parameters. A 
5% level of significance was used in the analysis. Logistic regression analysis was applied to 
calculate the adjusted p value for mean age in the identification of subgroups of disease patients 
according to clinical-pathological features. The Pearson Correlation test was used to analyse 
expression correlations between the different proteins. 
 
5.3. RESULTS 
 
5.3.1. XRCC1, XRCC3 and P53 protein expressions in normal, benign and malignant breast 
tissues samples and in human breast cancer cell lines 
The predominant pattern for XRCC1, XRCC3 and P53 protein expression observed in all 
breast tissue samples was nuclear; although, XRCC3 expression was also detected in the 
cytoplasm. XRCC1 nuclear staining was observed in 66.7% epithelial cells from normal-like 
tissues, in 85.7% of BBD lesions, 66.7% of DCIS and 61.3% of invasive carcinomas (Figure 1 A-
G). Regarding XRCC3 nuclear expression, we detected a positive staining in 25.0% of normal-like 
breast tissues, 28.6% of benign lesions, 30.8% of DCIS and 31.9% of invasive breast carcinomas. 
Cytoplasmic expression of XRCC3 was found in 75.0% of breast normal-like tissues, 42.9% of 
BBD, 53.8% of DCIS and 61.3% of invasive breast carcinomas (Figure 1 H-Q). About P53 nuclear 
expression, all normal-like breast tissues and BBD lesions were negative (Figure 1 R-S). In 
contrast, DCIS cases showed 27.3% of P53 positivity, whereas the invasive carcinomas showed 
12.4% (Figure 1 T-Y). 
We also assessed the correlation between XRCC1, XRCC3 and P53 IHC protein expression, 
where we found a statistically significant correlation between XRCC1 (Pearson p=0.023) and P53 
(Pearson p=0.022) with XRCC3 cytoplasmic expression. 
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Figure 1 – Immunohistochemistry expression of XRCC1, XRCC3 and P53 protein in breast 
tissue samples. XRCC1 expression (A-G): (A) normal tissue (original magnification 200x); (B) – 
benign lesion (original magnification 200x); (C) – DCIS (original magnification 200x); (D-E) – 
negative staining of invasive ductal carcinomas (original magnification 200x); (F-G) - positive stain 
of invasive ductal carcinomas (original magnification 200x). XRCC3 expression (H-Q): (H) normal 
tissue (original magnification 200x); (I) – benign lesion (original magnification 200x); (J) – DCIS 
(original magnification 200x); (K-N) negative nuclear stain and low (L), moderate (M) and high (N) 
cytoplasmic intensity of invasive ductal carcinomas (original magnification 200x); (O-Q) – positive 
nuclear stain and low (O), moderate (P) and high (Q) cytoplasmic intensity of invasive ductal 
carcinomas (original magnification 200x). P53 expression (R-Y): (R) - normal tissue (original 
magnification 200x); (S) – benign lesion (original magnification 100x); (T) – DCIS (original 
magnification 100x); (U-W) – negative stain of invasive ductal carcinomas (original magnification 
100x); (X-Y) - positive stain of invasive ductal carcinomas (original magnification 100x). 
 
The XRCC1, XRCC3 and P53 expression levels in the 10 different breast cancer cell lines 
studied were determined by IHC and WB. A representative positive and negative nuclear IHC 
staining of the three proteins studied are revealed in Figure 2 and all the results are presented in 
Table1. Almost all cell lines presented a positive XRCC1 expression, except the BT-549 and MDA-
MB-231 cell lines. Regarding XRCC3 expression, only MDA-MB-231 and MDA-MB-468 cell lines 
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showed a negative pattern to this protein. MCF7, BT-549, ZR-75-1 and MDA-MB-435 cell lines 
were negative for P53 expression. 
 
 
Figure 2 – Representative IHC expression of XRCC1, XRCC3 and P53 proteins in human 
breast cancer cell lines. XRCC1 negative (A) and nuclear staining expression (B) (original 
magnification 200x). XRCC3 negative nuclear and positive cytoplasmic expression (C) (original 
magnification 400x) and nuclear expression (with lack of cytoplasmatic expression) (D) (original 
magnification 200x). P53 negative (E) and positive (F) nuclear expression (original magnification 
200x). 
 
Table 1 – XRCC1, XRCC3 and P53 protein expression analysed by IHC and WB in a panel of 
10 human breast cancer cell lines. 
XRCC1 XRCC3 P53 Human Breast 
Cancer Cell Line IHC WB IHC WB IHC WB 
MCF7 1 2+ 1 2+ 0 1+ 
ZR-75-1 1 3+ 1 3+ 0 0 
SkBr3 1 3+ 1 2+ 1 2+ 
T47D 1 3+ ND 2+ 1 3+ 
BT-474 1 0 1 2+ 1 1+ 
BT-549 0 2+ 1 2+ 0 2+ 
Hs598T 1 2+ 1 3+ 1 2+ 
MDA-MB-231 1 2+ 1 3+ 1 3+ 
MDA-MB-435 1 3+ 1 3+ 0 3+ 
MDA-MB-468 1 2+ 1 3+ 1 3+ 
1- positive expression; 0 – negative expression; ND – not possible to determine. 
 
The immunoblot expression pattern observed was presented in Figure 3. All the human breast 
cancer cell lines demonstrated moderate to strong expression levels of XRCC1 protein, except, 
BT-474 that expressed negative levels (Figure 3 – upper panel and Table 1). In relation to P53 
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expression, we observed moderate to strong levels in SkBr-3, T47D, BT-549, Hs578T, MDA-MB-
231, MDA-MB-435 and MDA-MB-468 cell lines. In the other hand, MCF7, ZR-75-1 and BT-474 
cell lines showed negative to low P53 expression (Figure 3 – middle panel and Table 1). XRCC3 
protein was expressed in moderate to a strong manner in all the cell lines analysed (Figure 3 – 
lower panel and Table 1).  
IHC analysis demonstrated expression patterns similar to WB analysis in almost all human 
breast cancer cell lines studied (correlation in 70 to 90%). 
 
 
Figure 3 – Western blotting for XRCC1, P53 and XRCC3 expression protein analysis, from cell 
lysates derived from 10 human breast cancer cell lines used in this study. Protein expression 
levels were determined, intensity of the bands was measured, and normalised to an internal 
control. 
 
 
5.3.2. Correlation of XRCC1, XRCC3 and P53 protein expressions in breast cancer patients and 
human breast cancer cell lines with genetic polymorphic status 
The correlation analysis of XRCC1, XRCC3 and P53 IHC expression with their respective 
polymorphisms were performed in patients where we had both information. No correlation was 
found considering XRCC1, XRCC3 or P53 nuclear staining or XRCC3 cytoplasmic staining with 
respective genotypes (Table 2).  
Next, we decided to use the WB results to see whether there was any correlation between the 
protein levels, expressed in the different cell lines, and their respective polymorphic status (Table 
3). No correlation was found between XRCC1, XRCC3 and P53 protein levels and the respective 
polymorphic status. 
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Table 2 – Correlation between XRCC1, XRCC3 and P53 proteins IHC expression and XRCC1 
Arg399Gln, XRCC3 Thr241Met and TP53 PIN3 Ins16bp polymorphisms. 
Positive Nuclear 
staining (%) 
Positive Cytoplasmic 
staining (%) Genotypes 
Negative Positive 
P  
value 
Negative Positive 
P  
Value 
XRCC1 Arg399Gln       
Arg/Arg  10 (58.8) 15 (53.6) 
Arg/Gln 5 (29.9) 11 (39.3) 
 
Gln/Gln 2 (11.8) 2 (7.1) 
0.742 NA 
 
XRCC3 Thr241Met       
Thr/Thr  22 (55.0) 6 (66.7) 9 (56.3) 19 (57.6) 
Thr/Met 12 (30.0) 2 (22.2) 4 (25.0) 10 (30.3) 
Met/Met 6 (15.0) 1 (11.1) 
0.815 
3 (18.8) 4 (12.1) 
0.802 
P53 PIN3 Ins16bp       
A1A1  13 (48.1) 4 (80.0) 
A1A2 11 (40.7) 0 (0.0) 
A2A2 3 (11.1) 1 (20.0) 
0.211 NA  
NA: not applicable. 
 
Table 3 – XRCC1 Arg399Gln, XRCC3 Thr241Met and TP53 PIN3 Ins16bp polymorphisms 
genotypes and protein expression in human breast cancer cell lines. 
XRCC1 Arg399Gln XRCC3 Thr241Met TP53 PIN3 Ins16bp Human Breast 
Cancer Cell 
Line 
Genotypes WB 
P 
value Genotypes WB 
P 
value Genotypes WB 
P 
value 
MCF7 Arg/Arg 1  Thr/Thr 1  A1A1 0  
ZR-75-1 Arg/Arg 1  Met/Met 1  A1A1 
 
 
 
 
 
 
 
0  
SkBr3 Arg/Arg 1  Met/Met 1  A1A1 1  
T47D Arg/Arg 1  Thr/Met ND  A2A2 1  
BT-474 Gln/Gln 0 0.200 Met/Met 1 ND A1A1 0 0.301 
BT-549 Gln/Gln 1  Thr/Thr 1  A2A2 1  
Hs598T Arg/Arg 1  Thr/Met 1  A1A1 1  
MDA-MB-231 Arg/Arg 1  Thr/Thr 1  A1A1 1  
MDA-MB-435 Arg/Arg 1  Met/Met 1  A1A1 1  
MDA-MB-468 Arg/Arg 1  Thr/Thr 1  A1A1 1  
1- positive expression; 0 – negative expression; ND – not possible to determine. 
 
 
5.3.3. Correlation of XRCC1, XRCC3 and P53 protein expressions in breast cancer patients and 
clinical-pathological features 
The correlation between protein expression and genetic polymorphisms was performed by 
logistic regression analysis, adjusted for age. As shown in Table 4, there is no statistical 
significant relationship between XRCC1 nuclear staining and any of the clinical-pathological 
parameters considered. Likewise, no association was obtained between P53 nuclear staining or 
XRCC3 cytoplasmic expression with clinical-pathological features (Table 4). On the other hand, 
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positive XRCC3 nuclear staining showed correlation with lower tumor grade (grade I and II) 
(p=0.070), as well as estrogen receptor (ER) positivity status in the tumor (p=0.060) (Table 4), 
with relative statistically significant differences. No correlation was found between XRCC3 nuclear 
expression and any other of the clinical-pathological parameters analysed. 
 
Table 4 – Correlation between XRCC1, XRCC3 and P53 proteins IHC expression and clinical-
pathological features of invasive breast carcinomas. 
XRCC1  
Nuclear Staining 
XRCC3 
Nuclear Staining 
XRCC3  
Cytoplasmic Staining 
P53 
Nuclear Staining 
Features 
Negative Positive 
P  
value 
Negative Positive 
P  
value 
Negative Positive 
P 
value 
Negative Positive 
P  
value 
Family  
History 
            
Negative  27 (71.1)  75 (75.0) 71 (68.9) 45 (86.5) 43 (78.2) 73 (73.0) 91 (79.1) 18 (85.7) 
Positive  11 (28.9) 26 (25.0) 
0.920 
32 (31.1) 7 (13.5) 
0.141 
12 (21.8) 27 (27.0) 
0.371 
24 (20.9) 3 (14.3) 
0.797 
Histological 
Grade 
            
I 5 (20.0) 10 (16.7) 11 (17.2) 6 (23.1) 7 (21.9) 10 (17.2) 15 (20.8) 1 (11.1) 
II 14 (56.0) 28 (46.7) 26 (40.6) 15 (57.7) 16 (50.0) 25 (43.1) 37 (51.4) 4 (44.4) 
III 6 (24.0) 22 (36.7) 
0.426 
27 (42.2) 5 (19.2)a 
0.156 
9 (28.1) 23 (39.6) 
0.239 
20 (27.8) 4 (44.4) 
0.358 
Lymph 
Nodes 
            
Negative 8 (61.5) 17 (48.6) 23 (63.9) 7 (41.2) 15 (71.4) 15 (46.9) 25 (53.2) 1 (25.0) 
Positive 5 (38.5) 18 (51.4) 
0.436 
13 (36.1) 10 (58.8) 
0.221 
6 (28.6) 17 (53.1) 
0.080 
22 (46.8) 3 (75.0) 
0.407 
ER status             
Negative 4 (20.0) 10 (19.6) 15 (27.3) 1 (4.5) 5 (17.9) 11 (22.4) 11 (18.0) 2 (33.3) 
Positive 16 (80.0) 41 (80.4) 
0.892 
40 (72.7) 21 (95.5) 
0.060 
23 (82.1) 38 (77.6) 
0.574 
50 (82.0) 4 (66.7) 
0.417 
a – comparison grade I/II vs III, p=0.007, p value adjusted for mean age, using logistic regression analysis. 
 
 
5.4. DISCUSSION 
 
Breast cancer cells, as most of the cancer cells, have high genomic instability, representing a 
critical feature to enable tumor initiation and progression (29). In this way, it is of extremely 
importance to maintain a DNA damage/repair balance, through the perfect function of DNA 
damage signalling pathways and cell cycle checkpoints, such as those regulated by P53, BER, 
NER and HRR DNA repair pathways. In breast cancer, the importance of these systems is 
evident, since TP53, ATM, BRCA1 and BRCA2 genes, with a direct or indirect role in DNA repair 
processes, present mutations highly correlated with breast cancer development (30,31). 
Furthermore, several molecular epidemiological studies had shown that polymorphisms in genes 
involved in these pathways result in differential susceptibility to breast cancer (25,32-35). In 
previous studies (25), we showed that XRCC1 399Gln genotypes conferred a protective effect to 
development of sporadic breast cancer. Furthermore, we demonstrated a strong association of 
increased breast cancer susceptibility in women carriers of XRCC3 241Met genotypes and 
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negative FH of breast cancer. In addition, other study performed by us suggested that PIN3 A2 
allele in a haplotype combination confer increased breast cancer susceptibility among women 
carriers of FH of the disease.  Therefore, we decided to evaluate the XRCC1, XRCC3 and P53 
proteins expression profiles in a series of invasive ductal breast carcinoma and in a panel of 
human breast cancer cell lines assessing the possible correlations between their respective 
genetic polymorphic status. 
To the best of our knowledge, this study represents the first report where XRCC1 expression 
profile in breast tissues was evaluated. Our results showed that XRCC1 nuclear expression is a 
common event in human breast tissues, either in normal-like, benign lesions, DCIS and invasive 
carcinomas. Similar results where obtained in other types of human cancer. Crnogorac-Jurcevic 
et al (36) described positive nuclear XRCC1 IHC expression in 100% of normal pancreatic tissues 
evaluated, whereas just 77% of the neoplastic pancreatic samples presented moderate/strong 
expression. In invasive bladder carcinoma, a mean percentage of positive nuclear staining of near 
95% was observed (37). No correlation of XRCC1 expression was found with clinical-pathological 
features. 
Regarding XRCC3 expression, the frequency of cytoplasmic positive breast cancer cases is 
comparable to what has been previously reported (38). However, XRCC3 nuclear expression 
frequency differs from that obtained by Honrado et al (38), mainly in the sporadic breast cancer 
patients. These differences could be explained by clinical features heterogeneity in sporadic 
cases used in both studies. Moreover, our study demonstrated that XRCC3 nuclear expression 
correlates with well/moderate differentiated tumors and with positivity to estrogen receptors. 
XRCC3 expression reveals an operational protein, working in order to achieve a state of relative 
genomic stability. Thus, cancer cells with active XRCC3 can exist in less aggressive tumors, 
traduced in more differentiated tumors and positive estrogens receptors. 
The frequency of P53 positive nuclear expression in invasive breast carcinoma samples 
(12.4%) was similar to other studies (39-41). Additionally, we did not obtain any association 
between P53 IHC expression and clinical-pathological characteristics, which is in agreement with 
other studies, demonstrating the weak value of P53 IHC in the prognostic and prediction of 
breast cancer (42). 
XRCC3 gene is required for several functions, like repair of double strand breaks through the 
HRR pathway (43), DNA cross-linking repair (44), and chromosomal segregation (45). During 
HRR, the XRCC3 protein interacts with the RAD51 protein, enabling RAD51 protein multimers to 
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assemble at the site of damage (44,46). Furthermore, RAD51 has also been found to colocalize 
with the XRCC1 protein after base damage, suggesting coordination between XRCC1-dependent 
single strand break repair and recombination events during DNA replication (47). This is in 
agreement to our results, since we found a great correlation between XRCC1 positive and XRCC3 
cytoplasmic positive expression in breast cancer tissues. Furthermore, we also observed a 
correlation between P53 positive expression and XRCC3 cytoplasmic positive expression. As 
already mentioned, P53 takes part directly or indirectly in several DNA repair pathways, such as 
HRR. Several studies demonstrated that P53 wild-type downregulates HRR through interaction 
with RAD51 or it paralogs, like XRCC3 (22). Since P53 expression suggests a deregulation of P53 
function, thus upregulation of HRR players, like XRCC3, can occur. The biologic meaning of 
cytoplasmic XRCC3 protein localization is unknown. However, evidences from in vitro studies 
have shown XRCC3 staining increased in the cytoplasm region after DNA damage (48,49), 
suggesting a biological role of this protein in the cytoplasmatic compartment. 
No association was found concerning the XRCC1, XRCC3 and P53 protein expression in 
breast cancer and their polymorphic status, either in case group and cell lines. The reason for it 
can be due to the high genetic heterogeneity within tumors, so that polymorphisms in these 
genes produce only subtle alterations in protein activity and effectiveness, which were not 
perceptible in IHC analysis. Furthermore, interpretation of IHC is a subjective issue, depending 
on the experience of the interpreter. 
In summary, our study was the first to describe XRCC1 IHC expression profile in breast 
tissues. We showed that XRCC3 expression may be associated with P53 regulation and XRCC1 
expression in breast tumors and XRCC3 positivity expression may be an important factor in 
prediction of less aggressive breast tumor. Moreover, we demonstrated that XRCC1, XRCC3 and 
P53 expressions do not correlate with the respective genetic polymorphisms analysed, in breast 
cancer patients and human breast cancer cell lines.  
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Breast cancer is a heterogeneous disease, sustained by a wide variable morphological 
appearance, many risks factors and distinct gene expression profiles (1,2). Common genetic 
alterations (e.g. polymorphisms), with possible effects on function and/or protein expression, 
within genes involved in essential cellular pathways, such as carcinogen metabolism, DNA repair, 
cell cycle control and cell proliferation, could predispose individuals to cancer (3-6), including  
breast cancer (4,7-10). 
Breast cancer cells, like all cancer cells, exhibit high genomic instability, representing a critical 
feature to enable tumor initiation and progression (11). In this way, it is of extremely important 
the maintenance of DNA damage/repair balance, through the perfect functions of DNA damage 
signalling/repair pathways and cell cycle checkpoints, such as those regulated by P53, and the 
BER, NER and HRR DNA repair pathways. In breast cancer, the importance of these systems is 
evident, since TP53, ATM, BRCA1 and BRCA2 genes, with a direct or indirect role in DNA repair 
processes, present mutations highly correlated with breast cancer development (12,13). 
Moreover, there is increasing data supporting the hypothesis that genetic polymorphisms in 
various DNA repair genes result in reduced DNA repair capacity (14-21). Furthermore, several 
molecular epidemiological studies have shown that polymorphisms in genes involved in these 
pathways result in differential susceptibility to breast cancer (22-26). 
In our Portuguese case-control study, we investigated the role of some of these DNA repair 
genes polymorphisms involved in BER, NER and HRR pathways (XRCC1 Arg399Gln, XPD 
Lys751Gln, RAD51 G135C and XRCC3 Thr241Met) and two separate TP53 polymorphisms 
(Arg72Pro and PIN3 Ins16bp), in two groups of breast cancer, familial and sporadic cases, as 
well as in matching control groups. The allelic frequencies of our control group for the different 
polymorphisms are in accordance with earlier reports from European populations (27-30). 
XRCC1 protein is thought to act as a scaffold protein for both single-strand break repair and 
base excision repair activities (31). It has been shown that XRCC1 interacts with DNA Polβ, DNA 
LigIII and APE1, through a BRCT domain at the C-terminus (32). XRCC1 seems to be essential to 
mammalian viability, since its disruption in mice leads to embryonic lethality (33). Several 
polymorphisms have been found in XRCC1 gene and some have been linked to several types of 
cancer (17). Our findings suggest a protective effect of the 399Gln genotypes of XRCC1 
6. General Discussion 
 
polymorphism to the development of breast cancer in women with no FH.  These results are 
consistent with those from previous studies of XRCC1 polymorphisms and cancer risk, which 
reported a protective association between the 399Gln carriers and cancer (28,34,35). However, 
other studies in breast cancer showed contradictory results. Some observed a positive correlation 
of 399Gln genotypes with breast cancer risk, specially when gene-exposure interactions were 
considered (36-38); others demonstrated no association (39,40) having also in account the 
presence of FH (9,41-43). Functional studies about XRCC1 suggest that the 399Gln allele may 
be associated with higher levels of different types of DNA damage in some cancers (16,44,45). 
These contradictory effects of 399Gln genotypes can be explained by two points. First, the gene 
variants can independently confer particular function to XRCC1 protein, since their effects can 
potentially depend from other biochemical pathways operating in the tissue being analyzed (46). 
The effects of any given genetic variant can also depend from other genetic or environmental 
factors that interact with it (47). Secondly, these variants can diminish the protein efficiency but 
still provide decreased cancer risk, since, in the presence of excessive damage, cells carriers of 
these variants will have decreased ability to repair and may be more likely to undergo apoptosis. 
XPD is a highly polymorphic gene and the correlation of its polymorphisms and cancer risk 
have been studied extensively (15,18,48). XPD protein is a subunit of the TFIIH complex and has 
important roles in transcription and NER pathway. It participates in the locally unwind of DNA 
helix to permit RNA transcription machinery to access the promoter and to permit the NER 
machinery to access the lesion (49). Some common XPD polymorphisms have been associated 
with a differential DNA repair capacity (19-21,50,51). In this study, we did not find an association 
between the XPD Lys751Gln polymorphism and breast cancer risk. To date, the results 
evaluating XPD Lys751Gln polymorphism are controversial. Our results are in agreement with 
other studies where no correlation was found between this polymorphism and breast cancer risk, 
among women without (36,52,53) and with breast cancer FH (9,41). In contrast, significant 
association between XPD 751Gln allele and breast cancer risk was seen in other recent studies 
(54). Furthermore, the functional significance of XPD polymorphism seems to be dependent from 
environmental factors which interact with that variant. Some studies showed that 751Gln allele 
was associated with reduced DNA repair efficiency of UV-light DNA damage, while others showed 
a suboptimal repair of X-ray-induced DNA damage related with 751Lys allele (44,48). 
RAD51 is a protein participating in DSBR pathway that forms a heterodimer with several 
genes (such as XRCC2, XRCC3, BRCA2) playing an important role in HRR (55). The majority of 
136 
6. General Discussion 
RAD51 polymorphisms described are in UTRs. Regarding RAD51 5’UTR G135C polymorphism, 
our results showed an association of RAD51 135C genotype and increased breast cancer risk, 
only among women with FH of breast cancer. This suggests that this polymorphism contributes 
to the familial breast cancer in the Portuguese population, in opposition to reported results in the 
Brazilian population (9). Other studies have demonstrated an association of RAD51 genotypes 
with familial breast cancer risk, only in women carriers of BRCA2 mutations (56-58). Since the 
number of BRCA1 and/or BRCA2 mutations detected in our familial breast cancer cases was too 
small (59), it was not possible to perform a separate analysis. The biological effect of the RAD51 
G135C polymorphism is currently unknown. This polymorphism can affect mRNA splicing, 
regulation of transcription, translation or mRNA stability by association of the 5’UTR region with 
regulatory elements (60). Furthermore, linkage disequilibrium can occur between RAD51 gene 
and another sequence in a regulatory region of the gene or with another nearby gene, affecting 
the incidence of breast cancer in familial breast cancer. Concerning sporadic breast cancer risk, 
others studies had obtained similar results in the Australian women (61) and in the Anglo-Saxon 
population (62), where no association was obtained.  
Another important protein in HRR is XRCC3, interacting directly with RAD51, helping the 
assembly of the nucleofilament protein and the selection and interaction with appropriate 
recombination substrates (63). Some common polymorphisms were described in XRCC3 gene 
(62), such as Thr241Met. Our results demonstrate a strong association of increased breast 
cancer susceptibility in women carriers of XRCC3 241Met genotypes and sporadic breast cancer. 
This is consistent with an earlier report in the United Kingdom population (62). Functional data 
supporting the hypothesis of damaging consequences due to XRCC3 Thr241Met polymorphism 
supports our results. The 241Met variant has been associated with higher levels of bulky DNA 
adducts, mitotic defects and lower DNA repair capacities of X-ray-induced DNA damage (16,64). 
However, other studies report no risk association (9,42,61,65-67).  
The TP53 is one of the major tumour suppressor genes which carry out essential functions in 
preservation of genome integrity. Thus, when the cell is under stress, which involves DNA 
damage, p53 promotes growth arrest, allowing the cell to repair the DNA lesions. If the damage 
is excessively hazardous, then p53 will lead to cell apoptosis. Several genetic polymorphisms 
have been described in TP53 gene (68). Concerning the Arg72Pro polymorphism, we did not find 
any association with breast cancer risk. Our results are in agreement with other studies 
(30,69,70), however, the literature remains highly controversial regarding the role of this 
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polymorphism in breast cancer risk (71-76). One study showed that TP53 72Pro variant induces 
transcription activation more efficiently than TP53 72Arg variant (74).  On the other hand, other 
authors revealed that TP53 72Pro variant induces cell cycle arrest better than 72Arg (77). Other 
reports have showed that TP53 72Arg variant is more efficient inducing apoptosis (76,78). 
Beside apoptosis and cell cycle control, p53 protein seems to be crucial in the regulation of the 
different DNA repair pathways (79). A recent study demonstrated the influence of TP53 Arg72Pro 
in DNA repair capacity, showing that TP53 72Pro variant activates several TP53 dependent target 
genes involved in DNA repair much more efficiently than the 72Arg variant expressing cells (80). 
These contradictory results in molecular epidemiologic studies can be explained by the 
differential effects of this alteration in p53 function.  
Another common TP53 polymorphism is the insertion of 16bp in intron 3 of the gene. Our 
findings suggest an association of A2A2 genotype and increased breast cancer risk among 
women with familial and sporadic breast cancer, suggesting that this polymorphism contributed 
to enhance susceptibility for breast cancer among Portuguese population, regardless of the 
presence of FH. Our results are supported by previously reported studies which suggested the 
same association (81). Although the biological effect of the TP53 PIN3 Ins16bp polymorphism is 
currently unclear, theoretically, this polymorphism can affect mRNA splicing, altering the coding 
regions and therefore being implicated in regulation of gene expression and DNA-protein 
interactions, resulting in a defective protein (82,83). Until now, just a single study  had showed 
that PIN3 A2 allele presents reduced mRNA stability (84). The linkage disequilibrium between 
TP53 polymorphisms region can be an important factor affecting the incidence of cancer in 
general (85,86), and breast cancer, in particular (76,81,87). Thus, haplotype analysis would be 
important to confirm the significance of TP53 variants on breast cancer susceptibility. A statistical 
significant association was found between Arg-A2 haplotype and breast cancer susceptibility 
among women with familial breast cancer. On the other hand, a recent study has found that Pro-
A1 haplotype individuals present increased breast cancer risk, however, only in BRCA2 mutation 
carriers (76). Nevertheless, other reports have also demonstrated a positive association of Arg-A2 
haplotype with cancer (81,85). Moreover, functional studies have shown that, in a specific 
haplotype combination, A2 allele is associated with decreased apoptotic and DNA repair capacity 
(30,85).  
The variance in results of association in different case-control studies on XRCC1, XPD, 
RAD51, XRCC3 and TP53 polymorphisms may be connected to variation in genetic/ethnic origin 
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and different carcinogenic exposures of the studied populations. Too small sample size and/or 
the inadequate controlling for certain confounders such as age and breast cancer FH may also 
contribute to differing results. 
The natural history of breast cancer can be influenced by several factors. We hypothesize that 
under the influence of genetic polymorphisms, chronic exposure to higher levels of several 
endogenous (e.g. estrogens) and exogenous breast carcinogens, resulting in a higher 
accumulation of DNA damage during an individual’s lifetime, may alter the waiting-time-to onset 
of disease. Moreover, it has been suggested that DNA repair genes are associated to age related 
disease (88), and TP53 polymorphisms are associated to familial breast cancer by the age of 50 
years (30). Our results are consistent with this hypothesis, in which XRCC1 Arg399Gln, XRCC3 
Thr241Met and TP53 PIN3 Ins16bp polymorphisms seem to influence directly the age to onset 
sporadic breast cancer and familial breast cancer, respectively.  
In this work, we performed the analysis of possible associations between XRCC1 Arg399Gln, 
XPD Lys751Gln, RAD51 G135C, XRCC3 Thr241Met and TP53 Arg72Pro and PIN3 Ins16bp 
polymorphisms and breast cancer clinical-pathological features. According to our results, XRCC1 
Gln/Gln genotype seems to be associated with less aggressive tumors, since this genotype was 
correlated with well differentiated tumors. Deficient efficiency of the XRCC1 protein has been 
described in XRCC1 Gln variant (44,45). Furthermore, repair of more complex base lesions (89-
91) by BER pathway can potentially convert non-lethal DNA lesion into lethal DSB (92,93). Thus, 
deficiency in BER, by low efficiency of XRCC1, may actually reflect a well differentiated nature of 
the cancer cells in less aggressive tumors, since less lethal DNA lesions are produced.  
We also observed that RAD51 C135 genotypes show a correlation with more aggressive 
tumors, since we found a significant association of them with moderate to poor differentiated 
grade. Additionally, assessment of the OS demonstrated that patients with RAD51 C135 
genotypes presented a poorer survival compared with others genotypes. These results can be 
explained by the location of this polymorphism in the 5’ UTR, affecting mRNA stability and/or 
translation efficiency, leading to altered RAD51 protein levels (60). Thus, RAD51, the key factor of 
homologous recombination process, can disturb the activity of the multiprotein DNA repair 
complex, including BRCA1, BRCA2 and XRCC3 proteins, contributing to high levels of genetic 
instability (94), and as a result, being correlated with more aggressive tumors as described for 
breast carcinomas associated with BRCA1 mutations (95).  
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No correlation was found between XPD Lys751Gln and XRCC3 Thr241Met polymorphisms 
and clinical-pathological features, such as histological grade, axillary lymph node metastases, 
estrogen receptor, survival and recurrence at last follow-up. 
Additionally, our findings suggest the Pro/Pro and A2A2 TP53 genotypes as predictor factors 
for the presence of lymph node metastases, being in agreement with previously functional 
studies regarding the biological consequences of these variants in P53 protein function, such as, 
on one hand, transcription activation and apoptosis inhibition, and, on the other hand, cell cycle 
arrest induction and DNA repair activation, by the 72Pro allele (74,77,78,80,84).   
In summary, we showed that XRCC1 399Gln genotypes confer a protective effect to the 
development of sporadic breast cancer. Furthermore, we also demonstrated a strong association 
of increased breast cancer susceptibility in women carriers of XRCC3 241Met genotypes and 
negative FH. In addition, our results suggested that PIN3 A2 allele in a haplotype combination 
confer increased breast cancer susceptibility among women FH carriers.  Therefore and based 
on the above mentioned results, we decided to evaluate the XRCC1, XRCC3 and P53 protein 
expression profiles in a series of invasive ductal breast carcinomas and in a panel of human 
breast cancer cell lines, assessing the possible correlations between their expression and with 
their respective genetic polymorphic status. 
Importantly, this work is the first report regarding XRCC1 protein expression in breast tissues. 
Our results show that XRCC1 nuclear expression is a common event in human breast tissues, 
either in normal-like, benign lesions, DCIS and invasive carcinomas. Similar results where 
obtained in other types of human cancers. Crnogorac-Jurcevic et al (96) described positive 
nuclear XRCC1 IHC expression in 100% of normal pancreatic tissues evaluated, whereas just 
77% of the neoplastic pancreatic samples presented moderate/strong expression. In invasive 
bladder carcinoma, a mean percentage of positive nuclear staining of near 95% was observed 
(97). No correlation of XRCC1 expression was found with clinical-pathological features within our 
series. 
Regarding XRCC3 expression, our percentage of cytoplasmatic positive breast cancer cases is 
comparable with the only other existent report (98). However, our frequency of XRCC3 nuclear 
expression differs from that obtained by Honrado et al (98), mainly in the sporadic breast cancer 
patients. These differences can be explained by clinical features heterogeneity in sporadic cases 
used in both studies. Moreover, our study demonstrated that XRCC3 nuclear expression 
correlates with well/moderate differentiated tumors and with positivity to estrogen receptors. 
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XRCC3 expression reveals an operational protein, working in order to achieve a state of relative 
genomic stability. Thus, cancer cells with active XRCC3 can exist in less aggressive tumors, 
translated in more differentiated tumors and estrogens receptors positive, corroborating our 
findings. 
Our frequency of P53 positive nuclear expression in invasive breast carcinoma samples 
(12.4%) were similar to other studies (99-101). Additionally, the lack of association between P53 
IHC expression and clinical-pathological characteristics was also in agreement with previous 
reports, which showed that prognostic and predictive value of P53 positive expression in breast 
cancer was found to be weak (102).  
XRCC3 gene is required for several functions, like repair of double strand breaks through the 
HRR pathway (103), for repair of DNA cross-linking (104), and chromosomal segregation (105). 
During HRR, the XRCC3 protein interacts with the RAD51 protein, enabling RAD51 protein 
multimers to assemble at the site of damage (104,106). Furthermore, RAD51 has also been 
found to colocalize with the XRCC1 protein after base damage, suggesting coordination between 
XRCC1-dependent single strand break repair and recombination events during DNA replication 
(107). This comes in direction to our finding, where we got a good correlation between XRCC1 
positive and XRCC3 cytoplasmatic positive expression in breast cancer tissues. Furthermore, we 
observed a correlation between P53 positive expression and XRCC3 cytoplasmatic expression. As 
already mentioned P53 takes part directly or indirectly in several DNA repair pathways, such as 
HRR. Several studies demonstrated that P53 wild-type downregulates HRR through interaction 
with RAD51 or it paralogs, like XRCC3 (108). Since P53 expression suggests a deregulation of 
P53 function, so an upregulation of HRR players, like XRCC3, can occur. The biological meaning 
of cytoplasmatic XRCC3 protein localization is still unknown. However, evidences of in vitro 
studies have shown increased XRCC3 staining in the cytoplasm region after DNA damage 
(109,110), suggesting a function of this expression in the biological role of the protein. 
Concerning the XRCC1, XRCC3 and P53 protein expression in breast cancer and no 
correlation was found with their polymorphic status, either in case group and human cell lines. 
The reasons for the lack of associations can be explain by the high genetic heterogeneity of the 
tumors, so that these polymorphisms in these genes produce only subtle alterations in protein 
activity and effectiveness, which are not perceptible in IHC analysis. Furthermore, interpretation 
of IHC is a subjective issue, depending on the experience of the interpreter. 
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In conclusion, our findings imply the RAD51 G135C polymorphism as a real risk modifier in 
familial breast cancer cases. Furthermore, we point out that XRCC1 Arg399Gln and XRCC3 
Thr241Met polymorphisms are important biomarkers to sporadic breast cancer susceptibility. 
Moreover, our results also propose that PIN3 A2 allele in a haplotype combination confer 
increased breast cancer susceptibility among women carriers of FH of breast cancer. A possible 
interpretation for different associations depending on the presence of FH may be due to this 
factor broadly represents shared genes and environmental factors. The presence of a single 
polymorphism has most likely weak effects on the individual phenotype, not being measurable 
except in the context of these additional supporting factors, such as the family history. Among 
individuals without a familial predisposition, the effect may be hidden by sum effects of other 
unidentified genetic and environmental factors (42). According to our findings with clinical-
pathological parameters, we clearly underlie the role of XRCC1 Arg399Gln and RAD51 G135C 
polymorphisms in the prediction of breast tumor aggressiveness and patients’ survival. 
Furthermore, our results suggest TP53 Arg72Pro and PIN3 Ins16bp polymorphisms as predictive 
factors of presence of lymph node metastases. Additionally, we demonstrated that XRCC1, 
XRCC3 and P53 expressions do not correlate with the respective genetic polymorphisms 
analysed, in breast cancer patients and human breast cancer cell lines.  
This work brings a significantly contribution to the characterization of the genetic breast 
cancer susceptibility profile, within familial breast cancer cases non-carriers of BRCA1/BRCA2 
mutations and sporadic breast cancer patients, in the Portuguese population. These findings can 
be helpful for an early and more efficient screening of breast cancer disease.  
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